[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

USRE47589E1 - Phosphoramidate compounds and methods of use - Google Patents

Phosphoramidate compounds and methods of use Download PDF

Info

Publication number
USRE47589E1
USRE47589E1 US15/279,611 US200415279611A USRE47589E US RE47589 E1 USRE47589 E1 US RE47589E1 US 200415279611 A US200415279611 A US 200415279611A US RE47589 E USRE47589 E US RE47589E
Authority
US
United States
Prior art keywords
nmr
mhz
mmol
cdcl
oph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/279,611
Inventor
Christopher McGuigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE47589(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nucana PLC filed Critical Nucana PLC
Priority to US15/279,611 priority Critical patent/USRE47589E1/en
Assigned to NuCana plc reassignment NuCana plc CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NUCANA BIOMED LIMITED
Application granted granted Critical
Publication of USRE47589E1 publication Critical patent/USRE47589E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to nucleotide derivatives and their use in the treatment of cancer.
  • Nucleoside analogues such as fluorodeoxyuridine (1), cytarabine (2) and gemcitabine (3) are well established as anticancer agents. They function as inhibitors of DNA synthesis after activation to their 5′-phosphate form.
  • the phosphate prodrugs have biological properties and therapeutic activities that are similar to, or somewhat lower than, the parent nucleoside analogue.
  • Lackey et al [Biochem Pharmacol., 2001, 61, 179-89] have reported the application of our phosphoramidate pro-drug method for antiviral nucleosides to the anti-herpetic agent bromovinyl-2′-deoxyuridine (BVDU) (6).
  • BVDU bromovinyl-2′-deoxyuridine
  • phenyl methoxyalaninyl phosphoramidate (7) has significant anti-cancer activity. This is in marked contrast to the parent (antiviral) nucleoside (6).
  • a pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, ester or salt of such ester or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) a compound of formula (I).
  • R is 2-Bu (—CH 2 —CH(CH 3 ) 2 ) and one of R′ and R′′ is H and one of R′ and R′′ is methyl (—CH 3 ), when n is 1 and X and Y are both H, then Ar is not unsubstituted phenyl (—C 6 H 5 ).
  • metabolite is meant a metabolite or residue of a
  • n, Q, R, R′, R′′, X, Y, Z and Z′ have the meanings described above and below for formula I, and additionally R can be H, with the proviso that when n is 1, X and Y are both H, R is methyl (—CH 3 ), one of R′ and R′′ is H and one of R′ and R′′ is methyl (—CH 3 ), then Z is not —CH ⁇ CHBr.
  • ROCOCR′R′′NH— corresponds neither to alanine (ie as above, R is not methyl (—CH 3 ), one of R′ and R′′ is not H and one of R′ and R′′ is not methyl (—CH 3 )) nor to tryptophan (ie ⁇ -amino- ⁇ -indolylpropionic acid).
  • ROCOR′R′′NH is neither derived from nor corresponds to any naturally occurring amino acid.
  • the moiety ROCOCR′R′′NH— does not correspond to alanine (ie R is not methyl (—CH 3 ), one of R′ and R′′ is is not H and one of R′ and R′′ is not methyl (—CH 3 )), does not preferably correspond to tryptophan, and even more preferably the said moiety does not correspond to any naturally occurring amino acid.
  • ROCOCR′R′′NH— in compounds of formula II corresponds to a non-naturally occurring amino acid.
  • an alkyl group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical.
  • the alkylene group is preferably C 3 to C 12 , more preferably C 5 to C 10 , more preferably C 5 to C 7 .
  • the alkyl group is preferably C 1 to C 16 , more preferably C 1 to C 6 .
  • an aryl group means an aromatic group containing 5 to 14 ring atoms, for example phenyl or naphthyl.
  • the aromatic group may be a heteroaromatic group containing one, two, three or four, preferably one, heteroatoms selected, independently, from the group consisting of O, N and S.
  • heteroaromatic groups include pyridyl, pyrrolyl, furanyl and thiophenyl.
  • the aryl group comprises phenyl or substituted phenyl.
  • alkyl and aryl groups may be substituted or unsubstituted. Where substituted, there will generally be one to three substituents present, preferably one substituent.
  • Substituents may include halogen atoms, by which is meant F, Cl, Br and I atoms, and halomethyl groups such as CF 3 and CCl 3 ; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyC 1-16 alkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl and aryloyloxy; nitrogen containing groups such as amino, C 1-6 alkylamino, diC 1-6 alkylamino, cyano, azide and nitro; sulphur containing groups such as thiol, C 1-6 alkylthiol, sulphonyl and sulphoxide; heterocyclic groups which may themselves be substituted; alkyl groups as defined above, which may themselves be substituted
  • alkoxy and aryloxy groups means, respectively, alkyl-O— (for example where alkyl is C 1 to C 16 , preferably C 1 to C 6 ) and aryl-O— (for example where aryl is a 5 to 14 membered aromatic mono- or bifused ring moiety, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
  • alkoyl and aryloyl groups means, respectively, alkyl-CO— (for example where alkyl is C 1 to C 16 , preferably C 1 to C 6 ) and aryl-CO— (for example where aryl is a 5 to 14 membered aromatic mono or bifused ring moiety, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
  • alkoyloxy and aryloyloxy means, respectively, alkyl-CO—O (for example where alkyl is C 1 to C 16 , preferably C 1 to C 6 ) and aryl-CO—O (for example where aryl is a 5 to 14 membered mono- or bifused aromatic ring system, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
  • heterocyclic groups means groups containing one or more, pyrrolyl, imidazolyl, pyraziolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronly, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, is
  • the group Ar comprises a substituted or unsubstituted aryl group, wherein the term “aryl group” and the possible substitution of said group is as defined herein.
  • Ar is a substituted or unsubstituted phenyl group.
  • Particularly preferred substituents are electron withdrawing groups such as halogen (preferably chlorine or fluorine), trihalomethyl (preferably trifluoromethyl), cyano and nitro groups.
  • Ar can be phenyl, 3,5-dichloro-phenyl, p-trifluoromethyl-phenyl, p-cyano-phenyl, or p-nitro-phenyl.
  • Ar is a heteroaromatic group, preferably it is optionally substituted pyridyl.
  • R is a C 1-16 primary or secondary alkyl group, a C 5-7 carbocyclic aryl group or a C 1-6 alkylC 5-11 aryl group. More suitably, R is a C 1-10 alkyl group, a phenyl group or C 1-3 alkylC 5-7 aryl group. Preferably R is unsubstituted.
  • R is methyl (—CH 3 ), ethyl (—C 2 H 5 ), n- or i-propyl (—C 3 H 7 ), n- or i-butyl (—C 4 H 9 ) or benzyl (—CH 2 C 6 H 5 ).
  • R is benzyl.
  • R is preferably benzyl when one of R′ and R′′ is H and one of R′ and R′′ is methyl (—CH 3 ), especially when Ar is unsubstituted phenyl, n is 0 and each of X and Y is F.
  • R′ and R′′ are each independently selected from the group comprising H, C 1-6 primary, secondary or tertiary alkyl, C 1-3 alkylC 5-7 aryl, or, when together they form an alkylene chain, they provide, together the C atom to which they are attached, a C 3-8 carbocyclic aliphatic ring.
  • R′ and R′′ are the same and are alkyl, more preferably they are both methyl, ethyl or n- or i-propyl.
  • R′ and R′′ are, independently, H, methyl (—CH 3 ), secondary butyl (—CH 2 —CH—(CH 3 ) 2 ), benzyl (—CH 2 C 6 H 5 ), or, together with the C atom to which they are attached, provide a C 5-6 ring.
  • Preferred compounds include those where R′ and R′′ are both methyl, one of R′ and R′′ is H and one of R′ and R′′ is methyl, and R′ and R′′, together with the C atom to which they are attached, provide a pentyl ring.
  • the C atom to which they are attached is chiral.
  • the present compounds can be L or D or a mixture of stereoiosomers. Preferably they are L.
  • R′ and R′′ when one of R′ and R′′ is H and one of R′ and R′′ is Me or PhCH 2 , the moiety corresponds to alanine or phenylalanine, respectively.
  • the stereochemistry at the asymmetric centre —CR′R′′ corresponds to an L-amino acid.
  • the stereochemistry at the asymmetric centre —CR′R′′ can, however, correspond to a D-amino acid.
  • mixtures of of compounds can be employed having asymmetric centres corresponding to L and D amino acids.
  • naturally occurring amino acid we mean Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Cystine, Glycine, Glutamic Acid, Glutamine, Histidine, Hydroxylysine, Hydroxyproline, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine and Valine.
  • the present invention is not, however, limited to compounds having a moiety corresponding to a naturally occurring amino acid.
  • the moiety ROCOCR′R′′NH— corresponds to or is derived from a non-naturally occurring amino acid.
  • ROCOCR′R′′NH— preferably neither corresponds to nor is derived from alanine, more preferably neither corresponds to nor is derived from either of alanine or tryptophan, even more preferably neither corresponds to nor is derived from any naturally occurring amino acid.
  • ROCOCR′R′′NH— preferably neither corresponds to nor is derived from alanine, more preferably neither corresponds to nor is derived from either of alanine or trytophan, even more preferably neither corresponds to nor is derived from any naturally occurring amino acid.
  • Q is O.
  • X and Y are, independently, selected from the group comprising F, H and OH.
  • n 1, preferably each of X and Y is H.
  • each of X and Y is F, or X is OH and Y is H, or X is H and Y is OH.
  • n is 0 and X is OH and Y is H.
  • Particularly preferred are compounds of formula I wherein n is 0, X is OH, Y is H, Q is O and Z is H, corresponding to phosphoramidated cytarabine.
  • n is 0 and X is H and Y is OH.
  • Particularly preferred are compounds of formula I wherein n is 0, X is H, Y is OH, Q is O and Z is H, corresponding to phosphoramidated cytidine.
  • Ar is a 5 to 14 membered aromatic ring moiety.
  • the one or two rings may include 1, 2, 3 or 4 heteroatoms, preferably 1, selected, independently, from O, S and N.
  • Ar is a carbomonocyclic aromatic ring moiety. More preferably, Ar is a C 6 monocyclic aromatic ring moiety, ie is optionally substituted phenyl.
  • One, two, three or four substituents which may be the same or different, may be present on Ar and are selected from the group comprising halogen, which may —F, —Cl, —Br or —I; —NO 2 ; —NH 2 ; optionally substituted —C 1-3 alkyl; optionally substituted —C 1-3 alkoxy, preferably methoxy (—OCH 3 ); optionally substituted —SC 1-3 alkyl; —CN; optionally substituted —COC 1-3 alkyl; and optionally substituted —CO 2 C 1-3 alkyl.
  • halogen which may be —F, —Cl, —Br or —I
  • —NO 2 ; —NH 2 ; optionally substituted —C 1-3 alkyl; optionally substituted —C 1-3 alkoxy, preferably methoxy (—OCH 3 ); optionally substituted —SC 1-3 alkyl; —CN; optionally substituted —COC
  • the optional substitutents are one or more up to six, preferably three, members selected from the group comprising halogen which may be F, Cl, Br and I and NO 2 .
  • Preferred substituents on Ar include F, Cl, CF 3 , and NO 2 .
  • the substituents may be at any position on the ring moiety. Where the ring moiety is C 6 ie phenyl, a single substituent at the 2 (ortho) or 4 (para) position is preferred. Where Ar is phenyl, a single substituent at the 4 position is more preferred.
  • Ar is an optionally substituted phenyl moiety. More preferably, Ar is selected form the group comprising: Ph—, pCF 3 C 6 H 4 —, pFC 6 H 4 —, pNO 2 C 6 H 4 —, pClC 6 H 4 — and oClC 6 H 4 —.
  • Z is selected from the group comprising H, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkenyl, substituted C 1-6 alkenyl, C 1-6 alkynyl, substituted C 1-6 alkynyl and halogen, where halogen is F, Cl, Br or I.
  • Substituents that may be present on the alkenyl or alkynyl moiety are selected from the group comprising F, Cl, Br, I, and —CO 2 Me. One, two or three substituents may be present.
  • the alkenyl and alkynyl groups may contain one or more sites of unsaturation.
  • Z is substituted alkenyl or alkynyl
  • the substituent is preferably on the terminal C atom.
  • Z is selected from the group comprising H, F, optionally substituted C 1-6 alkyl particularly Me (—CH 3 ), optionally substituted C 1-6 alkenyl and optionally substituted C 1-6 alkynyl, the optional substituents being as recited immediately above.
  • Z′ is O
  • Q is O
  • X and Y are each H
  • Z is a substituted C 2 alkenyl (i.e. ethenyl or vinyl) moiety (—CH ⁇ CH—); more preferably, Z is bromovinyl (—CH ⁇ CHBr) or methylpropenoate (—CH ⁇ CHCO 2 Me); and most preferably, Z is —CH ⁇ CHBr.
  • n 1 and X and Y are both H, then Z is not F.
  • X is not H and Y is not OH, more preferably X is OH and Y is H or X and Y are both F.
  • a preferred compound embodying the present invention is the benzyl ester (8). It has surprisingly been found that the benzyl ester (8) is very significantly more potent against several cancer cell lines than the methyl ester (7):
  • Compound (8) inhibits the growth of colon cancer cell line HT115 by 50% at 1.4 ⁇ M, whilst (7) requires a concentration of 244 ⁇ M; (8) is thus 174 times more potent. Compound (8) is also 8 times more potent than (7) versus prostate cancer cell line PC-3 (19 ⁇ M vs. 155 ⁇ M).
  • compound (11) has simultaneous modification in these two regions, being the p-trifluoromethylphenyl benzyl [ ⁇ , ⁇ -dimethylglycinyl ]phosphoramidate.
  • Compound 11 shows high potency against a range of cancer cell types and is significantly and surprisingly more potent than (7).
  • breast cancer (11) is 60-fold more active (1.3 ⁇ M vs 79 ⁇ M)
  • prostate cancer (11) is 254-fold more potent (0.61 ⁇ M vs. 155 ⁇ M).
  • colon cancer (11) is 35-fold more potent (7 ⁇ M vs 244 ⁇ M).
  • the degree of enhancement of the analogue (11) vs. (7) is surprising based on prior art.
  • comparing (12) [dimethyl glycine modification] and (13) [p-CF 3 phenyl modification] to (9) shows no significant difference in potency.
  • compounds embodying the present invention and having variations in one or more of the ester (R), amino acid (R′, R′′) and aryl (Ar) region of the phosphoramidate structure compared to phenyl methoxyalaninyl phosphoramidate can give surprising and substantial potency boosts of pro-tides derived from BVDU against a range of cancer cell types.
  • a compound having formula I according to the present invention for use in a method of treatment, preferably in the prophylaxis or treatment of cancer.
  • a method of phrophylaxis or treatment of cancer comprising administration to a patient in need of such treatment an effective dose of a compound having formula I according to the present invention.
  • a pharmaceutical composition comprising a compound having formula I of the present invention in combination with a pharmaceutically acceptable excipient, carrier or diluent.
  • a method of preparing a pharmaceutical composition comprising the step of combining a compound having formula I of the present invention with a pharmaceutically acceptable excipient, carrier or diluent.
  • the present invention is particularly applicable for the treatment of a patient having breast cancer, colon cancer or prostate cancer.
  • cancers include breast MDA MB231, colon HT115 and prostate PC-3.
  • the compound having formula I or pharmaceutical composition according to the present invention can be administered to a patient, which may be human or animal, by any suitable means.
  • the medicaments employed in the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
  • oral or parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
  • the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
  • Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
  • suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while cornstarch and alginic acid are suitable disintegrating agents.
  • Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.
  • the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
  • Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin.
  • Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
  • the compounds of the invention may also be presented as liposome formulations.
  • a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day.
  • a preferred lower dose is 0.5 mg per kilogram body weight of recipient per day, a more preferred lower dose is 6 mg per kilogram body weight of recipient per day, an even more preferred lower dose is 10 mg per kilogram body weight per recipient per day.
  • a suitable dose is preferably in the range of 6 to 150 mg per kilogram body weight per day, and most preferably in the range of 15 to 100 mg per kilogram body weight per day.
  • the desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.
  • TLC Thin layer chromatography
  • Phosphorus oxychloride (1.0 mol eq.) and the appropriate substituted phenol (1.0 mol) were stirred with anhydrous diethylether (31 mol eq.). To this was added anhydrous triethylamine (1.0 mol eq) at ⁇ 80° C. and left to rise to room temperature over 16 hrs the triethylamine hydrochloride salt was filtered off, and the filtrate reduced to dryness to give the crude product as a clear liquid.
  • the experimental procedures used human colon cancer cell line (HT115), human prostate cancer cell line (PC-3), human breast cancer cell line (MDA MB 231) and normal human umbilical vein endothelial cell (HUVEC). Compounds were diluted over a range of concentrations and added to cells over 1 to 3 days. The cytotoxity was determined using a MTT assay at the end of each experiment.
  • ArO refers to Ar as defined above with respect to formula I;
  • BVU stands for 2-bromovinyl uridine.
  • GemCyt stands for Gemcitabine.
  • Examples A, 1, 67 and G are comparative Examples.
  • Example A is 5-(2-Bromovinyl)-2′-deoxyuridine.
  • Example 1 is Example 1 above corresponding to compound (7) above.
  • Example 67 is propenate-2′-deoxyuridine.
  • Example G is gemcitabine.
  • Examples 51, 52 and 53 are compounds embodying formula II above.
  • Gemcitabine (Example G in the Table) and compound CPF31 (Example 31 in the Table: gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate) were compared in a mouse model with xenografts of human cancer (colon HT115 and prostrate PC3).
  • mice were dosed daily at a range of concentrations (0.01-10 ⁇ M) and tumour volume assessed versus control.
  • FIG. 1 shows for the mouse xenograft the tumour volume for prostate data at day 13 using GemzarTM (gemcitabine available ex. Lilly);
  • FIG. 2 shows for the mouse xenograft the tumour volume for prostate data at day 13 using CPF31;
  • FIG. 3 shows the incident free survival functions v. day for each of CPF31 and gemcitabine.
  • FIG. 4 shows for the mouse xenograft the tumour volume for colon data at day 24 using, respectively, Gemzar and compound CPF31.
  • CPF31 can be seen to be significantly less toxic than gemcitabine.
  • CPF31 was significantly effective at reducing prostate and colon tumour volume relative to control at daily dosing of 5 and 10 ⁇ M (3 and 6 ⁇ g/ml). Gemcitabine was not effective at the highest non-toxic concentration.
  • Gemzar is seen from FIG. 1 to be toxic above 1 ⁇ M.
  • CPF31 is seen from FIG. 2 to have substantially lower toxicity.
  • FIG. 3 shows the Kaplan-Meier survival curve, incidence free survival: based on the loss according to weight loss.
  • FIG. 4 shows the results of testing both in vivo at 5 ⁇ M. The greater activity of CPF31 in reducing tumour volume is shown in FIG. 4 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety. The α-amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a reissue of U.S. Pat. No. 7,951,787, which is a U.S. National Stage application of International Application No. PCT/GB2004/003148, filed Jul. 20, 2004, which claims the benefit of Great Britain Application No. 0317009.9, filed Jul. 21, 2003.
The present invention relates to nucleotide derivatives and their use in the treatment of cancer.
Nucleoside analogues such as fluorodeoxyuridine (1), cytarabine (2) and gemcitabine (3) are well established as anticancer agents. They function as inhibitors of DNA synthesis after activation to their 5′-phosphate form.
Figure USRE047589-20190903-C00001
The free bioactive phosphate forms do not in general represent useful drugs due to their poor membrane permeation. In an effort to circumvent this a number of phosphate pro-drug approaches have been reported [Rosowsky et al, J. Med. Chem., 1982, 25, 171-8; Hong et al, J. Med. Chem., 1985, 28, 171-8; Kodama et al, Jpn. J. Cancer Res., 1989, 80, 679-85; Hong et al, 1979, 22, 1428-32; Ji et al, J. Med. Chem., 1990, 33, 2264-70; Jones et al, Nucleic Acids Res., 1989, 17, 7195-7201; Hunston et al, J. Med. Chem., 1984, 27, 440-4; Lorey et al, Nucleosides Nucleotides, 1997, 16, 1307-10; Farquhar et al, J. Med. Chem., 1983, 26, 1153-8; Shuto et al, Nucleosides Nucleotides, 1992, 11, 437-46; Le Bec et al, Tet. Letts., 1991, 32, 6553-6; Phelps et al, J. Med. Chem., 1980, 23, 1229-32].
In general the phosphate prodrugs have biological properties and therapeutic activities that are similar to, or somewhat lower than, the parent nucleoside analogue.
We have carried out extensive work in this area from an antiviral perspective, largely on dideoxy nucleosides, and have reported a phosphoramidate approach which has been widely adopted for the delivery of bio-active phosphates of antiviral nucleosides.
An example is the phosphoramidate (4) derived from anti-HIV d4T (5).
Figure USRE047589-20190903-C00002
We observed the effect of variations in the ester [McGuigan et al, AVCC, 1998, 9, 473-9], amino acid [McGuigan et al, Antiviral Res., 1997, 35, 195-204; AVCC, 2000, 11, 111-6], and aryl [Siddiqui et al, J. Med. Chem., 1999, 42, 393-9] regions of the phosphoramidate, as well as the effect of amino acid stereochemistry [McGuigan et al, AVCC, 1996, 7, 184-8), phosphate stereochemistry [Allender et al, Analytica Chim. Acta, 2001, 435, 107-13] and nucleoside [Balzarini et al, BBRC, 1996, 225, 363-9; McGuigan et al, BioOrg. Med, Chem. Lett., 1996, 6, 2369-62; McGuigan et al, Bioorg. Med. Chem. Lett., 2000, 10, 645-7].
This work has lead to the optimal description of phenyl methoxyalaninyl phosphoramidate as the prototype pro-moiety for the intracellular delivery of bioactive nucleotides [Balzarini et al, PNAS, 1996, 93, 7295-9; McGuigan et al, J. Med. Chem., 1996, 39, 1748-53].
Lackey et al [Biochem Pharmacol., 2001, 61, 179-89] have reported the application of our phosphoramidate pro-drug method for antiviral nucleosides to the anti-herpetic agent bromovinyl-2′-deoxyuridine (BVDU) (6). In particular, they have found that the phenyl methoxyalaninyl phosphoramidate (7) has significant anti-cancer activity. This is in marked contrast to the parent (antiviral) nucleoside (6).
Figure USRE047589-20190903-C00003
Limited SAR has been presented by this group, although in their patent applications [WO0239952, EP1200455, CA2317505, U.S. Pat. No. 6,339,151, EP116797, AU2451601] they claim a series of general variations in the base, and phosphate regions. However, based on our prior art, the phenyl methoxyalaninyl phosphoramidate (7) would be anticipated to be amongst the most optimal of structures.
Surprisingly, it has now been found that other derivatives of oxyamino acid-phosphoramidate nucleoside analogues are significantly more potent in the treatment of cancer than the phenyl methoxyalaninyl phosphoramidate (7).
According to a first aspect of the present invention there is provided a compound of formula I:
Figure USRE047589-20190903-C00004
wherein:
  • R is selected from the group comprising alkyl, aryl and alkylaryl;
  • R′ and R″ are, independently, selected from the group comprising H, alkyl and alkylaryl, or R′ and R″ together form an alkylene chain so as to provide, together with the C atom to which they are attached, a cyclic system;
  • Q is selected from the group comprising —O— and —CH2—;
  • X and Y are independently selected from the group comprising H, F, Cl, Br, I, OH and methyl (—CH3);
  • Ar is a monocyclic aromatic ring moiety or a fused bicyclic aromatic ring moiety, either of which ring moieties is carbocyclic or heterocyclic and is optionally substituted;
  • Z is selected from the group comprising H, alkyl and halogen; and
  • n is 0 or 1,
  • wherein
    • when n is 0, Z′ is —NH2 and a double bond exists between position 3 and position 4, and
    • when n is 1, Z′ is ═O;
  • or a pharmaceutically acceptable derivative or metabolite of a compound of formula I;
  • with the proviso that when n is 1, X and Y are both H, R is methyl (—CH3), one of R′ and R″ is H and one of R′ and R″ is methyl (—CH3), then Ar is not phenyl (—C6H5).
By “a pharmaceutically acceptable derivative” is meant any pharmaceutically acceptable salt, ester or salt of such ester or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) a compound of formula (I).
Suitably, except where R is 2-Bu (—CH2—CH(CH3)2) and one of R′ and R″ is H and one of R′ and R″ is methyl (—CH3), when n is 1 and X and Y are both H, then Ar is not unsubstituted phenyl (—C6H5).
By “pharmaceutically acceptable metabolite” is meant a metabolite or residue of a
Figure USRE047589-20190903-C00005
compound of formula (I) which gives rise in use to a compound of formula (II):
wherein n, Q, R, R′, R″, X, Y, Z and Z′ have the meanings described above and below for formula I, and additionally R can be H, with the proviso that when n is 1, X and Y are both H, R is methyl (—CH3), one of R′ and R″ is H and one of R′ and R″ is methyl (—CH3), then Z is not —CH═CHBr.
Suitably, with respect to compounds of formula II, when n is 1 and Z either is or is not —CH═CHBr, the moiety ROCOCR′R″NH— corresponds neither to alanine (ie as above, R is not methyl (—CH3), one of R′ and R″ is not H and one of R′ and R″ is not methyl (—CH3)) nor to tryptophan (ie α-amino-β-indolylpropionic acid).
More suitably with respect to compounds of formula II, when n is 1 and Z either is or is not —CH═CHBr, the moiety ROCOR′R″NH is neither derived from nor corresponds to any naturally occurring amino acid.
Even more suitably, with respect to compounds of formula II, when n is 1 or 0, the moiety ROCOCR′R″NH— does not correspond to alanine (ie R is not methyl (—CH3), one of R′ and R″ is is not H and one of R′ and R″ is not methyl (—CH3)), does not preferably correspond to tryptophan, and even more preferably the said moiety does not correspond to any naturally occurring amino acid.
Most preferably the moiety ROCOCR′R″NH— in compounds of formula II corresponds to a non-naturally occurring amino acid.
Reference in the present specification to an alkyl group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. Where cyclic, the alkylene group is preferably C3 to C12, more preferably C5 to C10, more preferably C5 to C7. Where acyclic, the alkyl group is preferably C1 to C16, more preferably C1 to C6.
Reference in the present specification to an aryl group means an aromatic group containing 5 to 14 ring atoms, for example phenyl or naphthyl. The aromatic group may be a heteroaromatic group containing one, two, three or four, preferably one, heteroatoms selected, independently, from the group consisting of O, N and S. Examples of such heteroaromatic groups include pyridyl, pyrrolyl, furanyl and thiophenyl. Preferably, the aryl group comprises phenyl or substituted phenyl.
The alkyl and aryl groups may be substituted or unsubstituted. Where substituted, there will generally be one to three substituents present, preferably one substituent. Substituents may include halogen atoms, by which is meant F, Cl, Br and I atoms, and halomethyl groups such as CF3 and CCl3; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyC1-16alkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl and aryloyloxy; nitrogen containing groups such as amino, C1-6alkylamino, diC1-6alkylamino, cyano, azide and nitro; sulphur containing groups such as thiol, C1-6alkylthiol, sulphonyl and sulphoxide; heterocyclic groups which may themselves be substituted; alkyl groups as defined above, which may themselves be substituted; and aryl groups as defined above, which may themselves be substituted, such as phenyl and substituted phenyl. Substituents on said heterocyclic, alkyl and aryl groups are as defined immediately above.
Reference in the present specification to alkoxy and aryloxy groups means, respectively, alkyl-O— (for example where alkyl is C1 to C16, preferably C1 to C6) and aryl-O— (for example where aryl is a 5 to 14 membered aromatic mono- or bifused ring moiety, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
Reference in the present specification to alkoyl and aryloyl groups means, respectively, alkyl-CO— (for example where alkyl is C1 to C16, preferably C1 to C6) and aryl-CO— (for example where aryl is a 5 to 14 membered aromatic mono or bifused ring moiety, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
Reference in the present specification to alkoyloxy and aryloyloxy means, respectively, alkyl-CO—O (for example where alkyl is C1 to C16, preferably C1 to C6) and aryl-CO—O (for example where aryl is a 5 to 14 membered mono- or bifused aromatic ring system, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
Reference in the present specification to heterocyclic groups means groups containing one or more, pyrrolyl, imidazolyl, pyraziolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronly, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carbolinyl.
The group Ar comprises a substituted or unsubstituted aryl group, wherein the term “aryl group” and the possible substitution of said group is as defined herein. Preferably, Ar is a substituted or unsubstituted phenyl group. Particularly preferred substituents are electron withdrawing groups such as halogen (preferably chlorine or fluorine), trihalomethyl (preferably trifluoromethyl), cyano and nitro groups. For example, Ar can be phenyl, 3,5-dichloro-phenyl, p-trifluoromethyl-phenyl, p-cyano-phenyl, or p-nitro-phenyl. When Ar is a heteroaromatic group, preferably it is optionally substituted pyridyl.
Suitably, R is a C1-16 primary or secondary alkyl group, a C5-7 carbocyclic aryl group or a C1-6alkylC5-11aryl group. More suitably, R is a C1-10 alkyl group, a phenyl group or C1-3 alkylC5-7 aryl group. Preferably R is unsubstituted.
Preferably, R is methyl (—CH3), ethyl (—C2H5), n- or i-propyl (—C3H7), n- or i-butyl (—C4H9) or benzyl (—CH2C6H5). Most preferably, R is benzyl. Particularly, R is preferably benzyl when one of R′ and R″ is H and one of R′ and R″ is methyl (—CH3), especially when Ar is unsubstituted phenyl, n is 0 and each of X and Y is F.
Suitably, R′ and R″ are each independently selected from the group comprising H, C1-6 primary, secondary or tertiary alkyl, C1-3alkylC5-7aryl, or, when together they form an alkylene chain, they provide, together the C atom to which they are attached, a C3-8 carbocyclic aliphatic ring.
Preferably, R′ and R″ are the same and are alkyl, more preferably they are both methyl, ethyl or n- or i-propyl.
Alternatively, preferably, R′ and R″ are, independently, H, methyl (—CH3), secondary butyl (—CH2—CH—(CH3)2), benzyl (—CH2C6H5), or, together with the C atom to which they are attached, provide a C5-6 ring.
Preferred compounds include those where R′ and R″ are both methyl, one of R′ and R″ is H and one of R′ and R″ is methyl, and R′ and R″, together with the C atom to which they are attached, provide a pentyl ring.
When R′ and R″ are different, the C atom to which they are attached is chiral. The present compounds can be L or D or a mixture of stereoiosomers. Preferably they are L.
It will be appreciated that the moiety —O—C(O)—CR′R″—NH— corresponds to a carboxy-protected α-amino acid. R′ and R″ can thus correspond to the side chains of a naturally occurring amino acid.
For example, when one of R′ and R″ is H and one of R′ and R″ is Me or PhCH2, the moiety corresponds to alanine or phenylalanine, respectively.
Preferably, the stereochemistry at the asymmetric centre —CR′R″ corresponds to an L-amino acid. The stereochemistry at the asymmetric centre —CR′R″ can, however, correspond to a D-amino acid. Alternatively, mixtures of of compounds can be employed having asymmetric centres corresponding to L and D amino acids.
In the present specification by “naturally occurring amino acid” we mean Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Cystine, Glycine, Glutamic Acid, Glutamine, Histidine, Hydroxylysine, Hydroxyproline, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine and Valine.
The present invention is not, however, limited to compounds having a moiety corresponding to a naturally occurring amino acid. The present invention specifically includes compounds having a moiety which corresponds to a non-naturally occurring amino acid, such as, for example, those where R′═R″=alkyl, or, where together with the C atom to which they are attached, R′ and R″ provide a cyclic moiety. Preferably with respect to the compound of formula I, the moiety ROCOCR′R″NH— corresponds to or is derived from a non-naturally occurring amino acid.
With respect to compounds of formula I when n is 1, the moiety ROCOCR′R″NH— preferably neither corresponds to nor is derived from alanine, more preferably neither corresponds to nor is derived from either of alanine or tryptophan, even more preferably neither corresponds to nor is derived from any naturally occurring amino acid.
With respect to compounds of formula I when n is 0, the moiety ROCOCR′R″NH— preferably neither corresponds to nor is derived from alanine, more preferably neither corresponds to nor is derived from either of alanine or trytophan, even more preferably neither corresponds to nor is derived from any naturally occurring amino acid.
Preferably Q is O.
Preferably, X and Y are, independently, selected from the group comprising F, H and OH.
When n is 1, preferably each of X and Y is H.
When n is 0, preferably each of X and Y is F, or X is OH and Y is H, or X is H and Y is OH.
When Z is F, Q is O, n is 1 and X and Y are each H, the base moiety of the compound of formula I corresponds to that of fluorodeoxyuridine i.e. compound (1) above.
When Z is H, Q is O, n is 0 and X is OH and Y is H, the base moiety of the compound of formula I corresponds to that of cytarabine i.e. compound (2) above.
When Z is H, Q is O, n is 0 and X and Y are each F, the base moiety of the compound of formula I corresponds to that of gemcitabine i.e. compound (3) above.
When Z is H, Q is O, n is 0 and X is H and Y is OH, the base moiety of the compound of formula I corresponds to that of cytidine.
Compounds of formula I wherein n is 0 and X and Y are F are preferred. Particularly preferred are compounds of formula I wherein n is 0, X and Y are F, Q is O and Z is H, corresponding to phosphoramidated gemcitabine.
Also preferred are compounds of formula I wherein n is 0 and X is OH and Y is H. Particularly preferred are compounds of formula I wherein n is 0, X is OH, Y is H, Q is O and Z is H, corresponding to phosphoramidated cytarabine.
Also preferred are compounds of formula I wherein n is 0 and X is H and Y is OH. Particularly preferred are compounds of formula I wherein n is 0, X is H, Y is OH, Q is O and Z is H, corresponding to phosphoramidated cytidine.
Suitably, Ar is a 5 to 14 membered aromatic ring moiety. The one or two rings may include 1, 2, 3 or 4 heteroatoms, preferably 1, selected, independently, from O, S and N.
Preferably, Ar is a carbomonocyclic aromatic ring moiety. More preferably, Ar is a C6 monocyclic aromatic ring moiety, ie is optionally substituted phenyl.
One, two, three or four substituents, which may be the same or different, may be present on Ar and are selected from the group comprising halogen, which may —F, —Cl, —Br or —I; —NO2; —NH2; optionally substituted —C1-3alkyl; optionally substituted —C1-3alkoxy, preferably methoxy (—OCH3); optionally substituted —SC1-3alkyl; —CN; optionally substituted —COC1-3alkyl; and optionally substituted —CO2C1-3alkyl. The optional substitutents are one or more up to six, preferably three, members selected from the group comprising halogen which may be F, Cl, Br and I and NO2. Preferred substituents on Ar include F, Cl, CF3, and NO2.
The substituents may be at any position on the ring moiety. Where the ring moiety is C6 ie phenyl, a single substituent at the 2 (ortho) or 4 (para) position is preferred. Where Ar is phenyl, a single substituent at the 4 position is more preferred.
Preferably, Ar is an optionally substituted phenyl moiety. More preferably, Ar is selected form the group comprising: Ph—, pCF3C6H4—, pFC6H4—, pNO2C6H4—, pClC6H4— and oClC6H4—.
Suitably, Z is selected from the group comprising H, C1-6 alkyl, substituted C1-6 alkyl, C1-6 alkenyl, substituted C1-6 alkenyl, C1-6 alkynyl, substituted C1-6 alkynyl and halogen, where halogen is F, Cl, Br or I. Substituents that may be present on the alkenyl or alkynyl moiety are selected from the group comprising F, Cl, Br, I, and —CO2Me. One, two or three substituents may be present. The alkenyl and alkynyl groups may contain one or more sites of unsaturation.
Where Z is substituted alkenyl or alkynyl, the substituent is preferably on the terminal C atom.
Preferably Z is selected from the group comprising H, F, optionally substituted C1-6alkyl particularly Me (—CH3), optionally substituted C1-6alkenyl and optionally substituted C1-6alkynyl, the optional substituents being as recited immediately above.
When n is 1, Z′ is O, Q is O and X and Y are each H, preferably Z is a substituted C2 alkenyl (i.e. ethenyl or vinyl) moiety (—CH═CH—); more preferably, Z is bromovinyl (—CH═CHBr) or methylpropenoate (—CH═CHCO2Me); and most preferably, Z is —CH═CHBr.
With respect to compounds of formula II, preferably when n is 1 and X and Y are both H, then Z is not F.
With respect to compounds of formula II, when n is 0, preferably X is not H and Y is not OH, more preferably X is OH and Y is H or X and Y are both F.
With respect to compounds of formula II, when n is 0, X is OH and Y is H, preferably neither R′ nor R″ is phenylmethyl (ie benzyl) or 3-methylindolyl (ie 3-CH2indolyl).
Surprisingly, modifying the ester moiety in compound (7) has been found to show a marked increase in potency with respect to cancer cell lines. A preferred compound embodying the present invention is the benzyl ester (8). It has surprisingly been found that the benzyl ester (8) is very significantly more potent against several cancer cell lines than the methyl ester (7):
Figure USRE047589-20190903-C00006
Compound (8) inhibits the growth of colon cancer cell line HT115 by 50% at 1.4 μM, whilst (7) requires a concentration of 244 μM; (8) is thus 174 times more potent. Compound (8) is also 8 times more potent than (7) versus prostate cancer cell line PC-3 (19 μM vs. 155 μM).
The degree of potency enhancement for (8) vs. (7) is surprising based on the prior art. Thus, comparing the equivalent phosphoramidates of d4T reveals a ca 4-fold potency boost of (10) over (9) [McGuigan et al, AVCC, 1998, 9, 473-9].
Figure USRE047589-20190903-C00007
This would imply that the benzyl phosphoramidate motif in (10) is ca 4-fold more efficient at the intracellular delivery of the bio-active free phosphate forms of d4T than is the methyl ester (9). A person skilled in the art would anticipate a similar degree of enhancement for the benzyl phosphoramidate of BVDU (8) over the methyl ester (7) whilst we observed an almost 200-fold enhancement for colon cancer as noted above.
Surprising efficacy of modifications in the amino acid and aryl moieties of the BVDU phosporamidate has also been found in compounds embodying the present invention.
Thus, compound (11) has simultaneous modification in these two regions, being the p-trifluoromethylphenyl benzyl [α,α-dimethylglycinyl ]phosphoramidate.
Figure USRE047589-20190903-C00008
Compound 11 shows high potency against a range of cancer cell types and is significantly and surprisingly more potent than (7). Thus, for breast cancer (11) is 60-fold more active (1.3 μM vs 79 μM), and for prostate cancer (11) is 254-fold more potent (0.61 μM vs. 155 μM). Against colon cancer, (11) is 35-fold more potent (7 μM vs 244 μM). Again, the degree of enhancement of the analogue (11) vs. (7) is surprising based on prior art. Thus, comparing (12) [dimethyl glycine modification] and (13) [p-CF3phenyl modification] to (9) shows no significant difference in potency.
Figure USRE047589-20190903-C00009
Thus 50% effective doses vs HIV-1 for (9), (12) and (13) are: 0.075, 0.29, and 0.01 μM respectively; within experimental error, (12) and (13) are identical in potency to (9). Thus a person skilled in the art would have predicted that (11) would show little enhancement over (7) as opposed to the 35 to 254-fold enhancements noted above.
Thus, compounds embodying the present invention and having variations in one or more of the ester (R), amino acid (R′, R″) and aryl (Ar) region of the phosphoramidate structure compared to phenyl methoxyalaninyl phosphoramidate can give surprising and substantial potency boosts of pro-tides derived from BVDU against a range of cancer cell types.
According to a further aspect of the present invention there is provided a compound having formula I according to the present invention for use in a method of treatment, preferably in the prophylaxis or treatment of cancer.
According to a further aspect of the present invention there is provided a method of phrophylaxis or treatment of cancer comprising administration to a patient in need of such treatment an effective dose of a compound having formula I according to the present invention.
According to a further aspect of the present invention there is provided use of a compound having formula I of the present invention in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound having formula I of the present invention in combination with a pharmaceutically acceptable excipient, carrier or diluent.
According to a further aspect of the present invention there is provided a method of preparing a pharmaceutical composition comprising the step of combining a compound having formula I of the present invention with a pharmaceutically acceptable excipient, carrier or diluent.
The present invention is particularly applicable for the treatment of a patient having breast cancer, colon cancer or prostate cancer. Examples of such cancers include breast MDA MB231, colon HT115 and prostate PC-3.
The compound having formula I or pharmaceutical composition according to the present invention can be administered to a patient, which may be human or animal, by any suitable means.
The medicaments employed in the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while cornstarch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
The compounds of the invention may also be presented as liposome formulations.
In general a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day. A preferred lower dose is 0.5 mg per kilogram body weight of recipient per day, a more preferred lower dose is 6 mg per kilogram body weight of recipient per day, an even more preferred lower dose is 10 mg per kilogram body weight per recipient per day. A suitable dose is preferably in the range of 6 to 150 mg per kilogram body weight per day, and most preferably in the range of 15 to 100 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.
According to a further aspect of the present invention there is provided a process for the preparation of a compound having formula I according to the present invention, the process 30 comprising reacting of a compound of formula (III):
Figure USRE047589-20190903-C00010
with a compound of formula (IV):
Figure USRE047589-20190903-C00011
wherein Ar,n Q, R, R′, R″, X, Y, Z′ and Z have the meanings described above with respect to formula (I).
Embodiments of the present invention will now be described, by way of example only, with reference to the following examples, experimental procedures and experimental data.
Data are presented for a range of structures against tumour cell types representing a range of common cancers in man with un-met clinical need: breast MDA MB231, colon HT115, prostate PC-3. Data from these assays are presented as Table 1.
EXPERIMENTAL PROCEDURE
General Methods
The following anhydrous solvents and reagents were bought from Aldrich with sure stopper: dichloromethane (DCM), diethyl ether (Et2O), tetrahydrofuran THF), N-methylimidazole (NMI), methanol (MeOH), dimethylformamide (DMF), 1,4-dioxane. triethylamine was dried on molecular sieves of 4 Angstrom.
Thin Layer Chromatography
Thin layer chromatography (TLC) was performed on commercially available Merck Kieselgel 60 F254 plates and separated components were visualized using ultraviolet light (254 nm and 366 nm).
Column Chromatography
Columns were performed using (Kieselgel 60, 35-70 μm, Fluka) as the stationary phase. Samples were applied as a concentrated solution in the same eluent, or pre-adsorbed onto silica gel.
NMR Spectroscopy
1H, 13C and 31P-NMR were recorded on a Bruker Avance DPX300 spectrometer with operating frequencies of 300 MHz, 75 MHz and 121 MHz respectively. 31P-NMR spectra are reported in units of δ relative to 85% phosphoric acid as external standard, positive shifts are downfield. The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad signal), dd (doublet of doublet), dt (doublet of triplet). Starred signal signal are splitted due to stereoisomeric mixtures.
Standard Procedures
For practical purposes, standard procedures are given where applicable.
Standard Procedure 1: Synthesis of Amino Ester Hydrochloride Salts.
To a stirring solution of anhydrous alcohol (10 mol eq.) was added thionyl chloride (2 mol eq.) at 0° C., and the resulting solution stirred for 1 hr. After warming to room temperature, the appropriate amino acid (1 mol eq) was added and the reaction heated at reflux for 6-16 hrs. Removal of solvent and recrystallisation from methanol/ether gave the amino ester hydrochloride salts.
Standard Procedure 2: Synthesis of Amino Benzyl Ester Hydrochloride Salts.
The appropriate amino acid (1.0 mol eq.), p-toluene sulfonic acid (1.0 mol eq.) and anhydrous benzyl alcohol (4.1 mol eq.) were heated at reflux in toluene (10 mol eq.) with Dean-Stark trap for 24 hrs. On cooling to room temperature, Et2O was added and the mixture was left in ice bath for 1 hr then filtrated and washed with Et2O. The solid was dissolved in DCM and washed with 10% K2CO3 and water. The organic layer was dried over MgSO4, filtered and the solvent removed under reduced pressure to give an oil. This was solubilized in acetone and neutralized with 1 M HCl. Et2O was added and the solid was filtered and washed with Et2O to give a white solid.
Standard Procedure 3: Synthesis of Phosphorodichloridate Species.
Phosphorus oxychloride (1.0 mol eq.) and the appropriate substituted phenol (1.0 mol) were stirred with anhydrous diethylether (31 mol eq.). To this was added anhydrous triethylamine (1.0 mol eq) at −80° C. and left to rise to room temperature over 16 hrs the triethylamine hydrochloride salt was filtered off, and the filtrate reduced to dryness to give the crude product as a clear liquid.
Standard Procedure 4: Synthesis of Phosphochloridate Species.
Phosphodichloridate (1.0 mol eq.) and the appropriate amino ester hydrochloric salt (1.0 mol eq.) were suspended in anhydrous DCM. Anhydrous triethylamine was added dropwise at −80° C. and after 1 hr the reaction was left to rise to room temperature. The formation of phosphochloridate was monitored by 31P-NMR. After 2-5 hrs the solvent was removed under reduced pressure and the solid obtained washed with anhydrous ether (2×20 ml), filtered, and the filtrate reduced to dryness to give the products as crude oil. These oils were usually used without further purification.
Standard Procedure 5: Synthesis of Phosphoroamidate Derivatives.
To a stirring solution of (E)-5-(2-bromovinyl)-2′-deoxyuridine (1.0 mol eq.) and the appropriate phosphochloridate (2.0-3.0 mol eq) in anhydrous THF at −80° C. was added dropwise over 1 min NMI (5.0 mol eq.). After 15 mins the reaction was left to rise to room temperature and stirred at room temperature for 2-19 hrs. The solvent was removed under reduced pressure and the yellow oil obtained was dissolved in DCM, washed with 0.5 M HCl, and water. The organic layer is dried over MgSO4, filtered, reduced to dryness and purified by flash chromatography (Chloroform/Methanol 97/3, Dichloromethane/Methanol 97/3).
Synthesis of Methyl-1-amino-1-cyclopentanoate hydrochloride salt
C6H14ClNO3, MW=179.68.
Figure USRE047589-20190903-C00012
This was synthesised according to Standard Procedure 1, using 1-amino-1-cyclopentanecarboxylic acid (3.876 g, 30 mmol) with thionyl chloride (4.44 mL, 45 mmol,) and anhydrous methanol (15.5 mL). The product was isolated as a white solid (4.81 g, yield 89%).
1H-NMR (CDCl3; 300 MHz): δ 9.1 (3H, bs, NH 3 +Cl−), 3.85 (3H, s, OCH 3), 2.3-2.2 (4H, m, 4H cyclopentane), 2.15 (2H, 2H cyclopentane), 1.95 (2H, m, 2H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 26.6 (2CH2 cyclopent), 38.1 (2CH2 cyclopent), 54.8 (CH 3O), 66.6 (Cq cyclopentane), 174.1 (COOMe).
Synthesis of Ethyl-1-amino-1-cyclopentanoate hydrochloride salt
C8H16ClNO2, MW=193.71.
Figure USRE047589-20190903-C00013
This was synthesised according to Standard Procedure 1, using 1-amino-1-cyclopentanecarboxylic acid (5.0 g, 38.6 mmol) with thionyl chloride (5.72 mL, 58 mmol) and anhydrous ethanol (29 mL). The product was isolated as a white solid (6.98 g, yield 93%).
1H-NMR (CDCl3; 300 MHz): δ 9.0 (3H, bs, NH 3 +Cl−), 4.3 (2H, q, 3J=8, OCH 2CH3), 2.3-2.2 (4H, m, 4H cyclopentane), 2.15 (2H, 2H cyclopentane), 1.95 (2H, m, 2H cyclopentane), 1.4 (3H, t, 3J=8, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2), 25.8 (2CH2 cyclopent), 37.4 (2CH2 cyclopent), 63.0 (CH3 CH2), 66.2 (Cq cyclopentane), 172.1 (COOEt).
Synthesis of Benzyl-1-amino-1-cyclopentanoate hydrochloride salt
C14H18ClNO2, MW=255.78.
Figure USRE047589-20190903-C00014
This was synthesised according to Standard Procedure 2, using 1-amino-1-cyclopentanecarboxylic acid (3.682 g, 28.5 mmol) with p-toluene sulfonic acid monohydrate (5.625 g, 29.55 mmol) and anhydrous benzylic alcohol (12 mL, 116 mmol), in Toluene (20 mL). The product was isolated as a white solid (6.441 g, yield 88.5%) Hydrochloride salt. 1H-NMR (CDCl3; 300 MHz): δ 9.05 (3H, bs, NH 3 +Cl−), 7.4-7.25 (5H, m, Ph), 5.15 (2H, s, CH2 Ph), 2.3 (4H, m, 4H cyclopentane), 2.15 (2H, 2H cyclopentane), 1.95 (2H, m, 2H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 25.9 (2CH2 cyclopent), 37.3 (2CH2 cyclopent), 66.3 (Cq cyclopentane), 68.3 (CH2Ph), 129.2, 129.0, 128.8 (‘o’, ‘m’, CH2 Ph), 135.5 (‘p’, CH2 Ph), 172.1 (COOBn).
Synthesis of methyl-2-amino-2-methylpropanoate hydrochloride salt
C5H12ClNO3, MW 153.61.
Figure USRE047589-20190903-C00015
This was synthesised according to Standard Procedure 1, using 2-amino-isobutyric acid (5.102 g, 48.49 mmol) with thionyl chloride (11.538 g, 96.98 mmol, 7.04 mL) and anhydrous methanol (19.6 mL). The product was isolated as a white solid (6.636 g, yield 89.2%).
1H-NMR (CDCl3; 300 MHz): δ 8.81 (3H, bs, NH 3Cl), 3.83 (3H, s, OCH 3), 1.74 (6H, s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 24.1, 24.3 ([CH3]2C), 57.9 (C[CH3]2), 172.4 (COOCH3).
Synthesis of ethyl-2-amino-2-methylpropanoate hydrochloride salt
C6H14ClNO2, MW 167.63.
Figure USRE047589-20190903-C00016
This was synthesised according to Standard Procedure 1, using 2-amino-isobutyric acid (5.102 g, 48.49 mmol) with thionyl chloride (11.772 g, 98.95 mmol, 7.2 mL) and anhydrous ethanol (29 mL). The product was isolated as a white solid (7.159 g, yield 86.3%).
1H-NMR (CDCl3; 300 MHz): δ 8.93 (3H, bs, NH 2Cl), 4.3 (2H, q, 3J=7.1 Hz, OCH 2CH3), 1.75 (6H, s, [CH 3]2C), 1.33 (3H, t, 3J=7.1 Hz, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.4 (CH3CH2O), 24.3 ([CH3]2C), 57.9 (C[CH3]2), 63.1 (OCH2CH3), 171.6 (COOCH2CH3).
Synthesis of benzyl-2-amino-2-methylpropanoate hydrochloride salt
C11H16ClNO2, MW 229.70.
Figure USRE047589-20190903-C00017
This was synthesised according to Standard Procedure 2, using 2-amino-isobutyric acid (1.960 g, 19.00 mmol) with p-toluene sulfonic acid monohydrate (3.750 g, 19.7 mmol) and benzylic alcohol (8.360 g, 77.30 mmol, 8 mL), in toluene (20 mL). The product was isolated as a white solid (2.556 g, yield 87.4%)
p-toluenesulfonate salt: 1H-NMR (CDCl3, 300 MHz): δ 8.40 (3H, bs, NH 3Cl), 7.79 (2H, d, 3J=8.0 Hz, ‘m’ p-TSA), 7.34 (5H, m, CH2 Ph), 7.14 (2H, d, 3J=8.0 Hz, ‘o’ p-TSA), 5.16 (2H, s, CH 2Ph), 2.38 (3H, s, CH 3 p-TSA), 1.57 (6H, s, [CH 3]2C)
13C-NMR (CDCl3; 75 MHz): δ 21.8 (CH3, p-TSA), 23.9 ([CH3]2C), 57.8 (C[CH3]2), 68.3 (CH2Ph), 126.55, 128.5, 128.8, 129.0, 129.3 (CH2 Ph+p-TSA), 135.4 (‘ipso’, CH2 Ph), 140.8 (‘p’, p-TSA), 141.9 (‘ipso’, p-TSA), 171.9 (COOCH2Ph).
Hydrochloride salt: 1H-NMR (CDCl3; 300 MHz): δ 9.10 (3H, bs, NH 3Cl), 7.41-7.31 (5H, m, CH2 Ph), 5.27 (2H, s, CH2 Ph), 1.77 ([CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 24.2 ([CH3]2C), 58.0 (C[CH3]2), 68.5 (CH2Ph), 128.62, 129.0, 129.1 (‘o’, ‘m’, ‘p’, CH2 Ph), 135.2 (‘ipso’, CH2 Ph), 171.8 (COOCH2Ph).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (E)-5-(2-Carbomethoxyvinyl)-2′-deoxyuridine
Figure USRE047589-20190903-C00018
A mixture of Pd(OAc)2 (0.316 g, 1.41 mmol), PPh3 (0.741 g, 2.82 mmol), and triethylamine (4.9 mL) in 1,4-dioxane (50 mL) was stirred at 70° C. until an intense red colour had developed. To this 5-iodo-2′-deoxyuridine (10 g, 28.24 mmol) and methylacrilate (4.862 g, 56.48 mmol, 5.1 mL) in 1,4-dioxane (20 mL) were added and the mixture stiffed at refluxed for 30 mins. The reaction was filtered while still hot and the 20 filtrate cooled over night at 4° C. The resulting pale yellow precipitate was filtered, washed with DCM and dried in vacuo to give the product as white solid (6.2 g, yield 70.7%).
1H-NMR (DMSO-d6; 300 MHz) δ 11.64 (1H, bs, NH-3), 8.42 (1H, s, H-6), 7.37 (1H, d, 3J=15.8 Hz, H vinylic), 6.86 (1H, d, 3J=15.8 Hz, H vinylic), 6.13 (1H, t, 3J=6.5 Hz, H-1′), 5.27-5.20 (2H, 2bs, OH-3′, OH-5′), 4.27 (1H, m, H-3′), 3.81 (1H, m, H-4′), 3.68 (3H,s CH 3), 3.60 (2H, m, H-5′), 2.18 (2H, m, H-2′).
13C-NMR (DMSO-d6; 75 MHz): δ 40.4 (C-2′), 51.6 (CH3), 66.7 (C-5′), 70.0 (C-3′), 85.2 (C-4′), 88.0 (C-1′), 108.5 (C-5), 116.5 (C-5b), 138.5 (C-5a), 144.4 (C-6), 149.6, 162.1 (C-2, C-4),167.6 (COO).
(E-5-(2-Carboxyvinyl)-2′-deoxyuridine
Figure USRE047589-20190903-C00019
(E)-5-(2-carbomethoxyvinyl)-2′-deoxyuridine (6.0 g, 19.33 mmol) was dissolved in 300 mL of 1 M NaOH and the mixture stirred at room temperature for 3 hrs, filtered and the filtrate adjusted to pH 2 with 1M HCl. On cooling at 4° C. a white precipitate formed. This was filtered off and washed with cold water (2×20 ml) and acetone (2×20 mL) and dred to give a white solid (4.441 g, yield 77.1%).
1H-NMR (DMSO-d6; 300 MHz): δ 12.18 (1H, bs, CO2 H), 11.64 (1H, s, NH-3), 8.40 (1H, s, H-6), 7.30 (1H, d, 3J=15.6 Hz, H vinylic), 6.78 (1H, d, 3J=15.8 Hz, H vinylic), 6.14 (1H, t, 3J=6.4 Hz, H-1′), 5.38-5.08 (2H, bs, OH-3′, OH-5′), 4.26 (1H, m, H-3′), 3.80 (1H, m H-4′), 3.64 (2H, m, H-5′), 2.18 (2H, m, H-2′).
13C-NMR (DMSO-d6; 75 MHz): δ 40.1 (C-2′), 61.2 (C-5′), 70.1 (C-3′), 85.1 (C-4′), 88.0 (C-1′), 108.7 (C-5), 118.0 (C-5b), 137.9 (C-5a), 143.9 (C-6), 149.6, 162.1 (C-2, C-4), 168.4 (COOH).
(E)-5-(2-bromovinyl)-2′-deoxyuridine
Figure USRE047589-20190903-C00020
To a solution of (E)-5-(2-carboxyvinyl)-2′-deoxyuridine (5.777 g, 19.37 mmol) in dimethylforamide (29 mL) was added K2CO3 (5.890 g, 42.61 mmol) and the suspension stirred at room temperature for 15 mins. A solution of N-bromosuccinimide (3.655 g, 20.53 mmol) was added dropwise over 30 mins at 20° C. The resulting suspension was filtered and the solid washed with DMF. The combined filtrate and washings were evaporated to dryness in vacuo and the residue dissolved in MeOH. To this silica gel was added and the suspension evaporated to dryness and the solid applied to the top of chromatographic column. The column was eluted with chloroform/methanol 92/8 to give a white solid (5787 g, 71.9%). Crystallisation from water gave a white powder.
1H-NMR (DMSO-d6; 300 MHz) δ 11.59 (1H, bs, NH-3), 8.08 (1H, s, H-6), 7.25 (1H, d, 3J=13.6 Hz, H-5b), 6.85 (1H, d, 3J=13.6 Hz, H-5a), 6.13 (1H, t, 3J=6.5 Hz, H-1′), 5.29 (1H, bs, OH-3′), 5.13 (1H, bs, OH-5′), 4.24 (1H, m, H-3′), 3.79 (1H, m, H-4′), 3.66 (2H, m, H-5′), 2.51 (1H, m, H-2′), 2.14 (1H, m, H-2′).
13C-NMR (DMSO-d6; 75 MHz): δ 40.2 (C-2′), 61.3 (C-5), 70.3 (C-4′), 84.8 (C-3′), 87.8 (C-1′), 108.9 (C-5b), 110.0 (C-5), 130.3 (C-5a), 149.6, 162.1 (C-2, C4).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(methoxy-L-alaninyl)]-phosphate (CPF 1)
C21H25BrN3O9P, MW 574.32.
Figure USRE047589-20190903-C00021
This was synthesised according to Standard procedure 5, using BVdU (300 mg, 0.90 mmol), Phenyl-(methoxy-L-alaninyl)-phosphorochloridate (472 mg, 1.7 mmol), NMI (4.5 mmol, 378 μL) in THF (9 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (356 mg, yield 69%).
31P-NMR (CDCl3, 121 MHz): δ 4.72, 4.40.
1H-NMR (CDCl3; 300 MHz): δ 9.9 (1H, bs, H-3), 7.64 (1H, 2×s, H-6), 7.44-7.39 (1H, 2d, 3J=14 Hz, H-5b), 7.37-7.15 (5H, m, OPh), 6.75-6.67 (1H, 2d, 3J=14 Hz, H-5a), 6.30-6.21 (1H, 2t, 3J=6 Hz, H1′), 4.57-4.29 (3H, m, H-5′+H-3′), 4.2-3.96 (3H, H-4′, NH, CHala), 3.72 (3H, s, CH3O), 2.49-2.40 (1H, m, one of H-2′), 2.12-2.01 (1H, m, one of H-2′), 1.38 (3H, d, 3J=7 Hz, CH3 ala).
13C-NMR (DMSO; 75 MHz): δ 22.4 (CH3 ala), 41.9, 41.8 (C-2′), 51.9 (CH[CH3]), 54.3 (CH3O), 67.5 (C-5′), 72.3, 71.9 (C-3′), 87.3, 87.2, 86.9, 86.8 (C-1′, C-4′), 110.6 (C-5b), 113.1 (C-5), 121.7 (‘o’, OPh), 127.0 (‘p’, OPh), 130.1 (C-5a), 131.5 (‘m’, OPh), 139.2 (C-6),150.9 (‘ipso’, OPh) 151.9 (C-4), 163.2(C-2), 175.7 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(ethoxy-L-alaninyl)]-phosphate(CPF 3)
C22H27BrN3O9P, MW=588.34.
Figure USRE047589-20190903-C00022
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), Phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (249 mg, 0.9 mmol), NMI (2.8 mmol, 190 μL) in THF (4 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (145 mg, yield 55%).
31P-NMR (CDCl3, 121 MHz): δ 4.48, 4.86.
1H-NMR (CDCl3, 300 MHz): δ 7.65 (1H, 2×s, H-6), 7.44-7.39 (1H, 2d, 3J=13 Hz, H-5b), 7.35-7.10 (5H, m, OPh), 6.78-6.65 (1H, 2d, 3J=13 Hz, H-5a), 6.35-6.25 (1H, 2t, 3J=6 Hz, H1′), 4.62-3.95 (8H, m, H-5′, H-3′, H-4′, CHala, NH, CH3CH 2O), 2.49-2.40 (1H, m, one of H-2′), 2.10-2.00 (1H, m, one of H-2′), 1.40 (3H, d, 3J=7 Hz, CH3 ala), 1.25 (3H, 2t, 3J=7 Hz, CH 4CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O) 21.2, 21.1 (CH3ala), 40.9, 40.7 (C-2′), 50.8, 50.7 (CHala), 62.2, 62.1 (CH3 CH2O), 66.5, 66.3 (C-5′), 70.9, 70.6 (C-3′), 86.0, 85.6 (C-1′, C-4′), 110.1 (C-5b), 111.8 (C-5), 120.6 (‘o’, OPh), 125.0 (‘p’, OPh), 129.0 (C-5a), 130.2 (‘m’, OPh), 138.2 (C-6), 149.9 (C-4), 150.7 (‘ipso’, OPh), 162.3 (C-2), 174.2, 174.1 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(benzoxy-L-alaninyl)]-phosphate (CPF 2)
C27H29BrN3O9P, MW=649.08.
Figure USRE047589-20190903-C00023
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), Phenyl-(benzyloxy-L-alaninyl)-phosphorochloridate (249 mg, 0.9 mmol), NMI (2.8 mmol, 190 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (228 mg, yield 78%).
31P-NMR (CDCl3, 121 MHz): δ 4.74, 4.44.
1H-NMR (CDCl3, 300 MHz): δ 10.31 (1H, bs, H-3), 7.63 (1H, 2×s, H-6), 7.45-7.14 (11H, m, OPh+CH2 Ph, H-5b), 6.75-6.66 (1H, 2d, 3J=14 Hz, H-5a), 6.30-6.25 (1H, m, H-1′), 5.18-50.9 (1H, s, CH 2Ph), 4.70-4.04 (6H, m, H-3′, H-5′,H-4′, NH, CHala), 2.42 (1H, m, one of H-2′), 2.02 (1H, m, one of H-2′), 1.40 (3H, d, 3J=7 Hz, CH3ala).
13C-NMR (CDCl3, 75 MHz): δ 20.7, 20.8 (CH3ala), 40.4 (C-2′), 50.4 (CHala), 66.0 (C-5′) 67.4 (CH2Ph), 70.6 (C-3′), 85.4, 85.5, 85.6, 85.8 (C-1′, C-4′), 109.9 (C-5b), 111.5 (C-5b), 120.2 (‘o’, OPh), 125.4 (‘p’, OPh), 128.5, 128.6, 129.9 (‘m’ OPh, Bn, C-5a), 135.1(‘ipso’, CH2 Ph) 137.8 (C-6), 149.8 (C-4) 150.2 (‘ipso’, OPh), 161.8 (C-2), 173.6 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-fluorophenyl-(methoxy-L-alaninyl)]-phosphate (CPF 5)
C21H24BrFN3O9P, MW=592.31.
Figure USRE047589-20190903-C00024
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-fluorophenyl-(methoxy-L-alaninyl)-phosphorochloridate (442 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (177 mg, yield 50%).
31P-NMR (CDCl3, 121 MHz): δ 5.10, 4.81.
1H-NMR (CDCl3; 300 MHz): δ 10.1 (1H, bs, H-3), 7.60 (1H, 2×s, H-6), 7.39-7.32 (1H, 2d, 3J=14 Hz, H-5b), 7.20-6.95 (4H, m, OPh), 6.70-6.60 (1H, 2d, 3J=14 Hz, H-5a), 6.30-6.15 (1H, 2t, 3J=6 Hz, H1′), 4.55-4.29 (3H, m, H-5′+H-3′), 4.15 (1H, NH), 4.05-3.85 (2H, H-4′, CHala), 3.72 (3H, 2s, CH3O), 2.49-2.32 (1H, m, one of H-2′), 2.15-2.05 (1H, m, one of H-2′), 1.35 (3H, 2d, 3J=6 Hz, CH3 ala).
13C-NMR (DMSO; 75 MHz): δ 21.2 (CH3 ala), 40.8 (C-2′), 50.8, 50.6 (CH[CH3]), 53.2 (CH3O), 66.7, 66.3 (C-5′), 71.9, 71.8 (C-3′), 86.1, 85.7, 85.8 (C-1′, C-4′), 110.3 (C-5b), 111.9 (C-5), 117.0, 116.7 (‘o’, OPh), 122.0 (‘m’, OPh), 128.2 (C-5a), 138.2 (C-6), 149.0 (‘ipso’, OPh) 149.9 (C-4), 158.5 (‘p’, OPh), 163.2(C-2), 175.1 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-fluorophenyl-(ethoxy-L-alaninyl)]-phosphate (CPF 6)
C22H26BrFN3O9P, MW=606.33.
Figure USRE047589-20190903-C00025
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-fluorophenyl-(ethoxy-L-alaninyl)-phosphorochloridate (464 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (240 mg, yield 66%).
31P-NMR (CDCl3, 121 MHz): δ 5.14, 4.88.
1H-NMR (CDCl3, 300 MHz): δ 10.25 (1H, bs, H-3), 7.85 (1H, 2×s, H-6), 7.44-7.39 (1H, 2d, 3J=14 Hz, H-5b), 7.3-7.0 (4H, m, OPh), 6.8-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.35-6.25 (1H, 2t, 3J=6 Hz, H1′), 4.6-4.1 (6H, m, H-5′, H-3′, CHala, NH, CH3CH 2O), 4.02 (1H, m, H-4′), 2.55-2.45 (1H, m, one of H-2′), 2.20-2.10 (1H, m, one of H-2′), 1.40 (3H, d, 3J=8 Hz, CH3 ala), 1.25 (3H, 2t, 3J=7 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O) 21.3 (CH3ala), 40.8, 40.7 (C-2′), 50.8, 50.7 (CHala), 62.3 (CH3 CH2O), 66.7, 66.3 (C-5′), 71.1, 70.7 (C-3′), 86.1, 85.8, 85.6, 85.4 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 117.0 (‘o’, OPh), 122.2 (‘m’, OPh), 128.9 (C-5a), 138.2 (C-6), 146.4 (‘ipso’, OPh), 149.9 (C-4), 158.5 (‘p’, OPh), 162.2, 161.8 (C-2), 174.2 (COOCH2CH3).
Synthesis of (E-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-fluorophenyl-(benzoxy-L-alaninyl)]-phosphate (CPF 7)
C27H28BrFN3O9P, MW=668.40.
Figure USRE047589-20190903-C00026
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-fluorophenyl-(benzyloxy-L-alaninyl)-phosphorochloridate (556 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (256 mg, yield 64%).
31P-NMR (CDCl3, 121 MHz): δ 4.74, 4.44.
1H-NMR (CDCl3, 300 MHz): δ 7.69 (1H, 2×s, H-6), 7.45-7.39 (1H, 2d, 3J=14 Hz, H-5b), 7.37-7.00 (9H. m, OPh+CH2 Ph), 6.75-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.30-6.2 (1H, 2t, 3J=6 Hz, H-1′), 5.2 (1H, 2s, CH 2Ph), 4.85-4.00 (6H, m, H-3′, H-5′,H-4′, NH, CHala), 2.47 (1H, m, one of H-2′), 2.0-2.15 (1H, m, one of H-2′), 1.38 (3H, d, 3J=7 Hz, CH3ala).
13C-NMR (CDCl3, 75 MHz): δ 21.2, 21.1 (CH3ala), 40.7 (C-2′), 50.4 (CHala), 66.7, 66.4 (C-5′), 67.8 (CH2Ph), 71.1, 70.7 (C-3′), 86.0, 85.7, 85.4, 85.3 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 117.0 (‘o’, OPh), 122.0 (‘m’, OPh), 128.7, 128.6 (Bn, C-5a), 135.4(‘ipso’, CH2 Ph) 138.2 (C-6), 146.5 (‘ipso’, OPh), 149.9 (C-4), 158.5 (‘p’ OPh), 162.2 (C-2), 173.9 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2 ′-deoxyuridine-5′-[para-nitrophenyl-(methoxy-L-alaninyl)]-phosphate (CPF 10)
C21H24BrN4O11P, MW=619.31.
Figure USRE047589-20190903-C00027
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-nitrophenyl-(methoxy-L-alaninyl)-phosphorochloridate (483 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (211 mg, yield 57%).
31P-NMR (CDCl3, 121 MHz): δ 4.95.
1H-NMR (MeOD; 300 MHz): δ 8.3-8.2 (2H, m, OPh) 7.8-7.75 (1H, 2×s, H-6), 7.35-7.30, 7.55-7.4 (2H, m, OPh), 7.35-7.30 (1H, 2d, 3J=14 Hz, H-5b), 6.80-6.70 (1H, 2d, 3J=14 Hz, H-5a), 6.30-6.2 (1H, 2t, 3J=6 Hz, H1′), 4.5-4.3 (3H, m, H-5′,H-3′), 4.2-4.0 (2H, m, H-4′, CHala), 3.72 (3H, 2s, CH3O), 2.35-2.15 (2H, n, 2 H-2′), 1.35 (3H, 2d, 3J=7 Hz, CH3 ala).
13C-NMR (DMSO; 75 MHz): δ 20.9 (CH3 ala), 41.6, 41.5 (C-2′), 52.0, 51.9 (CH[CH3)), 53.4 (CH3O), 68.5 (C-5′), 72.4, 72.3 (C-3′), 87.7, 87.4, 87.0, 86.9 (C-1′, C-4′), 109.8 (C-5b), 112.8 (C-5), 122.6 (‘o’, OPh), 127.1 (‘m’, OPh), 130.8 (C-5a), 140.3 (C-6), 146.5 (‘ipso’, OPh), 151.4 (C-4), 157.2 (‘p’, OPh), 163.9 (C-2), 175.8, 175.5 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-nitrophenyl-(ethoxy-L-alaninyl)]-phosphate (CPF 9)
C22H26BrN4O11P, MW=633.34.
Figure USRE047589-20190903-C00028
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-nitrophenyl-(ethoxy-L-alaninyl)-phosphorochloridate (504 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 1 hr. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (232 mg, yield: 61%).
31P-NMR (CDCl3, 121 MHz): δ 4.28.
1H-NMR (CDCl3, 300 MHz): δ 10.25 (1H, bs, H-3), 8.25-8.2 (2H, 2d, 3J=9 Hz OPh), 7.7 (1H, 2×s, H-6), 7.5-7.45 (2H, 2d, 3J=9 Hz, OPh), 7.4-7.35 (1H, 2d, 3J=14 Hz, H-5b), 6.7-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.3-6.2 (1H, 2t, 3J=6 Hz, H1′), 4.8-4.1 (7H, m, H-5′, H-4′ H-3′, CHala, NH, CH3CH2O), 2.45-2.4 (1H, m, one of H-2′), 2.20-2.10 (1H, m, one of H-2′), 1.40 (3H, d, 3J=8 Hz, CH3 ala), 1.3 (3H, 2t, 3J=7 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O) 21.1 (CH3ala), 40.6 (C-2′), 50.8, 50.7 (CHala), 62.5 (CH3 CH2O), 66.9, 66.8 (C-5′), 71.2, 70.9 (C-3′), 86.3, 85.9, 85.4, 85.3 (C-1′, C-4′), 110.3 (C-5b), 111.8 (C-5), 121.3 (‘o’, OPh), 126.1 (‘m’, OPh), 128.8 (C-5a), 138.4 (C-6), 145.1 (‘ipso’, OPh), 149.9 (C-4), 155.5 (‘p’, OPh), 162.3 (C-2), 174.0, 173.9 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-nitrophenyl-(benzoxy-L-alaninyl)]-phosphate (CPF 8)
C27H28BrN4O11P, MW=695.41.
Figure USRE047589-20190903-C00029
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-nitrophenyl-(benzyloxy-L-alaninyl)-phosphorochloridate (597 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (228 mg, yield 55%).
31P-NMR (CDCl3, 121 MHz): δ 4.74, 4.44.
1H-NMR (CDCl3, 300 MHz): δ 10.4-10.3 (1H, bs, H-3), 8.2-8.1 (2H, m, OPh), 7.69 (1H, 2×s, H-6), 7.4-7.2 (1H, 2d, 3J=14 Hz, H-5b), 7.37-7.00 (7H. m, OPh+CH2 Ph), 6.75-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.25-6.15 (1H, 2t, 3J=6 Hz, H-1′), 5.2 (1H, d, CH 2Ph), 4.87 (1H, m, H-3′), 4.6-4.2 (3H, m, H-5′, CHala) 4.2-4.00 (2H, m, H-4′, NH,), 2.55-2.45 (1H, m, one of H-2′), 2.2-2.05 (1H, m, one of H-2′), 1.38 (3H, d, 3J=7 Hz, CH3ala).
13C-NMR (CDCl3, 75 MHz): δ 21.2, 21.1 (CH3ala), 40.6 (C-2′), 50.9 (CHala), 67.1, 670 (C-5′), 68.0 (CH2Ph), 71.3, 70.9 (C-3′), 86.3, 86.0, 85.3, 85.2 (C-1′, C-4′), 110.4 (C-5b), 111.9, 111.8 (C-5), 121.3 (‘o’, OPh), 126.2-126.1 (‘m’, OPh), 129.1, 128.7, 128.6 (Bn, C-5a), 135.4 (‘ipso’, CH2 Ph), 138.3 (C-6), 145.1 (‘ipso’, OPh), 149.9 (C4), 155.6 (‘p’ OPh), 162.2 (C-2), 173.8,173.7 (COOBn).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[para-(trifluoromethyl)-phenyl-(methoxy-L-alaninyl)]-phosphate (CPF 15)
C22H24BrF3N3O9, MW=642.31.
Figure USRE047589-20190903-C00030
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), phenyl-(methoxy-L-alaninyl)-phosphorochloridate (518.8 mg, 1.5 mmol), NMI (246.3 mg, 3.0 mmol, 239 μL) in THF (5 mL) for 4 hrs. The crude product was purified by column chromatography, eluting with chloroform/methanol 97:3 to give the pure product as a white foamy solid (211.1 mg, yield 54.7%).
31P-NMR (MeOD, 121 MHz): δ 5.23, 5.07.
1H-NMR (MeOD, 300 MHz): δ 7.80 (1H, s, H-6), 7.70 (2H, d, 3J=8.7 Hz, OPh), 7.47-7.42 (2H, m, OPh), 7.37 (1H, d, 3J=13.6 Hz, H-5b), 6.82-6.78 (1H, d, 3J=13.6 Hz, H-5a), 6.30-6.23 (1H, m, H-1′), 4.52-4.29 (3H, m, H-3′+H-5′), 4.17-4.13 (1H, m, H-4′), 4.05-3.91 (1H, m, CHCH3), 3.67 (3H, s, OCH 3), 2.35-2.32 (1H, m, one of H-2′), 2.23-2.16 (1H, m, one of H-2′), 1.37-1.34 (3H, d, 3J=7.1 Hz, CHCH 3.
13C-NMR (MeOD, 75 MHz): δ 20.6, 20.7, 20.8, 20.9 (CHCH3), 41.5, 41.7 (C-2′), 51.9, 52.0 (CHCH3), 68.2, 68.3 (C-5′), 72.4, 72.5 (C-3′), 87.1, 87.2, 87.4, 87.6 (C-1′, C-4′), 109.7 (C-5b), 112.6 (C-5), 122.5, 122.7 (‘o’, OPh), 125.8 (CF3, J=269 Hz), 128.7 (‘m’, OPh), 128.8 (‘p’, J=33 Hz, OPh), 130.9 (C-5a), 140.3 (C-6), 151.4, 151.5 (‘ipso’, OPh), 155.1, 155.2 (C-4), 164.0 (C-2), 175.6, 175.9, (COOCH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[para-(trifluoromethyl)-phenyl-ethoxy-L-alaninyl)]-phosphate (CPF 25)
C23H26BrF3N3O9P, MW=656.34.
Figure USRE047589-20190903-C00031
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (539.5 mg, 1.5 mmol), NMI (246.3 mg, 3.0 mmol, 239 μL) in THF (5 mL) for 20 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 95:5 to give the pure product as a white foamy solid (172.6 mg, yield 43.8%).
31P-NMR (CDCl3, 121 MHz): δ 4.65, 4.35.
1H-NMR (CDCl3, 300 MHz): δ 10.05 (1H, s, H-3), 7.69-7.64 (3H, m, H-6+OPh), 7.46-7.39 (3H, m, OPh+H-5b), 6.76-6.68 (1H, 2d, 3J=13.6 Hz, H-5a), 6.34-6.25 (1H, m, H-1′), 4.57-4.35 (4H, m, H-3′+H-5′+NH, 4.27-4.13 (4H, m, H-4′+OCH 2CH3+OH-3′), 4.12-3.98 (1H, m, CHCH3), 2.53-2.47 (1H, m, one of H-2′), 2.21-2.12 (1H, m, one of H-2′), 1.43-1.40 (3H, d, 3J=7.0 Hz, CHCH 3), 1.28, 1.27 (3H, 2t, 3J=7.0 Hz, OCH2CH 3)
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 21.2, 21.3 (CHCH 3), 40.7 (C-2′), 50.8, 50.9 (CHCH3), 62.4 (CH3 CH2O), 66.3, 66.7 (C-5′), 70.7, 71.1 (C-3′), 85.3, 85.4, 85.8, 86.1 (C-1′, C-4′), 110.5 (C-5b), 112.0 (C-5), 122.0 (‘o’, OPh), 124.2 (CF3, J=271 Hz), 127.7, 127.8, 128.7 (‘m’, ‘p’, OPh), 128.8 (C-5a), 138.0 (C6), 149.7 (‘ipso’, OPh), 153.2 (C-4), 161.9 (C-2), 174.0, 174.1 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-trifluorophenyl-(benzoxy-L-alaninyl)]-phosphate (CPF 4)
C28H28BrF3N3O9P, MW=718.41.
Figure USRE047589-20190903-C00032
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-trifluorophenyl-(benzyloxy-L-alaninyl)-phosphorochloridate (632 mg, 1.5 5 mmol), NMI (4.98 mmol, 332 μL) in THF (6 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (308 mg, yield 71%).
31P-NMR (CDCl3, 121 MHz): δ 5.31, 4.87.
1H-NMR (CDCl3, 300 MHz): δ 10.05 (1H, bs, H-3), 7.7, 7.25 (11H. m, H-5b, H-6 OPh+CH2 Ph), 6.75-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.35-6.2 (1H, 2t, 3J=6 Hz, H-1′), 5.15 (1H, 2s, CH 2Ph), 4.6-4.25 (4H, m, H-5′, H-3′, CHala) 4.2-4.00 (2H, m, H-4′, NH,), 2.55-2.4 (1H, m, one of H-2′), 2.2-2.05 (1H, m, one of H-2′), 1.38 (3H, d, 3J=7 Hz, CH3ala).
13C-NMR (CDCl3, 75 MHz): δ 21.2, 21.1 (CH3ala), 40.7 (C-2′), 50.9, 50.8 (CHala), 67.1, 67.0 (C-5′), 68.0 (CH2Ph), 71.2, 70.9 (C-3′), 86.1, 85.8, 85.5, 85.4 (C-1′, C-4′), 110.2 (C-5b), 111.9, 111.8 (C-5), 121.1 (‘o’, OPh), 125.1 (d, J=270 Hz, CF3), 127.6 (‘m’, OPh), 129.1, 128.7, 128.6 (Bn, C-5a), 130.1 (‘p’,q, J=32 Hz, OPh) 135.4 (‘ipso’, CH2 Ph) 138.2 (C-6), 150.2, 150.1 (C4), 153.6 (‘ipso’ OPh), 162.7 (C-2), 173.9, 173.6 (COOBn).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-chlorophenyl-(methoxy-L-alaninyl)]-phosphate (CPF 13)
C21H24BrClN3O9P, MW=608.76.
Figure USRE047589-20190903-C00033
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), 4-chlorophenyl-(methoxy-L-alaninyl)-phosphorochloridate (374.5 mg, 1.2 mmol), NMI (246.3 mg, 3.0 mmol, 239 μL) in THF (8 mL) for 5 hrs. The crude product was purified by column chromatography, eluting with Chloroform/Methanol 97:3 to give the pure product as a white foamy solid (139.0 mg, yield 38.0%).
31P-NMR (CDCl3, 121 MHz): δ 4.81, 4.54.
1H-NMR (CDCl3, 300 MHz): δ 10.11 (1H, bs, H-3), 7.68 (1H, s, H-6), 7.46-7.40 (1H, d, 3J=13.6 Hz, H-5b), 7.35-7.20 (4H, m, OPh), 6.76-6.67 (1H, 2d, 3J=13.6 Hz, H-5a), 6.34-6.24 (1H, m, H-1′), 4.58-4.40 (5H, m, H-3′+H-5′+NH), 4.36-4.19 (1H, m, H-4′), 4.07-3.99 (1H, m, CHCH3), 3.75 (3H, s, OCH 3), 2.49-2.48 (1H, m, one of H-2′), 2.17-2.15 (1H, m, one of H-2′), 1.42-1.39 (3H, d, 3J=7.0 Hz, CHCH 3).
13C-NMR (CDCl3, 75 MHz): δ 21.2 (CHCH 3), 40.7, 40.8 (C-2′), 50.6, 50.8 (CHCH3), 53.2, 53.3 (OCH3), 66.4, 66.7 (C-5′), 70.8, 71.2 (C-3′), 85.4, 85.5, 85.8, 86.2 (C-1′, C-4′), 110.5 (C-5b), 111.9, 112.0 (C-5), 122.0 (‘o’, OPh), 128.9 (C-5a), 130.3 (‘m’, OPh), 131.1 (‘p’, OPh), 138.2 (C-6), 149.1, 149.2 (‘ipso’, OPh), 149.8 (C-4), 162.1, 162.2 (C-2), 174.5, 174.6 (COOCH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-chlorophenyl-(ethoxy-L-alaninyl)]-phosphate (CPF 11)
C22H26BrN3O9P, Mw=622.79.
Figure USRE047589-20190903-C00034
This was synthesised according to Standard procedure 5, using BVdU (300 mg, 0.90 mmol), 4-chlorophenyl-(ethoxy-L-alaninyl)-phosphorochloridate (557.7 mg, 1.71 mmol), NMI (221.7 mg, 2.7 mmol, 215 μL) in THF (10 mL) for 16 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (168.4 mg, yield 30.0%).
31P-NMR (CDCl3, 121 MHz): δ 4.88, 4.65.
1H-NMR (CDCl3, 300 MHz): δ 9.51 (1H, bs, H-3), 7.69-7.68 (1H, 2s, H-6), 7.49-7.43 (1H, 2d, 3J=13.6 Hz, H-5b), 7.37-7.22 (4H, m, OPh), 6.79-6.71 (1H, 2d, 3J=13.6 Hz, H-5a), 6.33-6.24 (1H, m, H-1′), 4.62-4.34 (3H, m, H-3′+H-5′), 4.28-3.89 (5H, m, H-4′+OCH 2CH3+CHCH3+NH), 2.59-2.45 (1H, m, one of H-2′), 2.22-2.14 (1H, m, one of H-2′), 1.43-1.41 (3H, d, 3J=7.0 Hz, CHCH 3), 1.33-1.28 (3H, 2t, 3J=7.2 Hz, OCH2CH 3).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 21.2, 21.3 (CHCH3), 40.7 (C-2′), 50.7, 50.8 (CHCH3), 62.4 (CH3 CH2O), 66.7 (C-5′), 70.8, 71.2 (C-3′), 85.4, 85.8, 86.1 (C-1′, C-4′), 110.4 (C-5b), 112.0 (C-5), 122.0, 122.1 (‘o’, OPh), 128.9 (C-5a), 130.3 (‘m’, OPh), 131.1 (‘p’, OPh), 138.2 (C-6), 149.2 (‘ipso’, OPh), 150.0 (C-4), 162.2 (C-2), 174.1, 174.2 (COOCH2CH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-chlorophenyl-(benzoxy-L-alaninyl)]-phosphate (CPF 12)
C22H26BrN3O9P, MW=622.79.
Figure USRE047589-20190903-C00035
This was synthesised according to Standard procedure 5, using BVdU (300 mg, 0.90 mmol), 4-chlorophenyl-(benzoxy-L-alaninyl)-phosphorochloridate (698.7 mg, 1.80 mmol), NMI (369.5 mg, 4.5 mmol, 358.7 μL) in THF (10 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 95:5 to give the pure product as a white foamy solid (310.0 mg, yield 50.3%).
31P-NMR (CDCl3, 121 MHz): δ 4.81, 4.53.
1H-NMR (CDCl3, 300 MHz): δ 10.10 (1H, bs, H-3), 7.65-7.63 (1H, 2s, H-6), 7.69-7.68 (1H, 2s, H-6), 7.46, 7.41 (1H, 2d, 3J=13.6 Hz, H-5b), 7.40-7.17 (9H, m, OPh), 6.75-6.66 (1H, 2d, 3J=13.6 Hz, H-5a), 6.33-6.23 (1H, 2t, 3J=6.0 Hz, H-1′), 5.17 (2H, s, CH 2Ph), 4.60-4.23 (4H, m, H-3′+H-5′+NH), 4.20-3.97 (2H, m, H-4′+CHCH3), 2.48-2.44 (1H, m, one of H-2′), 2.15-2.05 (1H, m, one of H-2′), 1.43-1.40 (3H, d, 3J=7.0 Hz, CHCH 3).
13C-NMR (CDCl3, 75 MHz): δ 21.2 (CHCH3), 40.7 (C-2′), 50.8, 50.9 (CHCH3), 66.6 (C-5′), 67.9 (CH2Ph), 70.7, 71.1 (C-3′), 85.4, 85.5, 85.8, 86.1 (C-1′, C-4′), 110.5 (C-5b), 111.9, 112.0 (C-5), 122.0, (‘o’, OPh), 128.7, 129.0, 129.1, 130.3 (‘m’, OPh+C-5a), 131.1 (‘ipso’, CH2 Ph), 135.4 (‘p’, OPh), 138.2 (C-6), 149.1 (‘ipso’, OPh), 150.0 (C-4), 162.1 (C-2), 173.9, 174.0 (COOCH2Ph).
Synthesis of (E)-5-(2-bromovinyl)2′-deoxyuridine-5′-[phenyl-(methoxy-α,α-dimethylglycinyl)]-phosphate (CPF 26)
C22H27BrN3O9P, MW 588.34.
Figure USRE047589-20190903-C00036
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), phenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate (437.5 mg, 1.5 mmol), NMI (246.3 mg, 3.0 mmol, 239.1 μL) in THF (5 mL) for 4 hrs. The crude product was purified by column chromatography, eluting with chloroform/methanol 97:3 to give the pure product as a white foamy solid (117 mg, yield 33.1%).
31P-NMR (CDCl3, 121 MHz): δ 3.36, 3.14
1H-NMR (CDCl3; 300 MHz): δ 9.91 (1H, bs, H-3), 7.73, 7.65 (1H, 2s, H-6), 7.50-7.43 (1H 2d, 3J=13.6 Hz, H-5b), 7.41-7.02 (5H, m, OPh), 6.81-6.71 (1H, 2d, 3J=13.6 Hz, H-5a), 6.34-6.28 (1H, m, H1′), 4.55-4.17 (6H, m, H-5′+H-4′+H-3′, NH, OH-3′), 3.78 (3H, s, CH 3O), 2.53-2.39 (1H, m, one of H-2′), 2.25-1.99 (1H, m, one of H-2′), 1.60 (6H, s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 27.5, 27.4, 27.2 ([CH3]2C), 40.7, 40.6 (C-2′), 53.5 (CH3O), 57.6 (C[CH3]2), 66.5, 66.2 (C-5′), 70.7, 71.1 (C-3′), 85.4, 85.6, 85.5, 85.9 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 120.5, 120.6 (‘o’, OPh), 125.7 (‘p’, OPh), 128.9 (C-5a), 130.3 (‘m’, OPh), 138.0, 138.3 (C-6), 149.8 (‘ipso’, OPh) 150.9, 150.8 (C-4), 162.0, 162.1 (C-2), 176.4, 176.2 (COOCH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[phenyl-(ethoxy-α,α-dimethylglycinyl)]-phosphate (CPF 27)
C23H29BrN3O9P, MW=602.37
Figure USRE047589-20190903-C00037
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), phenyl-(ethyl-2-amino-2-methylpropanoate)-phosphorochloridate (458.0 mg, 1.5 mmol), NMI (246.3 mg, 3.0 mmol, 239.1 μL) in THF (5 mL) for 5 hrs. The crude product was purified by column chromatography, eluting with chloroform/methanol 97:3 to give the pure product as a white foamy solid (106 mg, yield 29.3%).
31P-NMR (MeOD, 121 MHz): δ 3.91, 3.85
1H-NMR (MeOD, 300 MHz): δ 7.84, 7.81 (1H, 2s, H-6), 7.44-7.20 (6H, m, OPh+H-5b), 6.88-6.81 (1H, 2d, 3J=13.6 Hz, H-5a), 6.34-6.28 (1H, m, H-1′), 4.50-4.34 (3H, m, H-5′+H-3′), 4.23-4.15 (3H, m, H-4′+CH3CH 2O), 2.38-2.28 (1H, m, one of H-2′), 2.22-2.09 (1H, m, one of H-2′), 1.51 (6H, s, [CH 3]2C), 1.29 (3H, t,3J=7 Hz, CH 3CH2O)
13C-NMR (MeOD, 75 MHz): δ 14.9 (CH3CH2O) 27.9, 28.3 ([CH3]2C), 41.5 (C-2′), 58.51 (C[CH3]2), 63.1 (CH3 CH2O), 68.2 (C-5′), 72.6 (C-3′), 87.1, 87.4 (C-1′, C-4′), 109.6 (C-5b), 112.7 (C-5b), 122.0, 122.1, 122.2, (‘o’, OPh), 126.7 (‘p’, OPh), 131.0, 131.2 (C-5a, ‘m’ OPh), 140.4 (C-6), 151.4 (‘ipso’, OPh) 152.5 (C-4), 164.0 (C-2), 177.2 (COOCH2CH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[phenyl-(benzoxy-α,α-dimethylglycinyl)]-phosphate (CPF 14)
C28H31BrN3O9P, MW=664.44.
Figure USRE047589-20190903-C00038
This was synthesised according to Standard procedure 5, using BVdU (242 mg, 0.73 mmol), phenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate (533.0 mg, 2.0 mmol), NMI (298.0 mg, 3.63 mmol, 289 μL) in THF (5 mL) for 4 hrs. The crude product was purified by column chromatography, eluting with chloroform/methanol 97:3 to give the pure product as a white foamy solid (129.0 mg, yield 26.7%).
31P-NMR (CDCl3, 121 MHz): δ 3.39, 3.12.
1H-NMR (CDCl3, 300 MHz): δ 9.92 (1H, bs, H-3), 7.67-7.60 (1H, 2s, H-6), 7.48-7.41 (1H, 2d, 3J=13.6 Hz, H-5b), 7.40-7.16 (10H. m, OPh+CH2 Ph), 6.78-6.67 (1H, 2d, 3J=13.6 Hz, H-5a), 6.31-6.25 (1H, m, H-1′), 5.18 (1H, s, CH 2Ph), 4.50-4.09 (6H, m, H-3′+H-5′+H-4′, NH, OH-3′), 2.48-2.25 (1H, m, one of H-2′), 2.16-1.82 (1H, m, one of H-2′), 1.60 (6H, s, [CH 3]2C).
13C-NMR (CDCl3, 75 MHz): δ 27.3, 27.4, 28.5 ([CH3]2C), 40.6, 40.7 (C-2′), 57.6, 57.6 (C[CH3]2), 66.2, 66.5 (C-5′), 68.1 (CH2Ph), 70.6, 71.1 (C-3′), 85.4, 85.5, 85.6, 85.8 (C-1′, C-4′), 110.4 (C-5b), 112.0 (C-5), 120.4, 120.5, 120.6, 125.7, 128.4, 128.5, 128.8, 128.9, 130.3 (OPh, C-5a), 135.7(‘ipso’, CH2 Ph) 138.1, 138.3 (C-6), 149.8, 150.8, 150.9 (‘ipso’ OPh, C-4), 162.1 (C-2), 177.5, 175.7 (COOCH2Ph).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-nitrophenyl-(methoxy-α,α-dimethylglycinyl)]-phosphate (CPF 45)
C22H26BrN4O11P, MW=633.34.
Figure USRE047589-20190903-C00039
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), 4-nitrophenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate (378.8 5 mg, 1.13 mmol), NMI (184.7 mg, 2.25 mmol, 179.4 μL) in THF (5 mL) for 3 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (145.7 mg, yield 50.9%).
31P-NMR (MeOD, 121 MHz): δ 3.61, 3.56.
1H-NMR (MeOD, 300 MHz): δ 8.30-8.25 (2H, 2d, 3J=9.0 Hz, OPh), 7.79-7.78 (1H, 2s, H-6), 7.49-7.46 (2H, d, 3J=9.0 Hz, OPh), 7.37-7.32 (1H, 2d, 3J=13.6 Hz, H-5b), 6.79-6.72 (1H, 2d, 3J=13.6 Hz, H-5a), 6.32-6.25 (1H, m, H-1′), 4.48-4.35 (3H, m, H-3′+H-5′), 4.15-4.14 (1H, m, H-4′), 3.71 (3H, s, CH 3O), 2.41-2.17 (2H, m, H-2′), 1.51 (6H, s, [CH 3]2C.
13C-NMR (CDCl3, 75 MHz): δ 28.0, 28.1, 28.2, 28.3 ([CH3]2C), 41.4, 41.5 (C-2′), 53.6 (CH3O), 58.7 (C[CH3]2), 68.5 (C-5′), 72.3, 72.4 (C-3′), 86.9, 87.0, 87.4, 87.5 (C-1′, C-4′), 109.7 (C-5b), 112.6 (C-S), 122.8, 122.9 (‘o’, OPh), 127.0 (‘m’, OPh), 130.9 (C-5a), 140.5 (C-6),146.5 (‘p’, OPh), 151.5 (‘ipso’, OPh), 157.3 (C-4), 164.0 (C-2), 177.5 (COOCH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-nitrophenyl-(ethoxy-α,α-dimethylglycinyl)]-phosphate (CPF 46)
C23H28BrN4O11P, MW=647.3.
Figure USRE047589-20190903-C00040
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), 4-nitrophenyl-(ethyl-2-amino-2-methylpropanoate)-phosphorochloridate (442.1 mg, 1.26 mmol), NMI (184.7 mg, 2.25 mmol, 179.4 μL) in THF (5 mL) for 4 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (152.9 mg, yield 52.5%).
31P-NMR (CDCl3, 121 MHz): δ 3.00, 2.96.
1H-NMR (CDCl3, 300 MHz): δ 10.28 (1H, bs, H-3), 8.25.-8.12 (2H, 2d, 3J=9.0 Hz, OPh), 7.68-7.67 (1H, 2s, H-6), 7.46-7.32 (3H, m, OPh+H-5b), 6.69-6.67 (1H, 2d, 3J=13.5 Hz, H-5a), 6.32-6.26 (1H, m, H-1′), 4.75-4.36 (5H, m, H-3′+H-5′+NH), 4.25-4.17 (3H, m, OCH 2CH3, H-4′), 2.60-2.98 (1H, m, one of H-2′), 2.31-2.10 (1H, m, one of H-2′), 1.58 (6H, s, [CH 3]2C), 1.30-1.28 (3H, 2t, 3J=7.1 Hz, OCH2CH 3).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 27.1, 27.2, 27.3, 27.4 ([CH3]2C), 40.6 (C-2′), 57.7 (C[CH3]2), 62.7 (CH3 CH2O), 67.0 (C-5′), 71.0, 71.2 (C-3′), 85.4, 85.9, 86.1 (C-1′, C-4′), 110.3 (C-5b), 111.9 (C-5), 121.2, 121.3 (‘o’, OPh), 126.2 (‘m’, OPh), 128.8 (C-5a), 138.4 (C-6), 145.0 (‘p’, OPh), 150.0 (C-4), 155.7-155.9 (‘ipso’, OPh), 162.2 (C-2), 175.0-175.1 (COOCH2CH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-nitrophenyl-(benzoxy-α,α-dimethylglycinyl)]-phosphate (CPF 47)
C28H30BrN4O11P, MW=709.44.
Figure USRE047589-20190903-C00041
This was synthesised according to Standard procedure 5, using BVdU (100 mg, 0.30 mmol), 4-nitrophenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate (309.6 mg, 1.07 mmol), NMI (123.7 mg, 1.5 mmol, 120.1 μL) in THF (5 mL) for 5 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (160.2 mg, yield 50.2%).
31P-NMR (CDCl3, 121 MHz): δ 2.95, 2.89.
1H-NMR (CDCl3, 300 MHz): δ 10.16 (1H, bs, H-3), 8.26-8.24 (2H, 2d, 3J=9.1 Hz, OPh), 7.71-7.69 (1H, 2s, H-6), 7.48-7.37 (8H, m, OPh+CH2 Ph, H-5b), 6.75-6.72 (1H, 2d, 3J=13.5 Hz, H-5a), 6.36-6.29 (1H, m, H-1′), 5.24 (2H, s, CH 2Ph), 4.81-4.40 (5H, m, H-3′+H-5′+OH-3′, NH, 4.22-4.21 (1H, m, H-4′), 2.57-2.36 (1H, m, one of H-2′) 2.27-2.22 (1H, m, one of H-2′), 1.64 (6H, s, [CH 3]2C).
13C-NMR (CDCl3, 75 MHz): δ 27.4 ([CH3]2C), 40.6 (C-2′), 57.8 (C[CH3]2), 67.0 (C-5′), 68.2 (CH 2Ph), 71.1, 71.2 (C-3′), 85.3, 86.2 (C-1′, C-4′), 110.5 (C-5b), 111.9 (C-5), 111.9 (C-5), 121.2, 126.2, 128.5, 128.8, 129.0, 129.1 (‘o’, ‘m’, ‘p’, CH2 Ph+OPh+C-5a), 135.5 (‘ipso’, CH2 Ph), (C-5a), 138.4 (C-6), 145.0 (‘p’, OPh), 150.0 (C-4), 155.7 (‘ipso’, OPh), 162.2 (C-2), 175.4-175.5 (COOCH2Ph).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-chlorophenyl-(methoxy-α,α-dimethylglycinyl)]-phosphate (CPF 42)
C22H26BrClN3O9P, MW=622.79.
Figure USRE047589-20190903-C00042
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), 4-chlorophenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate (440.2 mg, 1.35 mmol), NMI (184.7 mg, 2.25 mmol, 179.4 μL) in THF (5 mL) for 6 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (146.7 mg, yield 56.5%).
31P-NMR (MeOD, 121 MHz): δ 3.98 (s).
1H-NMR (MeOD, 300 MHz): δ), 7.71-7.69 (1H, 2s, H-6), 7.31-7.13 (5H, m, OPh+H-5b) 6.73-6.66 (1H, 2d, 3J=13.6 Hz, H-5a), 6.23-6.16 (1H, m, H-1′), 4.39-4.22 (3H, m, H-3′+H-5′), 4.05-4.03 (1H, m, H-4′), 3.61 (3H, s, CH 3O), 2.29-2.19 (1H, m, one of H2′), 2.15-2.05 (1H, m, one of H-2′), 1.38 (6H, s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 28.0, 28.2, 28.3, 28.4 ([CH3]2C), 41.5, 41.6 (C-2′), 53.5, 53.6 (CH3O), 58.6 (C[CH3]2), 68.2 (C-5′), 72.4, 72.5 (C-3′), 87.1, 87.2, 87.3, 87.4 (C-1′, C-4′), 109.7 (C-5b), 112.7 (C-5), 123.7, 123.8 (‘o’, OPh), 130.9, 131.1 (‘m’, OPh+C-5a), 131.9 (‘p’, OPh), 140.4 (C-6), 151.1, 151.2, 151.4 (‘ipso’, OPh+C-4), 164.0 (C-2), 177.6, 177.7 (COOCH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-chlorophenyl-(ethoxy-α,α-dimethylglycinyl)]-phosphate (CPF 43)
C23H28BrClN3O9P, MW=636.81.
Figure USRE047589-20190903-C00043
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), 4-chlorophenyl-(ethyl-2-amino-2-methylpropanoate)-phosphorochloridate (413.3 mg, 1.22 mmol), NMI (184.7 mg, 2.25 mmol, 179.3 μL) in THF (5 mL) for 16 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (74 mg, yield 25.8%).
31P-NMR (CDCl3, 121 MHz): δ 3.47, 3.33.
1H-NMR (CDCl3, 300 MHz): δ 10.03-9.99 (1H, 2bs, H-3), 7.70-7.67 (1H, 2s, H-6), 7.47-7.43 (1H, 2d, 3J=13.6 Hz, H-5b), 7.35-7.20 (4H, m, OPh), 6.77-6.68 (1H, 2d, 3J=13.6 Hz, H-5a), 6.33-6.27 (1H, m, H-1′), 4.55-4.29 (5H, m, H-3′+H-5′+OH-3′+NH), 4.22-4.17 (2H, q, 3J=7.1 Hz, OCH 2CH3+H-4′), 2.53-2.42 (1H, m, one of H-2′), 2.22-2.08 (1H, m, one of H-2′), 1.57-1.54 (6H, 2s, [CH 3]2C), 1.31-1.30 (3H, 2t, 3J=7.1 Hz, OCH2CH 3).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 27.2, 27.3, 27.4 ([CH3]2C), 40.7 (C-2′), 57.6 (C[CH3]2), 62.6 (CH3 CH2O), 66.5, 66.6 (C-5′), 70.8, 71.1 (C-3′), 85.5, 85.74, 86.0 (C-1′, C-4′), 110.4 (C-5b), 112.0 (C-5), 121.9, 122.0, 122.1 (‘o’, OPh), 128.9, 130.2 (‘m’, OPh+C-5a), 130.9 (‘p’, OPh), 138.3 (C-6), 149.4 (‘ipso’, OPh), 149.9 (C-4), 162.1, 162.2 (C-2), 175.7-175.9 (COOCH2CH3).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[4-chlorophenyl-(benzoxy-α,α-dimethylglycinyl)]-phosphate (CPF 44)
C28H30BrClN3O9P, MW=698.88.
Figure USRE047589-20190903-C00044
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), 4-chlorophenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate (505.0 mg, 1.25 mmol), NMI (184.7 mg, 2.25 mmol, 179.3 μL) in THF (5 mL) for 16 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (134.8 mg, yield 42.9%).
31P-NMR (CDCl3, 121 MHz): δ 3.44, 3.26.
1H-NMR (CDCl3, 300 MHz): δ 9.96-9.93 (1H, 2bs, H-3), 7.66-7.65 (1H, 2s, H-6), 7.47-7.41 (1H, 2d, 3J=13.5, H-5b), 7.39-7.18 (9H, m, OPh+CH2 Ph) 6.74-6.69 (1H, 2d, 3J=13.5 Hz, H-5a), 6.31-6.25 (1H, m, H-1′), 5.19 (2H, CH 2Ph), 4.51-4.29 (4H, m, H-3′+H-5′+NH), 4.15-4.12 (2H, m, H-4′+OH-3′), 2.48-2.40 (1H, m, one of H-2′), 2.18-2.05 (1H, m, one of H-2′), 1.60-1.59 (6H, 2s, [CH 3]2C).
13C-NMR (CDCl3, 75 MHz): δ 27.1, 27.5 ([CH3]2C), 40.7 (C-2′), 57.7 (C[CH3]2), 66.4, 66.6 (C-5′), 68.2 (CH 2Ph), 70.7, 71.1 (C-3′), 85.4, 85.5, 85.7, 86.0 (C-1′, C-4′), 110.5 (C-5b), 112.0 (C-5), 121.9, 122.0, 128.4, 128.5, 128.9, 129.1 (‘o’, ‘m’, ‘p’, CH2 Ph+OPh+C-5a), 131.0 (‘ipso’, CH2 Ph), 135.6 (‘p’, OPh), 138.1 (C-6), 149.3 (‘ipso’, OPh), 149.8 (C-4), 162.1 (C-2), 175.6 (COOCH2Ph).
Synthesis of (E)-5-(2-bromovinyl)-2′-deoxyuridine-5′-[para-(trifluoromethyl)phenyl-(benzoxy-α,α-dimethylglycinyl)]-phosphate (CPF 48)
C29H30BrF3N3O9P, MW=732.44.
Figure USRE047589-20190903-C00045
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), 4-(trifluoromethyl)-phenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate (529.4.5 mg, 1.22 mmol), NMI (184.7 mg, 2.25 mmol, 179.4 μL) in THF (5 mL) for 4 hrs. The crude product was purified by column chromatography, eluting with dichloromethane/methanol 97:3 to give the pure product as a white foamy solid (142.1 mg, yield 43.1%).
31P-NMR (CDCl3, 121 MHz): δ 3.16, 3.01.
1H-NMR (CDCl3, 300 MHz): δ 10.06-10.02 (1H, 2bs, H-3), 7.67-7.66 (1H, s, H-6), 7.64-7.60 (2H, 2d, 3J=8.8 Hz, OPh), 7.46-7.32 (8H, m, OPh+CH2 Ph+H-5b), 6.77-6.68 (1H, 2d, 3J=13.6 Hz, H-5a), 6.31-6.26 (1H, m, H-1′), 5.18 (2H, s, CH 2Ph), 4.61-4.32 (4H, m, H-3′+H-5′+NH), 4.16-4.15 (2H, m, H-4′+OH-3′), 2.48-2.41 (1H, m, one of H-2′), 2.23-2.09 (1H, m, one of H-2′), 1.60-1.58 (6H, 2s, C[CH 3]2)
13C-NMR (CDCl3, 75 MHz): δ 27.0, 27.4, 27.5 (C[CH3]2), 40.6 (C-2′), 57.7, 57.8 (C[CH3)2), 66.8, 66.5 (C-5′), 68.2 (CH2Ph), 70.8, 71.1 (C-3′), 85.4, 85.7, 86.0 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 120.8, 120.9, 121.0, 127.6, 127.7, 128.0, 128.5, 128.8, 129.0 (‘o’, ‘m’, ‘p’, OPh+CH2 Ph+C-5a), 124.2 (CF3, J=267 Hz), 135.6 (‘ipso’, CH2 Ph), 138.2 (C-6),149.9 (C-4), 153.3 (‘ipso’, OPh), 162.1 (C-2),175.4 (COOCH2Ph).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(methoxy-α,α-cycloleucinyl)]-phosphate (CPF 16)
C24H29BrN3O9P, MW=614.38.
Figure USRE047589-20190903-C00046
This was synthesised according to Standard procedure 5, using BVdU (250 mg, 0.75 mmol), Phenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate (589 mg, 1.87 mmol), NMI (6.2 mmol, 415 μL) in THF (7 mL) for 3 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (234 mg, yield 51%).
31P-NMR (CDCl3, 121 MHz): δ 3.87, 3.82.
1H-NMR (CDCl3; 300 MHz): δ 10.35-10.2 (1H, bs, H-3), 7.65 (1H, 2×s, H-6), 7.44-7.39 (1H, 2d, 3J=13 Hz, H-5b), 7.37-7.15 (5H, m, OPh, 6.8 (1H, 2d, 3J=13 Hz, H-5a), 6.30 (1H, 2t, 3J=6 Hz, H1′), 4.4-4.2 (4H, m, H-5′, H-3′, NH), 4.1 (1H, H-4′), 3.72 (3H, 2s, CH3O), 2.49-2.40 (1H, m, one of H-2′), 2.35-2.01 (5H, m, one of H-2′+4H cyclopentane), 1.8-1.6 (4H, m, 4H cyclopentane).
13C-NMR (DMSO; 75 MHz): δ 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.2, 38.6, 38.5 (2CH2 cyclopent), 40.0 (C-2′), 53.2 (CH3O), 66.4 (Cq cyclopentane), 66.6 (C-5′), 70.9 (C-3′), 85.8, 85.6, 85.4, 85.3 (C-1′, C-4′), 110.2 (C-5b), 111.9 (C-5), 120.7-120.6 (‘o’, OPh, 125.7 (‘p’, OPh, 129.0 (C-5a), 130.2 (‘m’, OPh), 138.5 (C-6), 149.9 (C-4), 150.9, 150.8 (‘ipso’, OPh), 162.3(C-2), 176.3, 176.2 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(ethoxy-α, α-cycloleucinyl)]-phosphate (CPF 17)
C25H31BrN3O9P, MW=628.41.
Figure USRE047589-20190903-C00047
This was synthesised according to Standard procedure 5, using BVdU (250 mg, 0.75 mmol), Phenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate (642 mg, 1.87 mmol), NMI (6.2 mmol, 415 μL) in THF (7 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (258 mg, yield 55%).
31P-NMR (CDCl3, 121 MHz): δ 4.23, 4.1.
1H-NMR (CDCl3, 300 MHz): δ 10.3-10.1 (1H, bs, H-3), 7.8-7.75 (1H, 2×s, H-6), 7.51 (1H, 2d, 3J=14 Hz, H-5b), 7.45-7.10 (5H, m, OPh), 6.8 (1H, 2d, 3J=14 Hz, H-5a), 6.22 (1H, 2t, 3J=4 Hz, H1′), 4.55-4.05 (7H, m, H-5′, H-3′, H-4′, NH, CH3CH 2O), 2.50-2.40 (1H, m, one of H-2′), 2.35-1.95 (5H, m, one of H-2′+4H cyclopentane), 1.95-1.75 (4H, m, 4H cyclopentane), 1.25 (3H, 2t, 3J=7 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 24.5, 24,4 (2CH2 cyclopent), 39.2, 38.9 38.8, 38.4 (2CH2 cyclopent), 40.6 (C-2′), 62.2, 62.1 (CH3 CH2O), 66.2 (Cq cyclopentane), 66.6 (C-5′), 70.8 (C-3′), 85.7, 85.5 (C-1′, C-4′), 110.2 (C-5b), 111.5 (C-5), 120.7, 120.6 (‘o’, OPh, 125.6 (‘p’, OPh), 129.7 (C-5a), 130.2 (‘m’, OPh), 138.5, 138.3 (C-6), 149.7 (C-4), 150.9, 150.8 (‘ipso’, OPh), 162.3 (C-2),176.3 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(benzoxy-α, α-cycloleucinyl)]-phosphate (CPF 18)
C30H33BrN3O9P, MW=690.48.
Figure USRE047589-20190903-C00048
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.6 mmol), Phenyl-(benzyloxy-α,α-cycloleucinyl)-phosphorochloridate (589 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 10 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (127 mg, yield 31%).
31P-NMR (CDCl3, 121 MHz): δ 4.11, 4.01.
1H-NMR (CDCl3, 300 MHz): δ 10.2 (1H, bs, H-3), 7.8-7.6 (1H, 2×s, H-6), 7.45-7.4 (1H, 2d, 3J=14 Hz, H-5b), 7.40-7.10 (10H. m, OPh+CH2 Ph), 6.85 (1H, 2d, 3J=14 Hz, H-5a), 6.20 (1H, m, H-1′), 5.15 (1H, s, CH 2Ph), 4.4-4.2 (3H, m, H-3′,H-4′, NH), 4.1 (2H, m, H-5′), 2.45-2.35 (1H, m, one of H-2′), 2.35-1.95 (5H, m, one of H-2′+4H cyclopentane), 1.95-1.75 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3, 75 MHz): δ 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.9, 39.7 38.6, 38.5 (2CH2 cyclopent), 40.5 (C-2′), 66.2 (Cq cyclopentane), 66.5 (C-5′), 67.8 (CH2Ph), 70.8, 70.7 (C-3′), 85.7, 85.6, 85.5, 85.4 (C-1′, C-4′), 110.2 (C-5b), 111.8, 118.7 (C-5b), 120.7, 120.5 (‘o’, OPh), 125.7 (‘p’, OPh), 130.2, 129.0, 128.8, 128.7, 128.5 (‘m’ OPh, Bn, C-5a), 135.8(‘ipso’, CH2 Ph) 138.4, 138.2 (C-6), 149.8 (C-4), 150.9, 150.8 (‘ipso’, OPh), 162.2 (C-2), 175.7, 175.5 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-nitrophenyl-(methoxy-α,α-cycloleucinyl)]-phosphate (CPF 19)
C24H28BrN4O11P, MW=659.38.
Figure USRE047589-20190903-C00049
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-nitrophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate (543 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (239 mg, yield 60%).
31P-NMR (CDCl3, 121 MHz): δ 3.73.
1H-NMR (CDCl3; 300 MHz): δ 10.5-10.2 (1H, bs, H-3), 8.35-8.25 (2H, 2d, 3J=6 Hz OPh) 7.8-7.75 (1H, 2×s, H-6), 7.47 (2H, 2d, 3J=6 Hz, OPh), 7.45-7.35 (1H, 2d, 3J=14 Hz, H-5b), 6.75-6.67 (1H, 2d, 3J=14 Hz, H-5a), 6.30 (1H, 2t, 3J=6 Hz, H1′), 4.65-4.4 (3H, m, H-5′,H-3′), 4.25-4.20 (1H, m, H-4′), 3.79 (3H, s, CH3O), 2.6-2.4 (1H, m, one of H-2′), 2.3-1.98 (5H, m, one of H-2′+4H cyclopentane), 1.9-1.76 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.2, 39.1 (2CH2 cyclopent), 40.5 (C-2′), 53.4, 53.3 (CH3O), 66.8 (Cq cyclopentane), 67.1 (C-5′), 70.9 (C-3′), 86.1, 86.0, 85.5, 85.4 (C-1′, C-4′), 110.2 (C-5b), 111.8 (C-5), 121.3, 121.2 (‘o’, OPh), 126.2 (‘m’, OPh), 128.9 (C-5a), 138.6 (C-6), 144.9 (‘ipso’, OPh) 149.9 (C-4), 155.9, 155.8 (‘p’, OPh), 162.3 (C-2), 176.3 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-nitrophenyl-(ethoxy-α,α-cycloleucinyl)]-phosphate (CPF 20)
C25H30BrN3O11P, MW=673.4.
Figure USRE047589-20190903-C00050
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-nitrophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate (563 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 1 hr. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (240 mg, yield: 59%).
31P-NMR (CDCl3, 121 MHz): δ 3.83, 3.79.
1H-NMR (CDCl3, 300 MHz): δ 8.25-8.2 (2H,2d,3J=9 Hz OPh), 7.66 (1H, s, H-6), 7.4 (2H, 2d, 3J=9 Hz, OPh), 7.3 (1H, 2d, 3J=14 Hz, H-5b), 6.85 (1H, 2d, 3J=14 Hz, H-5a), 6.3-6.2 (1H, m, H1′), 4.7-4.45 (4H, m, H-5′, H-3′, NH), 4.2-4.05 (3H, m, H-4′, CH3CH 2O), 2.55-2.4 (1H, m, one of H-2′), 2.2-1.95 (5H, m, one of H-2′+4H cyclopentane), 1.95-1.8 (4H, m, 4H cyclopentane), 1.2 (3H, 2t, 3J=8 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.9 (CH3CH2O), 24.5, 24,4 (2CH2 cyclopent), 39.1, 39.0, 38.8 (2CH2 cyclopent), 40.7 (C-2′), 62.4 (CH3 CH2O), 66.5 (Cq cyclopentane), 67.0 (C-5′), 70.9 (C-3′), 85.9, 85.4 (C-1′, C-4′), 110.2 (C-5b), 111.8 (C-5), 121.3 (‘o’, OPh), 126.2 (‘m’, OPh), 128.8 (C-5a), 138.5 (C-6), 144.9 (‘ipso’, OPh), 149.9 (C-4), 155.5 (‘p’, OPh), 162.3 (C-2), 175.8, 175.7 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-nitrophenyl-(benzoxy-α,α-cycloleucinyl)]-phosphate (CPF 21)
C30H32BrN4O11P, MW=735.47.
Figure USRE047589-20190903-C00051
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-nitrophenyl-(benzyloxy-α,α-cycloleucinyl)-phosphorochloridate (656 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 3 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (269 mg, yield 61%).
31P-NMR (CDCl3, 121 MHz): δ 3.72.
1H-NMR (CDCl3, 300 MHz): δ 10.3 (1H, bs, H-3), 8.22-8.12 (2H, 2d, J=7 Hz, OPh), 7.65 (1H, 2×s, H-6), 7.45-7.30 (8H, m, H-5b+OPh+CH2 Ph), 6.72-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.28 (1H, 2t, 3J=6 Hz, H-1′), 5.15 (1H, d, CH 2Ph), 4.6-4.35 (4H, m, H-3′, H-5′, H-4′, NH,), 2.55-2.4 (1H, m, one of H-2′), 2.3-1.92 (5H, m, one of H-2′+4H cyclopentane), 1.85-1.6 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3, 75 MHz): δ 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.1, 38.9, 38.7 (2CH2 cyclopent), 40.5 (C-2′), 66.9 (cyclopentane), 67.1 (C-5′), 68.0 (CH2Ph), 70.9 (C-3′), 85.3, 85.0 (C-1′, C-4′), 110.3 (C-5b), 111.8 (C-5), 121.2 (‘o’, OPh), 126.1 (‘m’, OPh), 129.0, 128.8 (Bn, C-5a), 135.7 (‘ipso’, CH2 Ph), 138.5 (C-6), 144.9 (‘ipso’, OPh), 149.9 (C-4), 155.8 (‘p’ OPh), 162.3 (C-2), 175.6 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-fluorophenyl-(methoxy-α,α-cycloleucinyl)]-phosphate (CPF 22)
C24H28BrFN3O9P, MW=632.37.
Figure USRE047589-20190903-C00052
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-fluorophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate (503 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (251 mg, yield 66%).
31P-NMR (CDCl3, 121 MHz): δ 4.22.
1H-NMR (CDCl3; 300 MHz): δ 10.3 (1H, bs, H-3), 7.70 (1H, 2×s, H-6), 7.4 (1H, 2d, 3J=14 Hz, H-5b), 7.25-7.15 (2H, m, OPh), 7.1-6.95 (2H, m, OPh), 6.70 (1H, 2d, 3J=14 Hz, H-5a), 6.30-6.15 (1H, 2t, 3J=5 Hz, H1′), 4.55-4.05 (5H, m, H-5′+H-3′, NH, H-4′), 3.72 (3H, 2s, CH3O), 2.55-2.35 (1H, m, one of H-2′), 2.25-1.92 (5H, m, one of H-2′+4H cyclopentane), 1.85-1.6 (4H, m, 4H cyclopentane).
13C-NMR (DMSO; 75 MHz): δ 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.3, 39.2, 38.9, 38.5 (2CH2 cyclopent), 40.6 (C-2′), 53.3, 53.2 (CH3O), 66.5 (Cq cyclopentane), 66.7 (C-5′), 70.9 (C-3′), 85.8, 85.7, 85.4 (C-1′, C-4′), 110.2 (C-5b), 111.9 (C-5), 116.9, 116.6 (‘o’, OPh), 122,2, 122.0 (‘m’, OPh), 128.5 (C-5a), 138.5 (C-6), 146.7 (‘ipso’, OPh) 149.9 (C-4), 158.5 (‘p’, OPh), 162.3(C-2), 176.4, 176.3 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-fluorophenyl- (ethoxy-α,α-cycloleucinyl)]-phosphate (CPF 23)
C25H30BrFN3O9P, MW=646.4.
Figure USRE047589-20190903-C00053
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-fluorophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate (524 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (274 mg, yield 71%).
31P-NMR (CDCl3, 121 MHz): δ 5.30.
1H-NMR (CDCl3, 300 MHz): δ 10.35 (1H, bs, H-3), 7.7 (1H, 2×s, H-6), 7.44 (1H, 2d, 3J=14 Hz, H-5b), 7.25-7.15 (2H, m, OPh), 7.1-6.95 (2H, m, OPh), 6.7 (1H, 2d, 3J=14 Hz, H-5a), 6.30 (1H, 2t, 3J=6 Hz, H1′), 4.55,4.3 (3H, m, H-5′, H-3′), 4.2-4.1 (4H, m, NH, H-4′, CH3CH 2O), 2.55-2.4 (1H, m, one of H-2′), 2.22-1.90 (5H, m, one of H-2′+4H cyclopentane), 1.8-1.6 (4H, m, 4H cyclopentane), 1.3-1.2 (3H, 2t, 3J=7 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 24.6, 24,4, 24.3 (2CH2 cyclopent), 39.3, 39.2, 38.9, 38.6 (2CH2 cyclopent), 40.6 (C-2′), 62.2 (CH3 CH2O), 66.5 (Cq cyclopentane) 66.7 (C-5′), 71.0 (C-3′), 85.8, 85.7, 85.5, 85.4 (C-1′, C-4′), 110.2 (C-5b), 111.9 (C-5), 116.9, 116.5 (‘o’, OPh), 122.2, 122.1 (‘m’, OPh), 129.0 (C-5a), 138.5 (C-6), 146.8, 146.7 (‘ipso’, OPh), 149.9 (C-4), 158.5 (‘p’, OPh), 162.3 (C-2), 175.9, 175.8 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-fluorophenyl-(benzoxy-α,α-cycloleucinyl)]-phosphate (CPF 24)
C30H32BrN3O9P, MW=708.47.
Figure USRE047589-20190903-C00054
This was synthesised according to Standard procedure 5, using BVdU (200 mg, 0.60 mmol), para-fluorophenyl-(benzyloxy-α,α-cycloleucinyl)-phosphorochloridate (616 mg, 1.5 mmol), NMI (4.98 mmol, 332 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (283 mg, yield 67%).
31P-NMR (CDCl3, 121 MHz): δ 4.27.
1H-NMR (CDCl3, 300 MHz): δ 10.3-9.85 (1H, bs, H-3), 7.65 (1H, 2×s, H-6), 7.45-7.35 (1H, 2d, 3J=14 Hz, H-5b), 7.40-7.30 (5H. m, CH2 Ph), 7.25-7.15 (2H, m, OPh), 7.05-6.95 (2H, m, OPh), 6.71 (1H, 2d, 3J=14 Hz, H-5a), 6.27 (1H, 2t, 3J=6 Hz, H-1′), 5.15 (1H, s, CH 2Ph), 4.45 (1H, m, H-3′), 4.40-4.30 (2H, m, H-5′) 4.20-4.05 (2H, m, H-4′, NH), 2.5-2.4 (1H, m, one of H-2′), 2.25-1.9 (5H, m, one of H-2′+4H cyclopentane), 1.8-1.6 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3, 75 MHz): δ 24.5, 24,3, 24.2 (2CH2 cyclopent), 39.7, 39.6, 39.3, 39.2 (2CH2 cyclopent), 40.5, 40.0 (C-2′), 66.6 (Cq cyclopentane), 67.2, 66.7 (C-5′), 67.9 (CH2Ph), 70.8, 70.7 (C-3′), 85.8, 85.7, 85.4, 85.3 (C-1′, C-4′), 110.3 (C-5b), 111.8 (C-5), 116.9, 116.6 (‘o’, OPh), 122.2, 122.1 (‘m’, OPh), 129.0, 128.9, 128.6, 128.5 (Bn, C-5a), 135.8(‘ipso’, CH2 Ph) 138.5 (C-6), 146.8, 146.7 (‘ipso’ OPh), 149.9 (C-4), 158.5 (‘p’ OPh), 162.2 (C-2), 175.7, 175.0 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-chlorophenyl-(methoxy-α,α-cycloleucinyl)]-phosphate (CPF 32)
C24H28BrClN3O9P, MW=648.82.
Figure USRE047589-20190903-C00055
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-chlorophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate (475 mg, 1.35 mmol), NMI (4.5 mmol, 300 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (187 mg, yield 64%).
31P-NMR (MeOD, 121 MHz): δ 4.64.
1H-NMR (MeOD; 300 MHz): δ 7.75 (1H, 2×s, H-6), 7.32 (1H, 2d, 3J=14 Hz, H-5b), 7.32-7.27 (2H, m, OPh), 7.20-7.11 (2H, m, OPh), 6.72 (1H, 2d, 3J=14 Hz, H-5a), 6.27-6.20 (1H, 2t,3J=6 Hz, H1′), 4.35 (1H, m, H-3′), 4.30 (2H, m, H-5′) 4.1 (2H, m, H-4′), 3.72 (3H, 2s, CH3O), 2.32-2.20 (1H, m, one of H-2′), 2.20-1.92 (5H, m, one of H-2′+4H cyclopentane), 1.8-1.6 (4H, m, 4H cyclopentane).
13C-NMR (MeOD; 75 MHz): δ 25.7, 25.6 (2CH2 cyclopent), 41.7, 41.6, 41.4, 41.3 (2CH2 cyclopent), 42.7 (C-2′), 54.1, 53.9 (CH3O), 67.8 (Cq cyclopentane), 69.1, 69.0 (C-5′), 73.8 (C-3′), 88.4, 88.3, 88.2 (C-1′, C-4′), 110.2 (C-5b), 111.8 (C-5), 122.1, 121.9 (‘o’, OPh), 128.9 (C-5a), 130.6 (‘m’, OPh), 130.8 (‘p’, OPh), 138.5 (C-6), 149.5, 149.4 (‘ipso’, OPh), 149.9 (C-4), 162.2(C-2), 175.6 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-chlorophenyl-(ethoxy-α,α-cycloleucinyl)]-phosphate (CPF 33)
C25H30BrClN3O9P, MW=662.85.
Figure USRE047589-20190903-C00056
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-chlorophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate (495 mg, 1.35 mmol), NMI (4.5 mmol, 300 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (240 mg, yield 66%).
31P-NMR (CDCl3, 121 MHz): δ 4.15.
1H-NMR (CDCl3, 300 MHz): δ 10.25-10.1 (1H, bs, H-3), 7.65 (1H, 2×s, H-6), 7.4-7.3 (1H, 2d, 3J=14 Hz, H-5b), 7.25-7.20 (2H, m, OPh), 7.20-7.10 (2H, m, OPh), 6.75 (1H, 2d, 3J=14 Hz, H-5a), 6.20 (1H, m, H1′), 4.35 (3H, m, H-3′, H-5′), 4.2-4.0 (4H, m, H-4′, NH, CH3CH 2O), 2.45-2.25 (1H, m, one of H-2′), 2.25-1.85 (5H, m, one of H-2′+4H cyclopentane), 1.75-1.55 (4H, m, 4H cyclopentane), 1.2 (3H, 2t, 3J=7 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 24.5, 24,4 (2CH2 cyclopent), 39.3, 39.2, 38.8, 38.6 (2CH2 cyclopent), 40.5 (C-2′), 62.3 (CH3 CH2O), 66.1 (Cq cyclopentane), 66.7 (C-5′), 70.8 (C-3′), 85.8, 85.4 (C-1′, C-4′), 110.3 (C-5b), 111.9 (C-5), 122.1, 121.9 (‘o’, OPh), 129.0 (C-5a), 130.2 (‘m’, OPh), 130.8 (‘p’, OPh), 138.5 (C-6), 149.5, 149.4 (‘ipso’, OPh), 149.9 (C-4),162.3 (C-2), 175.9 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-chlorophenyl-(benzoxy-α,α-cycloleucinyl)]-phosphate (CPF 34)
C30H32BrClN3O9P, MW=724.92.
Figure USRE047589-20190903-C00057
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-chlorophenyl-(benzyloxy-α,α-cycloleucinyl)-phosphorochloridate (578 mg, 1.35 mmol), NMI (4.5 mmol, 300 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (222 mg, yield 68%).
31P-NMR (CDCl3, 121 MHz): δ 4.11, 4.05.
1H-NMR (CDCl3, 300 MHz): δ 7.65 (1H, 2×s, H-6), 7.45-7.29 (10H, m, H-5b, 2H OPh+CH2 Ph), 7.20-7.15 (2H, m, OPh), 6.75-6.67 (1H, 2d, 3J=14 Hz, H-5a), 6.28 (1H, 2t, 3J=6 Hz, H-1′), 5.15 (1H, 2s, CH 2Ph), 4.5 (1H, m, H-3′), 4.35 (2H, m, H-5′) 4.1 (H, m, H-4′), 4.00 (1H, m, NH), 2.48-2.35 (1H, m, one of H-2′), 2.3-1.92 (5H, m, one of H-2′+4H cyclopentane), 1.8-1.6 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3, 75 MHz): δ 24.5, 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.3, 38.8, 38.6 (2CH2 cyclopent), 40.5 (C-2′), 66.7 (Cq cyclopentane), 67.9 (CH2Ph), 68.4 (C-5′), 70.7 (C-3′), 85.7, 85.7, 85.4, 85.3 (C-1′, C-4′), 110.3 (C-5b), 111.8 (C-5), 122.0, 121.9 (‘o’, OPh), 129.1, 128.3, 128.2 (Bn, ‘m’, OPh), 130.2 (C-5a), 135.8 (‘ipso’, CH2 Ph), 136.3 (‘p’ OPh), 138.2 (C-6), 149.5, 149.3 (‘ipso’, OPh), 149.9 (C-4), 162.2 (C-2), 175.7, 175.5 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-trifluorophenyl-(methoxy-α,α-cycloleucinyl)]-phosphate (CPF 28)
C25H28BrF3N3O9P, MW=682.38.
Figure USRE047589-20190903-C00058
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-trifluorophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate (521 mg, 1.35 mmol), NMI (4.5 mmol, 300 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (199 mg, yield 65%).
31P-NMR (CDCl3, 121 MHz): δ 3.80.
1H-NMR (CDCl3; 300 MHz): δ 7.70 (1H, 2s, H-6), 7.55 (1H, 2d, 3J=14 Hz, H-5b), 7.45-7.32 (4H, m, OPh), 6.72 (1H, 2d, 3J=14 Hz, H-5a), 6.28 (1H, 2t,3J=6 Hz, H1′), 4.55 (1H, m, H-3′), 4.45 (2H, m, H-5′), 4.25 (1H, H-4′), 4.15 (1H, NH), 3.71 (3H, 2s, CH3O), 2.6-2.4 (1H, m, one of H-2′), 2.3-1.9 (5H, m, one of H-2′+4H cyclopentane), 1.85-1.6 (4H, m 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.2, 39.1, 38.8, 38.6 (2CH2 cyclopent), 40.5 (C-2′), 53.9 (CH3O), 66.3 (Cq cyclopentane), 66.8 (C-5′), 70.9 (C-3′), 85.8, 85.4 (C-1′, C-4′), 110.3 (C-5b), 111.9 (C-5), 125.1 (d, J=270 Hz, CF3), 127.1, 127.0 (‘o’, OPh), 127.8 (‘m’, OPh), 128.9 (C-5a), 129.0 (‘p’, q, J=32 Hz, OPh), 138.5 (C-6), 149.9 (C-4), 153.5 (‘ipso’, OPh), 162.2 (C-2), 176.3, 176.2 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-trifluorophenyl-(ethoxy-α,α-cycloleucinyl)]-phosphate (CPF 29)
C26H30BrF3N3O9P, MW=696.40.
Figure USRE047589-20190903-C00059
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-trifluorophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate (540 mg, 1.35 mmol), NMI (4.50 mmol, 300 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (185 mg, yield 59%).
31P-NMR (CDCl3, 121 MHz): δ 4.30.
1H-NMR (CDCl3, 300 MHz): δ 10.35 (1H, bs, H-3), 7.70 (1H, 2×s, H-6), 7.40 (1H, 2d, 3J=14 Hz, H-5b), 7.28-7.14 (2H, m, OPh), 7.05-6.95 (2H, m, OPh), 6.70 (1H, 2d, 3J=14 Hz, H-5a), 6.3 (1H, m, H1′), 4.55-4.3 (3H, m, H-5′, H-3′), 4.2-4.1 (3H, m, H-4′, CH3CH 2O), 2.5-2.35 (1H, m, one of H-2′), 2.20-1.9 (5H, m, one of H-2′+4H cyclopentane), 1.85-1.6 (4H, m, 4H cyclopentane), 1.25 (3H, 2t, 3J=7 Hz, CH 3CH2O).
13C-NMR (CDCl3, 75 MHz): δ 14.5 (CH3CH2O), 24.5, 24,4 (2CH2 cyclopent), 39.3, 39.2, 38.9, 38.5 (2CH2 cyclopent), 40.6 (C-2′), 62.2 (CH3 CH2O), 66.7 (Cqcyclopentane), 67.4, 67.3 (C-5′), 70.9 (C-3′), 85.8, 85.7 (C-1′, C-4′), 110.2 (C-5b), 111.9 (C-5), 116.8, 116.5 (‘o’, OPh), 122.2, 122.1 (‘m’, OPh), 125.1 (d, J=270 Hz, CF3), 129.0 (C-5a), 131.1 (‘p’, q, J=32 Hz, OPh), 138.5 (C-6), 146.8, 146.7 (‘ipso’, OPh), 149.9 (C-4), 162.3 (C-2), 175.9, 175.8 (COOCH2CH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-trifluorophenyl-(benzoxy-α,α-cycloleucinyl)]-phosphate (CPF 30)
C31H32BrF3N3O9P, MW=758.47.
Figure USRE047589-20190903-C00060
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-trifluorophenyl-(benzyloxy-α,α-cycloleucinyl)-phosphorochloridate (623 mg, 1.35 mmol), NMI (4.5 mmol, 300 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (218 mg, yield 64%).
31P-NMR (CDCl3, 121 MHz): δ 4.30.
1H-NMR (CDCl3, 300 MHz): δ 10.35 (1H, bs, H-3), 7.65 (1H, 2×s, H-6), 7.55 (2H, m, 2H OPh), 7.45-7.25 (8H. m, 2H OPh+CH2 Ph+H-5b), 6.7 (1H, 2d, 3J=14 Hz, H-5a), 6.30 (1H, 2t, 3J=6 Hz, H-1), 5.15 (1H, 2s, CH 2Ph), 4.55-4.35 (3H, m, H-3′+H-5′), 4.25 (1H, H-4′), 4.10 (1H, NH), 2.55-2.35 (1H, m, one of H-2′), 2.30-1.92 (5H, m, one of H-2′+4H cyclopentane), 1.8-1.6 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3, 75 MHz): δ 25.5, 24.4, 24,3, 24.2 (2CH2 cyclopent), 39.2, 39.1, 38.7, 38.6 (2CH2 cyclopent), 40.5, 40.0 (C-2′), 66.4 (Cq cyclopentane), 66.8 (C-5′), 68.0 (CH2Ph), 70.9 (C-3′), 86.0, 85.8, 85.4, 85.3 (C-1′, C-4′), 110.3 (C-5), 111.9 (C-5), 121.8, 120.8 (‘o, m’, OPh), 125.2 (d, J=270 Hz, CF3), 128.5, 127.7, 127.5 (Bn, C-5a), 129,2 (‘p’,q, J=32 Hz, OPh, 135.4 (‘ipso’, CH2 Ph), 138.5 (C-6), 149.9 (C-4), 153.5 (‘ipso’ OPh), 162.2 (C-2), 175.6, 175.5 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2 ′-deoxyuridine-5′-[phenyl-(methoxy-L-phenylalaninyl)]-phosphate (CPF 36)
C27H29BrN3O9P, MW=650.41.
Figure USRE047589-20190903-C00061
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), Phenyl-(methoxy-L-phenylalaninyl)-phosphorochloridate (477 mg, 1.35 mmol), NMI (4.42 mmol, 190 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (169 mg, yield 58%).
31P-NMR (CDCl3, 121 MHz): δ 4.79, 4.71.
1H-NMR (CDCl3; 300 MHz): δ 9.95 (1H, bs, H-3), 7.60-7.55 (1H, 2×s, H-6), 7.48-7.4 (1H, 2d, 3J=14 Hz, H-5b), 7.3-7.1 (10H, m, CH2Ph+OPh), 6.75-6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.27-6.18 (1H, m, H1′), 4.57-4.29 (6H, m, H-5′,H-3′,H-4′, NH, CHphenylala), 3.70 (3H, 2s, CH3O), 3.01 (2H, m, CH2Ph), 2.35-2.20 (1H, m, one of H-2′), 2.07-1.95 (1H, m, one of H-2′).
13C-NMR (CDCl3; 75 MHz): δ 36.3 (CH2phenylalanine), 41.9, 41.8 (C-2′), 53.0 (CH3O), 56.6, 56.1 (CHphenylala), 67.1 (C-5′), 71.3, 70.7 (C-3′), 85.7, 85.6, 85.5, 85.4 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 120.6, 120.5 (‘o’, OPh), 127.8 (‘p’, OPh), 130.1, 129.9, 129.8, 129.1 (CH2Ph, C-5a, ‘m’ OPh), 138.0, 137.9 (C-6), 149.8 (C-4), 150.7, 150.6 (‘ipso’, OPh), 162.1, 162.0 (C-2), 173.5 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(methoxy-L-leucinyl)]-phosphate (CPF 35)
C24H31BrN3O9P, MW=616.40.
Figure USRE047589-20190903-C00062
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), Phenyl-(methoxy-L-leucinyl)-phosphorochloridate (432 mg, 1.35 mmol), NMI (4.42 mmol, 190 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (167 mg, yield 60%).
31P-NMR (CDCl3, 121 MHz): δ 5.14, 4.60.
1H-NMR (CDCl3; 300 MHz): δ 10.1 (1H, bs, H-3), 7.75 (1H, 2×s, H-6), 7.45 (1H, 2d, 3J=14 Hz, H-5b), 7.4-7.2 (5H, m, OPh), 6.85 (1H, 2d, 3J=14 Hz, H-5a), 6.27-6.18 (1H, 2t, 3J=6 Hz, H1′), 4.5-4.2 (4H, m, H-5′,H-3′, NH), 4.1 (1H, m,H-4′), 3.95 (1H, m, CHCH2CH(CH3)2), 3.70 (3H, 2s, CH3O), 2.40-2.20 (1H, m, one of H-2′), 2.05-1.95 (1H, m, one of H-2′), 1.8 (1 H, m, CHCH2CH(CH3)2), 1.8-1.5 (2H, m, CHCH2CH(CH3)2), 1.0-0.9 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.2, 23.1, 22.0, 21.9 (2C, CHCH2CH(CH3)2), 24.9, 24.7 (CHCH2CH(CH3)2), 40.6 (C-2′), 43.7, 43.6 (CHCH2CH(CH3)2), 53.0 (CH3O), 53.7, 53.6 (CHCH2CH(CH3)2), 66.6, 66.3 (C-5′), 71.1, 70.8 (C-3′), 86.0, 85.7, 85.6, 85.5 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 120.6, 120.5, 120.4 (‘o’, OPh), 125.8, 125.7 (‘p’, OPh), 128.9 (C-5a), 130.2 (‘m’ OPh), 138.1 (C-6), 149.9 (C-4), 150.8, 150.7 (‘ipso’, OPh), 162.2 (C-2), 175.1, 174.9 (COOCH3).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[phenyl-(benzoxy-L-leucinyl)]-phosphate (CPF 37)
C30H35BrN3OP, MW=692.49.
Figure USRE047589-20190903-C00063
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), Phenyl-(benzoxy-L-leucinyl)-phosphorochloridate (534 mg, 1.35 mmol), NMI (4.42 mmol, 190 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (199 mg, yield 64%).
31P-NMR (CDCl3, 121 MHz): δ 5.18, 4.54.
1H-NMR (CDCl3; 300 MHz): δ 9.95-9.85 (1H, bs, H-3), 7.55 (1H, 2×s, H-6), 7.38 (1H, 2d, 3J=14 Hz, H-5b), 7.3-7.1 (5H, m, CH2Ph+OPh), 6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.26-6.14 (1H, 2t, 3J=6 Hz, H1′), 5.1 (2H, 2s, CH2Ph) 4.4-3.8 (6H, m, H-5′,H-3, NH, H-4′, CHCH2CH(CH3)2), 2.35-2.25 (1H, m, one of H-2′), 1.95-1.85 (1H, m, one of H-2′), 1.6-1.4 (3H, m, CHCH2CH(CH3)2), 0.8 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.2, 23.1, 22.0, 21.9 (2C, CHCH2CH(CH3)2), 24.9, 24.7 (CHCH2CH(CH3)2), 40.7 (C-2′), 43.9, 43.8 (CHCH2CH(CH3)2), 53.9, 53.7 (CHCH2CH(CH3)2), 66.4, 66.2 (C-5′), 67.8,67.7 (CH2Ph), 71.1, 70.7 (C-3′), 85.9, 85.6, 85.4, 85.3 (C-1′, C-4′), 110.4 (C-5b), 111.9 (C-5), 120.6, 120.5 (‘o’, OPh), 125.8, 125.7 (‘p’, OPh), 130.2, 129.1, 128.9 (C-5a, CH2Ph, ‘m’ OPh), 135.4 (‘ipso’, CH2 Ph), 138.1 (C-6),149.8 (C4),150.2 (‘ipso’, OPh), 162.1 (C-2),175.7, 174.6 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-(para-nitrophenyl-(benzoxy-L-leucinyl)]-phosphate (CPF 38)
C30H34BrN4O11P, MW=737.49.
Figure USRE047589-20190903-C00064
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-nitrophenyl-(benzoxy-L-leucinyl)-phosphorochloridate (595 mg, 1.35 mmol), NMI (4.42 mmol, 190 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (176 mg, yield 53%).
31P-NMR (CDCl3, 121 MHz): δ 5.72, 4.35.
1H-NMR (CDCl3; 300 MHz): δ 10.2 (1H, bs, H-3), 8.1(2H, m, 2H OPh), 7.65 (1H, 2×s, H-6), 7.45-7.2 (8H, m, H-5b, CH2Ph+2H OPh), 6.65 (1H, 2d, 3J=14 Hz, H-5a), 6.35-6.2 (1H, 2t, 3J=6 Hz, H1′), 5.15 (2H, 2s, CH2Ph) 4.7-3.9 (6H, m, H-5′,H-3′, NH, H-4′, CHCH2CH(CH3)2), 2.55-2.4 (1H, m, one of H-2′), 2.15-2.05 (1H, m, one of H-2′), 1.7-1.5 (3H, m, CHCH2CH(CH3)2), 0.95-0.8 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.2, 23.1, 22.0, 21.9 (2C, CHCH2CH(CH3)2), 24.9, 24.8 (CHCH2CH(CH3)2), 40.6 (C-2′), 43.7, 43.6 (CHCH2CH(CH3)2), 53.9, 53.7 (CHCH2CH(CH3)2), 66.9 (C-5′), 67.9 (CH2Ph), 71.2, 70.8 (C-3′), 85.8, 85.3, 85.2 (C-1′, C-4′), 110.6 (C-5b), 111.9 (C-5), 121.3 (‘o’ OPh), 129.2, 129.1, 128.8, 126.2 (C-5a, CH2Ph, ‘m’ OPh), 135.4, 135.3 (‘ipso’, CH2 Ph), 138.2 (C-6), 145.2, 145.1 (‘ipso’, OPh), 149.9 (C-4), 155.5 (‘p’, OPh), 162.1 (C-2), 174.2 (COOBn).
Synthesis of (E)-5-(2-Bromovinyl)-2′-deoxyuridine-5′-[para-chlorophenyl-(benzoxy-L-leucinyl)]-phosphate (CPF 39)
C30H34BrClN3O9P, MW=726.94.
Figure USRE047589-20190903-C00065
This was synthesised according to Standard procedure 5, using BVdU (150 mg, 0.45 mmol), para-chlorophenyl-(benzoxy-L-leucinyl)-phosphorochloridate (581 mg, 1.35 mmol), NMI (4.42 mmol, 190 μL) in THF (5 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 97:3 to give the pure product as a white foamy solid (221 mg, yield 68%).
31P-NMR (CDCl3, 121 MHz): δ 5.27, 4.76.
1H-NMR (CDCl3; 300 MHz): δ 10.25-10.15 (1H, bs, H-3), 7.65 (1H, 2×s, H-6), 7.45 (1H, 2d, 3J=14 Hz, H-5b), 7.4-7.15 (9H, m, CH2Ph+OPh), 6.7 (1H, 2d, 3J=14 Hz, H-5a), 6.35-6.2 (1H, 2t, 3J=6 Hz, H1′), 5.15 (2H, 2s, CH2Ph) 4.55-3.9 (6H, m, H-5′, H-3′, NH, H-4′, CHCH2CH(CH3)2), 2.5-2.4 (1H, m, one of H-2′), 2.15-2.0 (1H, m, one of H-2′), 1.7-1.45 (3H, m, CHCH2CH(CH3)2), 0.94-0.82 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.1, 23.0, 22.2, 22.0 (2C, CHCH2CH(CH3)2), 24.9, 24.7 (CHCH2CH(CH3)2), 40.7 (C-2′), 43.9, 43.8 (CHCH2CH(CH3)2), 53.9, 53.7 (CHCH2CH(CH3)2), 66.7, 66.3 (C-5′), 67.8 (CH2Ph), 71.1, 70.7 (C-3′), 85.8, 85.7, 85.4 (C-1′, C-4′), 110.5 (C-5b), 111.9 (C-5),122.1, 122.0 (‘o’, OPh), 130.2, 129.1, 129.0 (C-5a, CH2Ph, ‘m’ OPh), 131.1, 130.9 (‘p’, OPh), 135.5, 135.4 (‘ipso’, CH2 Ph), 138.2 (C-6), 149.2, 149.1 (‘ipso’, OPh), 149.2, 149.1 (C-4),162.2 (C-2), 174.2, 174.2 (COOBn).
Synthesis of Gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate
C25H27F2N4O8P, MW=580.47 (CPF 31).
Figure USRE047589-20190903-C00066
This was synthesised according to Standard procedure 5, using gemcitabine (131 mg, 0.5 mmol), Phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (529 mg, 1.5 mmol), NMI (4.42 mmol, 300 μL) in THF/pyridine (4/2 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 95:5 to give the pure product as a white foamy solid (46 mg, yield 16%).
31P-NMR (MeOD, 121 MHz): δ 5.05, 4.94.
1H-NMR (MeOD, 300 MHz): δ 7.6-7.5 (1H, 2d, 3J=7 Hz H-6), 7.4-7.2 (10H. m, OPh+CH2 Ph), 6.25 (1H, m, H-1′), 5.95 (1H, 2d, 3J=7 Hz, H-5), 5.19 (1H, 2s, CH 2Ph), 4.55-4.1(3H, m, H-3′, H-4′, CHala), 4.05 (2H, m, H-5′), 1.20 (3H, 2t, 3J=6 Hz, CH3ala).
13C-NMR (MeOD, 75 MHz): δ 20.8, 20.7 (CH3ala), 52.2, 52.0 (CHala), 66.1 (C-5′), 68.4 (CH2Ph), 71.9, 71.3 (C-3′), 80.6 (C-4′), 85.9 (C-1′), 97.1 (C-5), 121.8, 121.6 (‘o’, OPh), 123 (C-2′), 126.2 (‘p’, OPh), 131.8, 130.0, 129.7 (‘m’ OPh, Bn), 137.9(‘ipso’, CH2 Ph), 142.7, 142.6 (C-6), 152.5, 152.4 (‘ipso’, OPh), 158.2 (C-2), 168.0 (C-4), 175.3, 174.9 (COOBn).
Synthesis of Gemcitabine-[para-chlorophenyl-(benzoxy-L-alaninyl)]-phosphate
C25H26ClF2N4O8P, MW=614.92 (CPF 40).
Figure USRE047589-20190903-C00067
This was synthesised according to Standard procedure 5, using gemcitabine (131 mg, 0.5 mmol), para-chlorophenyl-(benzoxy-L-alaninyl)-phosphorochloridate (582 mg, 1.5 mmol), NMI (4.42 mmol, 300 μL) in THF/pyridine (4/2 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 95:5 to give the pure product as a white foamy solid (76 mg, yield 25%).
31P-NMR (MeOD, 121 MHz): δ 5.08.
1H-NMR (MeOD, 300 MHz): δ 7.65 (1H, 2d, 3J=7 Hz H-6), 7.5-7.2 (9H. m, OPh+CH2 Ph), 6.2 (1H, m, H-1′), 5.9 (1H, 2d, 3J=7 Hz, H-5), 5.12 (1H, 2s, CH 2Ph), 4.6-4.1 (3H, m, H-3′, H-4′, CHala), 4.05 (2H, m, H-5′), 1.45-1.35 (3H, 2t, 3J=6 Hz, CH3ala).
13C-NMR (MeOD, 75 MHz): δ 20.9, 20.7 (CH3ala), 52.2, 52.0 (CHala), 66.4, 66.2 (C-5′), 68.5 (CH2Ph), 71.5 (C-3′), 80.7 (C-4′), 86.4 (C-1′), 97.2 (C-5), 123.5 (‘o’, OPh), 126.9 (C-2′), 131.2, 130.6, 130.3 (‘m’ OPh, Bn), 131.9 (‘p’, OPh) 137.5 (‘ipso’, CH2 Ph), 142.8, 142.7 (C-6), 151.4, 151.0 (‘ipso’, OPh), 158.2 (C-2),166.9 (C-4), 175.1, 174.9 (COOBn).
Synthesis of Gemcitabine-[para-chlorophenyl-(benzoxy-α,α-dimethylglycinyl)]-phosphate (CPF 41)
C26H28ClF2N4O8P, MW=628.95.
Figure USRE047589-20190903-C00068
This was synthesised according to Standard procedure 5, using gemcitabine (131 mg, 0.5 mmol), para-chlorophenyl-(benzoxy-α,α-dimethylglycinyl)-phosphorochloridate (603 mg, 1.5 mmol), NMI (4.42 mmol, 300 μL) in THF/pyridine (4/3 mL) for 2 hrs. The crude product was purified by column chromatography, eluting with CH2Cl2/Methanol 95:5 to give the pure product as a white foamy solid (163 mg, yield 52%).
31P-NMR (MeOD, 121 MHz): δ 3.56, 3.52.
1H-NMR (MeOD, 300 MHz): δ 7.55 (1H, 2d, 3J=7 Hz, H-6), 7.4-7.15 (9H. m, OPh+CH2 Ph), 6.25 (1H, m, H-1′), 5.85 (1H, 2d, 3J=7 Hz, H-5), 5.15 (1H, 2s, CH 3Ph), 4.55-4.1 (3H, m, H-3′, H-4′), 4.05 (2H, m, H-5′), 1.50 (6H, m, 3J=6 Hz, 2CH3dimethygly).
13C-NMR (MeOD, 75 MHz): δ 28.2, 28.0 (CH3 dimethygly), 58.6 (Cq dimethygly), 66.2, 66.1 (C-5′), 66.7 (CH2Ph), 71.5 (C-3′), 80.6 (C-4′), 86.4 (C-1′), 97.0 (C-5), 123.9, 123.6 (‘o’, OPh), 127.3 (C-2′), 130.0, 129.7 (‘m’ OPh, Bn), 131.8 (‘p’, OPh), 137.6 (‘ipso’, CH2 Ph), 142.8, 142.7 (C-6), 151.2, 151.1 (‘ipso’, OPh), 158.1 (C-2), 167.9 (C-4), 176.8, 176.7 (COOBn).
Synthesis of Phenyl-(methoxy-L-alaninyl)-phosphorochloridate
C10H13ClNO4P, MW=277.64.
Figure USRE047589-20190903-C00069
This is synthesised according to Standard procedure 4, using L-alanine methyl ester hydrochloride (2 g, 14.3 mmol), phenyldichlorophosphate (3.02 g, 2.14 ml, 14.3 mmol), and TEA (2.9 g, 4.0 ml, 28.7 mmol) in DCM (60 mL), to yield 3.91 g (98%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.28, 8.97.
1H-NMR (CDCl3; 300 MHz): δ 7.39-7.34 (2H, m, ‘o’ OPh), 7.29-7.20 (2H, m ‘m+p’ OPh), 4.98 (1H, bs, NH), 4.27-4.09 (1H, m, CHala), 3.78 (3H, s, OCH 3), 1.52-1.49 (3H, 2×d, 3J=7 Hz, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.9 (CH3ala), 51.0 (CHala), 53.6 (OCH3), 120.9 (‘o’OPh), 126.4 (‘p’, OPh), 130.2 (‘m’, OPh), 150.1 (‘ipso’, OPh), 173.6(COOCH3).
Synthesis of Phenyl-(ethoxy-L-alaninyl)-phosphorochloridate
C11H15ClNO4P, MW-291.67.
Figure USRE047589-20190903-C00070
This is synthesised according to Standard procedure 4, using L-alanine ethyl ester hydrochloride (770 mg, 5.01 mmol), phenyldichlorophosphate (1.12 g, 5.01 mmol, 749 μL), and TEA (1.4 mL, 10.02 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 7:3) affording 1.02 (69%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 9.49, 9.07.
1H-NMR (CDCl3; 300 MHz): δ 7.39-7.34 (2H, m,‘o’ OPh), 7.29-7.20 (2H, m, ‘m+p’ OPh), 4.95 (1H, bs, NH, 4.3-4.1 (3H, m, OCH 2CH3, CHala), 1.50 (3H, 2×d, 3J=7 Hz, CH 3ala), 1.30 (3H, t, 3J=7.1 Hz, OCH2CH3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2), 20.9 (CH3ala), 51.0 (CHala), 62.6 CH3 CH2), 120.9 (‘o’ OPh), 126.5 (‘p’, OPh), 130.1 (‘m’, OPh), 150.1 (‘ipso’, OPh), 175.1 (COOCH2CH3).
Synthesis of Phenyl-(benzoxy-L-alaninyl)-phosphorochloridate
C16H17ClNO4P, MW=353.74.
Figure USRE047589-20190903-C00071
This is synthesised according to Standard procedure 4, using L-alanine benzyl ester hydrochloride (1.0 g, 4.64 mmol), phenyl-dichlorophosphate (980 mg, 0.69 ml, 4.64 mmol), and TEA (0.94 g, 1290 μL, 9.27 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 6:4) affording 1.61 (98%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 9.41, 9.23.
1H-NMR (CDCl3; 300 MHz): δ 7.41-7.21 (10H, m, OPh+CH2 Ph), 5.24 (2H, s, CH 2Ph), 4.95-4.88 (1H, bs, NH), 4.36-4.15 (1H, m, CHala), 1.52-1.49 (3H, 2×d, 3J=7 Hz, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.8 (CH 3ala), 51.1 (CHala), 68.0 (CH2Ph), 121.0 (‘o’ OPh), 126.4 (‘p’, OPh), 130.3, 129,0, 128.7 (‘m’OPh, CH2 Ph), 135.5 (‘ipso’, CH2Ph), 150.2 (‘ipso’, OPh), 172.9 (COOCH2Ph).
Synthesis of p-nitrophenyl-(methoxy-L-alaninyl)-phosphorochloridate
C10H12ClN2O6P, MW=322.64.
Figure USRE047589-20190903-C00072
This is synthesised according to Standard procedure 4, using L-alanine methyl ester hydrochloride (0.70 g, 5.01 mmol), p-nitrophenyldichlorophosphate (1.362 g, 5.01 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL), to yield 1.60 g (99%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.13, 9.03.
1H-NMR (CDCl3; 300 MHz): δ 8.1 (2H, 2d, 3J=8 Hz, OPh), 7.3 (2H, 2d, 3J=8 Hz, OPh), 5.0 (1H, bs, NH), 4.1 (1H, m, CHala), 3.75 (3H, s, OCH 3), 1.5-1.45 (3H, m, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.8, 20.7 (CH3ala), 51.1, 50.9 (CHala), 53.2, 53.2 (OCH3), 121.8, 121.6 (‘o’ OPh), 126.5 (‘m’, OPh), 145.7 (‘ipso’, OPh), 154.7, 154.6 (‘p’, OPh), 173.4, 173.2 (COOCH3).
Synthesis of p-nitrophenyl-(ethoxy-L-alaninyl)-phosphorochloridate
C11H14ClN2O6P, MW=336.67.
Figure USRE047589-20190903-C00073
This is synthesised according to Standard procedure 4, using L-alanine ethyl ester hydrochloride (770 mg, 5.01 mmol), p-nitrophenyldichlorophosphate (1.362 g, 5.01 mmol), and TEA (1.4 mL, 10.02 mmol) in DCM (40 mL), to yield 1.64 g (98%) of crude product used without further purification.
31P-NMR(CDCl3, 121 MHz): δ 9.06, 8.81.
1H-NMR (CDCl3; 300 MHz): δ & 8.1 (2H, m, OPh), 7.4 (2H, m, OPh), 4.9-4.7 (1H, bs, NH), 4.3-4.1 (3H, m, OCH 2CH3, CHala), 1.55-1.45 (3H, 2×d, 3J=7 Hz, CH 3ala), 1.40 (3H, t, 3J=7 Hz, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2), 21.1, 20.9 (CH3ala), 51.2, 51.0 (CHala), 62.6_CH3 CH2), 121.7, 121.3 (‘o’ OPh), 126.2, 126.0 (‘m’, OPh), 145.7 (‘ipso’, OPh), 154.5 (‘p’, OPh), 173.4, 173.3 (COOCH2CH3).
Synthesis of p-nitrophenyl-(benzoxy-L-alaninyl)-phosphorochloridate
C16H16ClN2O6P, MW=398.04.
Figure USRE047589-20190903-C00074
This is synthesised according to Standard procedure 4, using L-alanine benzyl ester hydrochloride (1.08 g, 5.01 mmol), para-nitrophenyl-dichloro phosphate (1.362 g, 5.01 mmol), and TEA (1.4 mL, 1.4 mmol) in DCM (40 mL), to yield 1.85 g (93%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.15, 9.06.
1H-NMR (CDCl3; 300 MHz): δ 8.15 (2H, m, OPh), 7.45 (2H,m, OPh), 7.35-7.25 (5H, m, CH2 Ph), 5.2 (2H, 2s, CH 2Ph), 5.00 (1H, bs, NH) 4.2 (1H, m, CHala), 1.64 (3H, 2×d, J=7 Hz, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.8 (CH3ala), 51.1 (CHala), 68.0 (CH2Ph), 121.4 (‘o’ OPh), 126.1 (‘m’OPh), 130.3, 129.0 (CH2 Ph), 145.7 (‘ipso’, CH2Ph), 150.2 (‘ipso’, OPh), 154.6 (‘p’, OPh), 172.9 (COOCH2Ph).
Synthesis of p-fluorophenyl-(methoxy-L-alaninyl)-phosphorochloridate
C10H12ClFNO4P, MW=295.63.
Figure USRE047589-20190903-C00075
This is synthesised according to Standard procedure 4, using L-alanine methyl ester hydrochloride (0.70 g, 5.01 mmol), p-fluorophenyldichlorophosphate (1.210 g, 5.01 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 7:3) affording 1.11 g (75%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 9.98, 9.96.
1H-NMR (CDCl3; 300 MHz): δ 7.1 (2H, m, OPh), 6.95 (2H, m, OPh), 5.0 (1H, bs, NH), 4.25-4.1 (1H, m, CHala), 3.78 (3H, 2s, OCH 3), 1.55 (3H, m, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.8 (CH3ala), 51.1, 50.9 (CHala), 53.3 (OCH3), 117.1, 117.0 (‘o’ OPh), 122.6, 122.5 (‘m’, OPh), 146.0 (‘ipso’, OPh), 159.1, 159.0 (‘p’, OPh), 173.4, 173.2 (COOCH3).
Synthesis of p-fluorophenyl-(ethoxy-L-alaninyl)-phosphorochloridate
C11H14ClFNO4P, MW=309.66.
Figure USRE047589-20190903-C00076
This is synthesised according to Standard procedure 4, using L-alanine ethyl ester hydrochloride (770 mg, 5.01 mmol), p-fluorophenyldichlorophosphate (1.210 g, 5.01 mmol), and TEA (1.4 mL, 10.02 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 7:3) affording 1.07 (69%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 10.04, 9.95.
1H-NMR (CDCl3; 300 MHz): δ 7.1 (2H, m, OPh), 6.95 (2H, m, OPh), 5.0 (1H, bs, NH), 4.25-4.1 (3H, m, OCH 2CH3, CHala), 1.55 (3H, m, CH 3ala), 1.40 (3H, t, 3J=7 Hz, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2), 21.1, 21.0 (CH3ala), 51.2, 51.1 (CHala), 62.6_CH3 CH2), 117.3 (‘o’OPh), 122.2, 122.0 (‘m’, OPh), 145.9, 145.8 (‘ipso’, OPh), 159.0 (‘p’, OPh), 173.6, 173.5 (COOCH2CH3).
Synthesis of p-fluorophenyl-(benzoxy-L-alaninyl)-phosphorochloridate
C16H16ClFNO4P, MW=371.73.
Figure USRE047589-20190903-C00077
This is synthesised according to Standard procedure 4, using L-alanine benzyl ester hydrochloride (1.08 g, 5.01 mmol), para-fluorophenyl-dichloro phosphate (1.210 mg, 5.01 mmol), and TEA (1.4 mL, 1.4 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 7:3) affording 1.599 (86%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 9.15, 9.06.
1H-NMR (CDCl3; 300 MHz): δ 7.35-7.25 (5H, m, CH2 Ph), 7.1 (2H, m, OPh), 6.95 (2H, m, OPh), 5.2 (2H, 2s, CH 2Ph), 5.00 (1H, bs, NH), 4.25-4.1 (1H, m, CHala), 1.55 (3H, m, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.8 (CH3ala), 51.1, 51.0 (CHala), 68.1 (CH2Ph), 117.0, 116.9 (‘o’ OPh), 122.6 (‘m’OPh), 130.3, 129.0 (CH2 Ph), 135.7 (‘ipso’, CH2Ph), 146.1, 146.0(‘ipso’, OPh), 158.9 (‘p’, OPh), 173.1 (COOCH2Ph).
Synthesis of 4-(trifluoromethyl)-phenyl-(methoxy-L-alaninyl)-phosphorochloridate
C11H12ClF3NO4P, MW=345.64.
Figure USRE047589-20190903-C00078
This is synthesised according to Standard procedure 4, using L-alanine methyl ester hydrochloride (1.0 g, 7.16 mmol), 4-(trifluoromethyl)-phenyl-phosphodichloridate (1.998 g, 7.16 mmol), and TEA (1.449 g, 14.32 mmol, 1916 μL) in DCM (30 mL), to yield 2.202 g (89.0%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.36, 9.22.
1H-NMR (CDCl3; 300 MHz): δ 7.66 (2H, d, 3J=8.1 Hz, OPh), 7.44-7.33 (2H, m, OPh), 5.10 (1H, bs, NH), 3.81-3.78 (3H, 2s, CH 3O), 3.77-3.68 (1H, m, CH3CH), 1.56-1.52 (3H, m, CHCH 3).
13C-NMR (CDCl3; 75 MHz): δ 20.6, 20.7 (CH3CH), 50.9, 51.1 (CHCH3), 53.2 (CH3O), 121.4 (‘o’, OPh), 124.1 (CF 3, J=270 Hz), 128.0 (‘m’, OPh), 128.6 (‘p’, J=34 Hz), 152.4, 152.6 (‘ipso’, OPh), 173.4, 173.5 (COOCH3).
Synthesis of 4-(trifluoromethyl)-phenyl-(ethoxy-L-alaninyl)-phosphorochloridate
C12H14ClF3NO4, MW=359.67.
Figure USRE047589-20190903-C00079
This is synthesised according to Standard procedure 4, using L-alanine ethyl ester hydrochloride (1.0 g, 6.50 mmol), 4-(trifluoromethyl)-phenyl-phosphodichloridate (1.813 g, 6.50 mmol), and TEA (1.316 g, 13.00 mmol, 1740 μL) in DCM (30 mL), to yield 2.150 g (92.2%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.33, 9.28.
1H-NMR (CDCl3; 300 MHz): δ 7.70 (2H, d, 3J=8.2 Hz, OPh), 7.46-7.39 (2H, m, OPh), 4.78 (1H, bs, NH), 4.33-4.17 (3H, m, CH3CH 2O+CHCH3), 1.59-1.55 (1H, m, CHCH 3), 1.56-1.52 (3H, m, CH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2O), 20.8, 20.9 (CH3CH), 50.3, 50.9 (CHCH3), 62.3, 62.5 (CH3 CH2O), 121.4 (‘o’, OPh), 124.1 (CF 3, J=270 Hz), 127.7 (‘m’, OPh), 128.7 (‘p’, J=33 Hz), 152.4 (‘ipso’, OPh), 172.9 (COOCH2CH3).
Synthesis of p-trifluorophenyl-(benzoxy-L-alaninyl)-phosphorochloridate
C17H16ClF3NO4P, MW=421.73.
Figure USRE047589-20190903-C00080
This is synthesised according to Standard procedure 4, using L-alanine benzyl ester hydrochloride (1.08 g, 5.01 mmol), para-trifluorophenyl-dichloro phosphate (1.490 mg, 5.01 mmol), and TEA (1.4 mL, 1.4 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 6:4) affording 1.80 (85%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 9.11, 8.84.
1-NMR (CDCl3; 300 MHz): δ 7.65 (2H, m, OPh), 7.4-7.2 (7H, m, CH2 Ph+2H OPh), 5.25 (2H, 2s, CH 2Ph), 4.75-4.55 (1H, bs, NH), 4.25-4.1 (1H, m, CHala), 1.60-1.55 (3H, 2d, 3J=7 Hz, CH 3ala).
13C-NMR (CDCl3; 75 MHz): δ 20.9 (CH3ala), 51.3, 51.0 (CHala), 68.2, 68.1 (CH2Ph), 121.4, 120.9 (‘o’, OPh), 125.2 (d, J=270 Hz, CF3), 126.6 (‘m’, OPh), 129.1, 128.8, 127.8 (Bn), 130.0 (‘p’,q, J=32 Hz, OPh), 135.4 (‘ipso’, CH2Ph), 153.0 (‘ipso’, OPh), 172.8 (COOCH2Ph).
Synthesis of 4-chlorophenyl-(methoxy-L-alaninyl)-phosphorochloridate
C10H12Cl2NO4P, MW=312.09.
Figure USRE047589-20190903-C00081
This is synthesised according to Standard procedure 4, using L-alanine methyl ester hydrochloride (1.0 g, 7.16 mmol), 4-chlorophenylphosphorodichloridate (1.757 g, 7.16 mmol), and TEA (1.449 g, 14.32 mmol, 1995 μL) in DCM (30 mL), to yield 1.621 g (72.5%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.36, 9.07.
1H-NMR (CDCl3; 300 MHz): δ 7.35-7.15 (4H, m, OPh), 4.48-4.36 (1H, bs, NH), 4.22-4.04 (1H, m, CHCH3), 3.76-3.74 (3H, 2s, CH 3O), 1.49-1.46 (3H, m, CHCH 3.
13C-NMR (CDCl3; 75 MHz): δ 21.0 (CH3CH), 50.8, 51.1 (CHCH3), 53.4 (CH3O), 121.9, 122.1, 122.3, 122.4 (‘o’, OPh), 130.6, 130.4, 130.2 (‘m’, OPh), 132.0 (‘p’, OPh), 148.6 (‘ipso’, OPh), 173.5 (COOCH3).
Synthesis of 4-chlorophenyl-(ethoxy-L-alaninyl)-phosphorochloridate
C11H14Cl2NO4P, MW=326.11.
Figure USRE047589-20190903-C00082
This is synthesised according to Standard procedure 4, using L-alanine ethyl ester hydrochloride (1.000 g, 6.50 mmol), 4-chlorophenylphosphorodichloride (1.595 g, 6.50 mmol), and TEA (1.315 g, 13.00 mmol, 1810 μL) in DCM (20 mL), to yield 1.794 mg (yield 84.7%) of product.
31P-NMR (CDCl3, 121 MHz): δ 9.54, 9.25.
1H-NMR (CDCl3; 300 MHz): δ 7.44-7.21 (4H, m, OPh), 4.59 (1H, bs, NH), 4.33-4.13 (3H, m, OCH 2CH3+CHCH3), 1.57-1.56 (3H, m, CH 3CH), 1.43-1.21 (3H, m, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5, 14.6 (OCH2 CH3), 21.0, 21.5 (CH3CH), 50.9, 51.2 (CHCH3), 62.4, 62.5 (OCH2CH3), 122.04, 122.3, 122.4 (‘o’, OPh), 130.4 (‘m’, OPh), 131.9 (‘p’, OPh), 148.5, 148.6 (‘ipso’, OPh), 173.0, 173.1 (COOCH2CH3).
Synthesis of 4-nitrophenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate
C16H16Cl2NO4P, MW=388.18.
Figure USRE047589-20190903-C00083
This is synthesised according to Standard procedure 4, using L-alanine benzyl ester hydrochloride (1.000 g, 4.63 mmol), 4-chlorophenylphosphodichloride (1.136 g, 4.63 mmol), and TEA (937.0 mg, 9.26 mmol, 1290 μL) in DCM (40 mL), to yield 1534 mg (yield 86.5%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.43, 9.16.
1H-NMR (CDCl3; 300 MHz): δ 7.42-7.08 (9H, m, OPh+CH2Ph), 5.19 (2H, s, CH 2Ph), 4.61-4.54 (1H, bs, NH), 4.26-4.10 (1H, m, CHCH3), 1.42-1.38 (3H, m, CH 3CH).
13C-NMR (CDCl3; 75 MHz): δ 20.9, 21.0 (CH3CH), 51.0, 51.2 (CHCH3), 68.1, 68.2 (OCH2Ph), 122.3, 122.4 (‘o’, OPh), 128.8, 129.1, 130.4 (‘o’, ‘m’, ‘p’, CH2 Ph+OPh), 131.9 (‘ipso’, CH2 Ph), 135.3 (‘p’, OPh), 148.5 (‘ipso’, OPh), 172.7, 172.8 (COOCH2Ph).
Synthesis of phenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate
C11H15ClNO4P, MW=291.67.
Figure USRE047589-20190903-C00084
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate methyl ester hydrochloride (583.5 mg, 3.75 mmol), phenyl dichlorophosphate (791.1 mg, 3.75, 560 μL), and TEA (758.9 mg, 7.5 mmol, 1045 μL) in DCM (20 mL), to yield 1.041 g (95.2%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 6.99 (s).
1H-NMR (CDCl3; 300 MHz): δ 7.41-7.17 (5H, m, OPh), 4.98 (1H, bs, NH), 3.80 (3H, s, OCH 3), 1.71-1.69 (6H, 2s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 27.3, 27.2, 27.0 ([CH3]2C), 53.6 (OCH3), 58.8 (C[CH3]2), 120.0, 121.1 (‘o’ OPh), 126.2 (‘p’, OPh), 130.3 (‘m’, OPh) 145.7 (‘p’, OPh), 150.2, 150.3 (‘ipso’, OPh), 175.6, 175.7 (COOCH3).
Synthesis of phenyl-(ethyl-2-amino2-methylpropanoate)-phosphorochloridate
C12H17ClNO4P, MW=305.69.
Figure USRE047589-20190903-C00085
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate ethyl ester hydrochloride (628.6 mg, 3.75 mmol), phenyl dichlorophosphate (791.1 mg, 3.75, 560 μL), and TEA (758.9 mg, 7.5 mmol, 1045 μL) in DCM (20 mL), to yield 1.018 g (88.8%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.02 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.23-7.37 (5H, m, OPh), 4.98 (1H, bs, NH), 4.24 (2H, q, 3J=7.1 Hz, OCH 2CH3), 1.70, 1.68 (6H, 2s, [CH 3]2C), 1.30 (3H, t, 3J=7.1 Hz, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2O), 27.3, 26.9 ([CH3]2C), 58.7 (C[CH3]2), 62.7 (OCH2CH3), 121.1, 121.0 (‘o’, OPh), 127.6 (‘p’, OPh), 130.7 (‘m’, OPh), 150.4 (‘ipso’, OPh), 175.2, 175.1 (COOCH2CH3).
Synthesis of phenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate
C17H19ClNO4P, MWV=367.76.
Figure USRE047589-20190903-C00086
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate benzyl ester hydrochloride (861.4 mg, 3.75 mmol), phenyl dichlorophosphate (791.1 mg, 3.75, 560 μL), and TEA (758.9 mg, 7.5 mmol, 1045 μL) in DCM (30 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 6:4) affording 580 mg (42.2%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 6.79 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.45-7.27 (10H, m, OPh+CH2 Ph), 5.28 (2H, s, CH 2Ph), 4.81, 4.78 (1H, 2bs, NH), 1.78, 1.75 (6H, 2s, [CH 3]C).
13C-NMR (CDCl3; 75 MHz): δ 27.3, 26.9 ([CH3]C), 53.9 (C[CH3]2), 60.9 (CH2Ph), 121.0, 126.3, 128.6, 129.0, 129.1, 130.3, 135.5 (OPh, CH2 Ph), 135.5 (‘ipso’, CH2Ph), 150.3, 150.2 (‘ipso’, OPh), 175.0, 175.2 (COOCH2Ph).
Synthesis of 4-nitrophenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate
C11H14ClN2O6P, MW=336.67.
Figure USRE047589-20190903-C00087
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate methyl ester hydrochloride (290.0 mg, 1.89 mmol), 4-nitrophenylphosphodichloride (483.3 mg, 1.89 mmol), and TEA (382.5 mg, 3.78 mmol, 526.9 μL) in DCM (15 mL), to yield 486 mg (yield 76.4%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 6.61 (s)
1H-NMR (CDCl3; 300 MHz): δ 8.25 (2H, d, 3J=9.0 Hz, OPh), 7.43 (2H, d, 3J=9.0 Hz, OPh), 4.91-4.87 (1H, 2bs, NH), 3.79 (3H, s, OCH 3), 1.69-1.66 (6H, 2s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 27.0, 27.1, 27.3 ([CH3]2C), 53.8 (OCH3), 59.2 (C[CH3]2), 121.7, 121.8 (‘o’ OPh), 126.2 (‘m’, OPh), 145.7 (‘p’, OPh), 154.8, 154.7 (‘ipso’, OPh), 175.4, 175.6 (COOCH3).
Synthesis of 4-nitrophenyl-(ethyl-2-amino-2-methylpropanoate)-phosphorochloridate
C12H16ClN2O6P, MW=350.69.
Figure USRE047589-20190903-C00088
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate ethyl ester hydrochloride (270.0 mg, 1.61 mmol), 4-nitrophenylphodichloride (412.3 mg, 1.61 mmol), and TEA (325.8 mg, 3.22 mmol, 448.8 μL) in DCM (15 mL), to yield 500 mg (yield 88.5%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 6.64 (s)
1H-NMR (CDCl3; 300 MHz): δ 8.35 (2H, d, 3J=9.0 Hz, OPh), 7.53 (2H, d, 3J=9.0 Hz, OPh), 4.99-4.96 (1H, 2bs, NH), 4.34 (2H, q, 3J=7.1 Hz, OCH 2CH3), 1.79-1.76 (6H, 2s, [CH 3]2C), 1.40 (3H, t, 3J=7.1 Hz, OCH2CH 3.
13C-NMR (CDCl3; 75 MHz): δ 14.5 (OCH2 CH3), 27.0, 27.3 ([CH3]2C), 59.1, 59.2 (C[CH3]2), 62.9, 63.0 (OCH2CH3), 121.7, 121.8 (‘o’ OPh, 126.2 (‘m’, OPh), 145.7 (‘p’, OPh), 154.7, 154.8 (‘ipso’ OPh), 175.4, 175.6 (CCOOCH2CH3).
Synthesis of 4-nitrophenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate
C17H18ClN2O6P, MW=412.76.
Figure USRE047589-20190903-C00089
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate benzyl ester hydrochloride (578 mg, 2.52 mmol), 4-nitrophenylphosphodichloride (645 mg, 2.52 mmol), and TEA (510 mg, 5.04 mmol, 702.5 μL) in DCM (20 mL), to yield 936 mg (yield 90.0%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 6.56 (s)
1H-NMR (CDCl3; 300 MHz): δ 8.29 (2H, d, 3J=9.0 Hz, OPh), 7.47 (2H, d, 3J=9.0 Hz, OPh), 7.40-7.37 (5H, m, CH2 Ph), 5.27 (2H, s, CH 2Ph), 5.04-5.01 (1H, 2bs, NH), 1.77-1.74 (6H, 2s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 27.0, 27.3, ([CH3]2C), 59.2 (C[CH3]2), 68.5 (OCH2Ph), 121.6, 121.7, 126.2, 128.6, 129.1, (‘o’, ‘m’, ‘p’, CH2 Ph+OPh), 135.7 (‘ipso’, CH2Ph), 145.7 (‘p’, OPh), 154.7, 154.8 (‘ipso’, OPh), 175.8, 175.9 (COOCH2Ph).
Synthesis of 4-chlorophenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate
C11H14Cl2NO4P, MW=326.11.
Figure USRE047589-20190903-C00090
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate methyl ester hydrochloride (280.0 mg, 1.82 mmol), 4-chlorophenylphosphodichloride (447.4 mg, 1.82 mmol), and TEA (368.3 mg, 3.64 mmol, 507.3 μL) in DCM (20 mL), to yield 554 mg (yield 91.1%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.05 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.38 (2H, d, 3J=9.0 Hz, OPh), 7.28-7.24 (2H, 2d, 3J=9.0 Hz, OPh), 4.87-4.83 (1H, 2bs, NH), 3.84 (3H, s, OCH 3), 1.73-1.71 (6H, 2s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 27.0, 27.3, ([CH3]2C), 53.7 (OCH3), 58.9 (C[CH3]2), 122.5 (‘o’, OPh), 129.7 (‘m’, OPh), 131.8 (‘p’, OPh) 148.7, 148.9 (‘ipso’, OPh), 175.5, 175.7 (COOCH3).
Synthesis of 4-chlorophenyl-(ethyl-2-amino-2-methylpropanoate)-phosphorochloridate
C12H16Cl2NO4P, MW=340.14.
Figure USRE047589-20190903-C00091
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate ethyl ester hydrochloride (293.4 mg, 1.75 mmol), 4-chlorophenylphosphodichloride (430.0 mg, 1.75 mmol), and TEA (354.2 mg, 3.50 mmol, 488.0 μL) in DCM (15 mL), to yield 571.7 mg (yield 96.1%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.09 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.38 (2H, d, 3J=9.1 Hz, OPh), 7.26 (2H, d, 3J=9.1 Hz, OPh), 4.88-4.84 (1H, 2bs, NH), 4.29 (2H, q, 3J=7.1 Hz, OCH 2CH3), 1.74-1.70 (6H, 2s, [CH 3]C), 1.35 (3H, t, 3J=7.1 Hz, OCH2CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (OCH2 CH3), 27.0, 27.3 ([CH3]2C), 58.9 (C[CH3]2), 62.8 (OCH2CH3), 122.5 (‘o’, OPh), 130.4 (‘m’, OPh), 131.8 (‘p’, OPh), 148.7, 148.8 (‘ipso’, OPh), 175.1, 175.3 (COOCH2CH3).
Synthesis of 4-chlorophenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate
C17H18Cl2NO4P, MW=402.21.
Figure USRE047589-20190903-C00092
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate benzyl ester hydrochloride (402.0 mg, 1.75 mmol), 4-chlorophenylphosphodichloride (430 mg, 1.75 mmol), and TEA (354.2 mg, 3.50 mmol, 488.0 μL) in DCM (15 mL), to yield 657.9 mg (yield 93.5%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.00 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.39-7.12 (9H, m, CH2 Ph+OPh), 5.18 (2H, s, CH 2Ph), 4.75-4.72 (1H, 2bs, NH), 1.68-1.65 (6H, 2s, [CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 27.0, 27.3, ([CH3]2C), 59.0 (C[CH3]2), 68.4 (OCH2Ph), 122.5, 128.6, 129.1, 130.7 (‘o’, ‘m’, ‘p’, CH2 Ph+OPh), 131.8 (‘p’, CH2Ph), 135.4 (‘p’, OPh), 148.6, 148.7 (‘ipso’, OPh), 174.9, 175.1 (COOCH2Ph).
Synthesis of 4-(trifluoromethyl)-phenyl-(benzyl-2-amino-2-methylpropanoate)-phosphorochloridate
C18H18ClF3NO4P, MW=435.76.
Figure USRE047589-20190903-C00093
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate benzyl ester hydrochloride (341.0 mg, 1.49 mmol), 4-(trifluoromethyl)-phenyl-phosphodichloridate (414.3 mg, 1.49 mmol), and TEA (300.5 mg, 2.97 mmol, 413.9 μL) in DCM (15 mL), to yield 623.9 mg (96.4%) of crude product used without further purification.
13P-NMR (CDCl3, 121 MHz): δ 6.74 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.66 (2H, d, 3J=8.8 Hz, OPh), 7.42-7.30 (7H, m, OPh+CH2 Ph), 5.25 (2H, s, CH 2Ph), 4.95-4.91 (1H, 2bs, NH), 1.75-1.72 (6H, 2s, (CH 3]2C).
13C-NMR (CDCl3; 75 MHz): δ 26.9, 27.0, 27.3 ([CH3]2C), 59.1 (C[CH3]2), 68.4 (CH2Ph), 121.1, 121.4, 127.7, 128.4, 128.5, 128.6, 128.9 (‘o’, ‘m’, ‘p’, OPh+CH2 Ph), 124.2 (CF3, J=265 Hz), 135.4 (‘ipso’, CH2 Ph), 152.6, 152.7 (‘ipso’, OPh), 174.9, 175.0 (COOCH2Ph).
Synthesis of Phenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate
C13H17ClNO4P, MW=317.70.
Figure USRE047589-20190903-C00094
This is synthesised according to Standard procedure 4, using methyl-1-amino-1-cyclopentanoate hydrochloride salt (0.885 g, 5.01 mmol), phenyldichlorophosphate (1.12 g, 0.749 ml, 5.01 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL), to yield 1.266 g (81%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.90.
1H-NMR (CDCl3; 300 MHz): δ 7.4-7.2 (5H, m, OPh), 4.3 (1H, bs, NH), 3.75 (3H, 2s, OCH 3), 2.15 (4H, m, 4H cyclopentane), 1.9-1.7 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4 (2CH2 cyclopent), 38.8, 38.7, 38.6 (2CH2 cyclopent), 53.3, 53.2 (CH3O), 66.6 (Cq cyclopentane), 121.1, 121.0 (‘o’ OPh), 126.3 (‘p’, OPh), 130.3, 130.2 (‘m’, OPh), 150.2 (‘ipso’, OPh), 174.8 (COOCH3).
Synthesis of Phenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate
C14H19ClNO4P, MW=331.73.
Figure USRE047589-20190903-C00095
This is synthesised according to Standard procedure 4, using ethyl-1-amino-1-cyclopentanoate hydrochloride salt (955 mg, 5.01 mmol), phenyldichlorophosphate (1.12 g, 5.01 mmol, 749 μL), and TEA (1.4 mL, 10.02 mmol) in DCM (40 mL). The crude was purified by flash chromatography (ethyl acetate/petroleum ether 7:3) affording 1.457 g (89%) of oil.
31P-NMR (CDCl3, 121 MHz): δ 8.04, 7.97.
1H-NMR (CDCl3; 300 MHz): δ 7.4-7.1 (5H, m, OPh), 4.7 (1H, bs, NH), 4.2 (2H, 2q, 3J=7.1 Hz, OCH 2CH3), 2.15 (4H, m, 4H cyclopentane), 1.9-1.7 (4H, m, 4H cyclopentane), 1.30 (3H, t, 3J=7.1 Hz, OCH2 CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.5 (CH3CH2), 24.5 (2CH2 cyclopent), 38.8, 38.7, 38.6, 38.5 (2CH2 cyclopent), 62.0_CH3 CH2), 68.3 (Cq cyclopentane), 120.9 (‘o’ OPh), 126.3 (‘p’, OPh), 130.3 (‘m’, OPh), 150.3-150.2 (‘ipso’, OPh), 174.9-174.8 (COOCH2CH3).
Synthesis of Phenyl-(benzoxy-α,α-cycloleucinyl)-phosphorochloridate
C19H21ClNO4P, MW=393.80.
Figure USRE047589-20190903-C00096
This is synthesised according to Standard procedure 4, using benzyl-1-amino-1-cyclopentanoate hydrochloride salt (0.984 g, 3.84 mmol), phenyl-dichlorophosphate (0.577 ml, 3.84 mmol), and TEA (1.08 mL, 7.69 mmol) in DCM (30 mL), to yield 1.485 g (98%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.85.
1H-NMR (CDCl3; 300 MHz): δ 7.3-7.0 (10H, m, OPh+CH2 Ph), 5.2 (2H, s, CH 2Ph), 4.95-4.65 (1H, bs, NH), 2.25-2.1 (4H, m, 4H cyclopentane), 1.9-1.7 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4, 24,3 (2CH2 cyclopent), 38.8, 38.7, 38.5 (2CH2 cyclopent), 67.3 (Cq cyclopentane), 68.0 (CH2Ph), 121.0 (‘o’ OPh), 126.4 (‘p’, OPh), 130.1, 129.0, 128.8 (‘m’OPh, CH2 Ph), 135.4 (‘ipso’, CH2Ph), 150.1 (‘ipso’, OPh), 173.4 (COOCH2Ph),
Synthesis of p-fluorophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate
C13H16ClNO4P, MW=335.70.
Figure USRE047589-20190903-C00097
This is synthesised according to Standard procedure 4, using methyl-1-amino-1-cyclopentanoate hydrochloride salt (0.885 g, 5.01 mmol), parafluorophenyldichlorophosphate (1.21 g, 5.01 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL), to yield 1.65 g (99%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 8.61.
1H-NMR (CDCl3; 300 MHz): δ 7.3-7.2 (2H, m, OPh), 7.1-7.0 (2H, m, OPh), 4.7 (1H, bs, NH), 3.78 (3H, 2s, OCH 3), 2.25-2.15 (4H, m, 4H cyclopentane), 2.0-1.8 (4H, m, 4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4 (2CH2 cyclopent), 38.7, 38.6, 38.5 (2CH2 cyclopent), 53.3 (CH3O), 66.3-66.2 (Cq cyclopentane), 117.1-116.8 (‘o’ OPh), 122.6-122.5 (‘m’, OPh), 146.1-145.9 (‘ipso’, OPh), 159.0 (‘p’, OPh), 175.3-175.2 (COOCH3).
Synthesis of p-fluorophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate
C14H18ClFNO4P, MW=349.72.
Figure USRE047589-20190903-C00098
This is synthesised according to Standard procedure 4, using ethyl-1-amino-1-cyclopentanoate hydrochloride salt (955 mg, 5.01 mmol), para-fluorophenyldichlorophosphate (1.21 g, 5.01 mmol), and TEA (1.4 mL, 10.02 mmol) in DCM (40 mL), to yield 1.64 g (94%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 8.70.
1H-NMR (CDCl3; 300 MHz): δ 7.3-7.2 (2H, m, OPh), 7.1-7.0 (2H, m, OPh), 4.8 (1H, bs, NH), 4.2 (2H, 2q,3J=7.1 Hz, OCH 2CH3), 2.25-2.1 (4H, m, 4H cyclopentane), 2.0-1.8 (4H, m, 4H cyclopentane), 1.4 (3H, t, 3J=7.1 Hz, OCH2 CH 3).
13C-NMR (CDCl3; 75 MHz): δ 14.4 (CH3CH2), 24.4 (2CH2 cyclopent), 38.8, 38.7, 38.6, 38.5 (2CH2 cyclopent), 62.3_CH3 CH2), 68.3 (Cq cyclopentane), 117.4, 117.0 (‘o’ OPh), 122.7, 122.6 (‘m’, OPh), 146.1, 146.0 (‘ipso’, OPh), 159.0 (‘p’, OPh), 174.9 (COOCH2CH3).
Synthesis of p-fluorophenyl-(benzoxy-α,α-cycloleucinyl)-phosphorochloridate
C19H20ClFNO4P, MW=411.79.
Figure USRE047589-20190903-C00099
This is synthesised according to Standard procedure 4, using benzyl-1-amino-1-cyclopentanoate hydrochloride salt (1.281 g, 5.01 mmol), para-fluorophenyl-dichlorophosphate (1.21 g, 5.01 mmol), and TEA (1.4 mL, 10 mmol) in DCM (40 mL), to yield 1.85 g (90%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.85.
1H-NMR (CDCl3; 300 MHz): δ 7.65-7.4 (5H, m, CH2 Ph), 7.3-7.2 (2H, m, OPh), 7.1-7.0 (2H, m, OPh), 5.2 (2H, s, CH 2Ph), 4.6 (1H, bs, NH), 2.2-2.1 (4H, m, 4H cyclopentane), 2.0-1.8 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.5 (2CH2 cyclopent), 38.9, 38.8, 38.6, 38.5 (2CH2 cyclopent), 68.1 (Cq cyclopentane), 68.4 (CH2Ph), 117.0, 116.8 (‘o’ OPh), 122.6, 122.5 (‘m’OPh) 129.1, 129.0, 128.8, 128.7 (CH2 Ph), 135.7 (‘ipso’, CH2Ph), 146.1, 145.9 (‘ipso’, OPh), 159.0 (‘p’, OPh), 174.6 (COOCH2Ph).
Synthesis of p-nitrophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate
C13H16ClN2O6P, MW=362.70.
Figure USRE047589-20190903-C00100
This is synthesised according to Standard procedure 4, using methyl-1-amino-1-cyclopentanoate hydrochloride salt (0.885 g, 5.01 mmol), para-nitrophenyldichlorophosphate (1.632 g, 5.01 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL), to yield 1.601 g (90%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 8.02.
1H-NMR (CDCl3; 300 MHz): δ 8.2 (2H, 2d, 3J=8 Hz, OPh), 7.32 (2H, 2d, 3J=8 Hz OPh), 4.9 (1H, bs, NH), 3.71 (3H, s, OCH 3), 2.25-2.00 (4H, m, 4H cyclopentane), 1.95-1.7 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.3 (2CH2 cyclopent), 38.7, 38.6 (2CH2 cyclopent), 53.3 (CH3O), 68.6 (Cq cyclopentane), 121.8, 121.7 (‘o’ OPh), 126.0 (‘m’, OPh), 145.6 (‘ipso’, OPh), 154.8, 154.7 (‘p’, OPh), 175.1-175.0 (COOCH3).
Synthesis of p-nitrophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate
C14H18ClN2O6P, MW=376.73.
Figure USRE047589-20190903-C00101
This is synthesised according to Standard procedure 4, using ethyl-1-amino-1-cyclopentanoate hydrochloride salt (955 mg, 5.01 mmol), para-nitrophenyldichlorophosphate (1.362 g, 5.01 mmol), and TEA (1.4 mL, 10.02 mmol) in DCM (40 mL), to yield 1.669 g (90%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.95.
1H-NMR (CDCl3; 300 MHz): δ 8.1 (2H, 2d, 3J=8 Hz, OPh), 7.28 (2H, 2d, 3J=8 Hz OPh), 4.8 (1H, bs, NH), 4.2 (2H, 2q, 3J=7.1 Hz, OCH 2CH3), 2.2-2.0 (4H, m, 4H cyclopentane, 1.95-1.7 (4H, m, 4H cyclopentane), 1.27 (3H, t, 3J=7.1 Hz, OCH2 CH 3.
13C-NMR (CDCl3; 75 MHz): δ 14.4 (CH3CH2), 24.4 (2CH2 cyclopent), 38.8, 38.7 (2CH2 cyclopent), 62.4_CH3 CH2), 68.5 (Cq cyclopentane), 121.8, 121.1 (‘o’ OPh), 126.1, 125.9 (‘m’, OPh), 145.6 (‘ipso’, OPh), 154.8 (‘p’, OPh), 174.9 (COOCH2CH3).
Synthesis of p-nitrophenyl-(benzoxy-α,α-cycloleucinyl)-phosphorochloridate
C19H20ClN2O6P, MW=438.80.
Figure USRE047589-20190903-C00102
This is synthesised according to Standard procedure 4, using benzyl-1-amino-1-cyclopentanoate hydrochloride salt (0.835 g, 3.25 mmol), para-nitrophenyl-dichlorophosphate (0.85 g, 3.25 mmol), and TEA (0.91 mL, 6.7 mmol) in DCM (30 mL), to yield 1.215 g (85%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.99, 7.90.
1H-NMR (CDCl3; 300 MHz): δ 8.1 (2H, 2d, 3J=8 Hz, OPh), 7.4-7.2 (7H, m, OPh+CH2 Ph), 5.18 (2H, s, CH 2Ph), 5.0 (1H, bs, NH), 2.2-2.0 (4H, m, 4H cyclopentane), 1.95-1.75 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4 (2CH2 cyclopent), 38.8, 38.7, 38.6, 38.5 (2CH2 cyclopent), 68.0 (CH2Ph), 68.6 (Cq cyclopentane), 121.8, 121.7 (‘o’ OPh), 126.1, 125.9 (‘m’OPh) 129.1, 129.0, 128.8, 128.6 (CH2 Ph), 135.7 (‘ipso’, CH2Ph), 145.6 (‘ipso’, OPh), 154.8, 154.7 (‘p’, OPh), 174.5, 174.4 (COOCH2Ph).
Synthesis of p-chlorophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate
C13H16Cl2NO4P, MW=352.15.
Figure USRE047589-20190903-C00103
This is synthesised according to Standard procedure 4, using methyl-1-amino-1-cyclopentanoate hydrochloride salt (0.443 g, 2.5 mmol), para-chlorophenyldichlorophosphate (0.613 g, 2.5 mmol), and TEA (0.7 ml, 5 mmol) in DCM (20 mL), to yield 0.852 g (98%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.55, 9.5.
1H-NMR (CDCl3; 300 MHz): δ 7.35-7.15 (4H, m, OPh), 4.95 (1H, bs, NH), 3.78 (3H, s, OCH 3), 2.2-2.00 (4H, m, 4H cyclopentane), 1.95-1.7 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.3 (2CH2 cyclopent), 38.7 (2CH2 cyclopent), 53.3 (CH3O), 68.6 (Cq cyclopentane), 122.0 (‘o’ OPh), 130.1 (‘m’, OPh), 133.2 (‘p’, OPh), 149.9 (‘ipso’, OPh), 175.1-175.0 (COOCH3).
Synthesis of p-chlorophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate
C14H18Cl2NO4P, MW=366.18.
Figure USRE047589-20190903-C00104
This is synthesised according to Standard procedure 4, using ethyl-1-amino-1-cyclopentanoate hydrochloride salt (0.477 g, 2.5 mmol), para-chlorophenyldichlorophosphate (0.613 g, 2.5 mmol), and TEA (0.7 mL, 5 mmol) in DCM (20 mL), to yield 0.880 g (97%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.85, 9.70.
1H-NMR (CDCl3; 300 MHz): δ 7.35-7.15 (4H, m, OPh), 4.9 (1H, bs, NH), 4.22 (2H, 2q, 3J=7.1 Hz, OCH 2CH3), 2.2-2.0 (4H, m, 4H cyclopentane), 1.95-1.7 (4H, m, 4H cyclopentane), 1.27 (3H, t, 3J=7 Hz, OCH2 CH 3.
13C-NMR (CDCl3; 75 MHz): δ 14.4 (CH3CH2), 24.4 (2CH2 cyclopent), 38.8, 38.7 (2CH2 cyclopent), 62.5, 62.4 CH3 CH2), 68.1 (Cq cyclopentane), 122.2, 122.1 (‘o’ OPh), 130.1 (‘m’, OPh), 133.2 (‘p’, OPh), 149.8 (‘ipso’, OPh), 174.8 (COOCH2CH3).
Synthesis of p-chlorophenyl-(benzoxy-α,α-cycloleucinyl)-phosphorochloridate
C19H20Cl2NO4P, MW=428.25.
Figure USRE047589-20190903-C00105
This is synthesised according to Standard procedure 4, using benzyl-1-amino-1-cyclopentanoate hydrochloride salt (0.640 g, 2.5 mmol), para-chlorophenyl-dichlorophosphate (0.613 g, 2.5 mmol), and TEA (0.7 mL, 5 mmol) in DCM (20 mL), to yield 1.041 g (97%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.39, 8.95.
1H-NMR (CDCl3; 300 MHz): δ 7.4-7.15 (9H, m, OPh+CH2 Ph), 5.20 (2H, s, CH2 Ph), 5.0 (2H, s, CH 2Ph), 5.0 (1H, bs, NH), 2.2-2.0 (4H, m, 4H cyclopentane), 1.95-1.75 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.4 (2CH2 cyclopent), 38.8, 38.7, 38.6 (2CH2 cyclopent), 68.1, 68.0 (CH2Ph), 68.2 (Cq cyclopentane), 121.9, 121.8 (‘o’ OPh), 130.5, 130.4, 129.3, 129.2 (‘m’OPh, CH2 Ph), 133.2 (‘p’, OPh), 135.7 (‘ipso’, CH2Ph), 149.9 (‘ipso’, OPh), 174.3, 174.2 (COOCH2Ph).
Synthesis of p-trifluorophenyl-(methoxy-α,α-cycloleucinyl)-phosphorochloridate
C14H16ClF3NO4P, MW=385.70.
Figure USRE047589-20190903-C00106
This is synthesised according to Standard procedure 4, using methyl-1-amino-1-cyclopentanoate hydrochloride salt (0.443 g, 2.5 mmol), para-trifluorophenyldichlorophosphate (0.700 g, 2.5 mmol), and TEA (0.7 ml, 5 mmol) in DCM (20 mL), to yield 0.931 g (97%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 8.80, 8.62.
1H-NMR (CDCl3; 300 MHz): δ 7.65 (2H, 2d, 3J=8 Hz, OPh), 7.35 (2H, 2d, 3J=8 Hz OPh), 5.02 (1H, bs, NH), 3.78 (3H, s, OCH 3), 2.25-2.05 (4H, m, 4H cyclopentane), 1.95-1.7 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 22.8 (2CH2 cyclopent), 37.5, 37.2 (2CH2 cyclopent), 51.5 (CH3O), 68.4 (Cq cyclopentane), 120.0 (‘o’, OPh), 124.8 (d, J=270 Hz, CF3), 126.6 (‘m’, OPh), 129.5 (‘p’,q, J=32 Hz, OPh), 152.8 (‘ipso’, OPh), 175.2 (COOCH3).
Synthesis of p-trifluorophenyl-(ethoxy-α,α-cycloleucinyl)-phosphorochloridate
C15H18ClF3NO4P, MW=399.73.
Figure USRE047589-20190903-C00107
This is synthesised according to Standard procedure 4, using ethyl-1-amino-1-cyclopentanoate hydrochloride salt (0.477 g, 2.5 mmol), para-trifluorophenyldichlorophosphate (0.700 g, 2.5 mmol), and TEA (0.7 mL, 5 mmol) in DCM (20 mL), to yield 0.950 g (89%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 8.49.
1H-NMR (CDCl3; 300 MHz): δ 7.45 (2H, m, OPh), 7.2 (2H, m, OPh), 5.12 (1H, bs, NH), 4.05 (2H, m, OCH 2CH3), 2.15-2.0 (4H, m, 4H cyclopentane), 1.9-1.65 (4H, m, 4H cyclopentane), 1.2 (3H, 2t, 3J=7 Hz, OCH2 CH 3.
13C-NMR (CDCl3; 75 MHz): δ 14.3 (CH3CH2), 24.2, 24.1 (2CH2 cyclopent), 38.6, 38.5, 38.4 (2CH2cyclopent), 62.0 CH3 CH 2), 68.4 (Cq cyclopentane), 121.5 (‘o’, OPh), 125.0 (d, J=270 Hz, CF3), 127.5 (‘m’, OPh), 129.9 (‘p’,q, J=32 Hz, OPh), 152.8, 152.7 (‘ipso’, OPh), 174.9, 174.6 (COOCH2CH3).
Synthesis of p-trifluorophenyl-(benzoxy-α,α-cycloleucinyl)-phosphorochloridate
C20H20ClF3NO4P, MW=461.80.
Figure USRE047589-20190903-C00108
This is synthesised according to Standard procedure 4, using benzyl-1-amino-1-cyclopentanoate hydrochloride salt (0.700 g, 2.73 mmol), para-trifluorophenyl-dichlorophosphate (0.75 g, 2.73 mmol), and TEA (0.75 mL, 5.47 mmol) in DCM (25 mL), to yield 1.089 g (86%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.39, 8.95.
1H-NMR (CDCl3; 300 MHz): δ 7.50 (2H, m, OPh), 7.4-7.15 (7H, m, OPh+CH2 Ph), 5.20 (2H, s, CH 2Ph), 4.95 (1H, bs, NH), 2.2-2.0 (4H, m, 4H cyclopentane), 1.95-1.75 (4H, m, 4H cyclopentane).
13C-NMR (CDCl3; 75 MHz): δ 24.3 (2CH2 cyclopent), 38.8, 38.7, 38.6 (2CH2 cyclopent), 68.1, 68.0 (CH2Ph), 68.2 (Cq cyclopentane), 121.4, 121.3 (‘o’, OPh), 125.1 (d, J=270 Hz, CF3), 126.6 (‘m’, OPh) 129.2, 128.8, 127.8 (Bn), 129.8 (‘p’,q, J=32 Hz, OPh), 135.7 (‘ipso’, CH2Ph), 153.5 (‘ipso’, OPh), 174.5, 174.4 (COOCH2Ph).
Synthesis of Phenyl-(methoxy-L-phenylalaninyl)-phosphorochloridate
C16H17ClNO4P, MW=353.74.
Figure USRE047589-20190903-C00109
This is synthesised according to Standard procedure 4, using L-phenylalanine methyl ester hydrochloride (1.08 g, 5 mmol), phenyldichlorophosphate (1.12 g, 0.75 ml, 5 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL), to yield 1.626 g (92%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.1, 8.95.
1H-NMR (CDCl3; 300 MHz): δ 7.3-7.1 (10H, m, CH2Ph+OPh), 5.00 (1H, bs, NH), 4.35 (1H, m, CHphenylala), 3.79 (3H, 2s, CH3O), 3.00 (2H, m, CH2Ph)
13C-NMR (CDCl3; 75 MHz): δ 36.3 (CH2phenylalanine), 53.0 (CH3O), 56.6, 56.5 (CHphenylala), 121.0 (‘o’ OPh), 126.4 (‘p’, OPh), 130.2 (‘m’, OPh), 150.2 (‘ipso’, OPh), 174.1 (COOCH3).
Synthesis of Phenyl-(methoxy-L-leucinyl)-phosphorochloridate C13H19ClNO4P, MW=319.72
Figure USRE047589-20190903-C00110
This is synthesised according to Standard procedure 4, using L-leucine methyl ester hydrochloride (0.91 g, 5 mmol), phenyldichlorophosphate (1.12 g, 0.75 ml, 5 mmol), and TEA (1.4 ml, 10 mmol) in DCM (40 mL), to yield 1.58 g (99%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.45. 9.35.
1H-NMR (CDCl3; 300 MHz): δ 7.4-7.2 (5H, m, OPh), 4.90 (1H, bs, NH), 3.95 (1H, m, CHCH2CH(CH3)2), 3.78 (3H, s, OCH 3), 1.8 (1H, m, CHCH2CH(CH3)2), 1.8-1.5 (2H, m, CHCH2CH(CH3)2), 1.0-0.9 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.2, 23.1, 22.4, 22.3 (2C, CHCH2CH(CH3)2), 24.9, 24.8 (CHCH2CH(CH3)2), 43.6 (CHCH2CH(CH3)2), 53.2 (CH30), 53.7, 53.6 (CHCH2CH(CH3)2), 120.9 (‘o’ OPh), 126.4 (‘p’, OPh), 130.2 (‘m’, OPh), 150.1 (‘ipso’, OPh), 173.6 (COOCH3).
Synthesis of Phenyl-(benzoxy-L-leucinyl)-phosphorochloridate. C19H23ClNO4P, MW=395.82
Figure USRE047589-20190903-C00111
This is synthesised according to Standard procedure 4, using L-leucine benzyl ester hydrochloride (1.29 g, 5.0 mmol), phenyl-dichlorophosphate (1.12 g, 0.75 ml, 5.0 mmol), and TEA (1.4 mL, 10.0 mmol) in DCM (40 mL), to yield 1.88 g (95%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.93, 9.57.
1H-NMR (CDCl3; 300 MHz): δ 7.5-7.2 (10H, m, OPh+CH2 Ph), 5.2 (2H, 2s, CH 2Ph), 4.95 (1H, bs, NH), 4.2-4.1 (1H, m, CHCH2CH(CH3)2), 1.95-1.80 (1H, m, CHCH2CH(CH3)2), 1.7 (2H, m, CHCH2CH(CH3)2), 1.0-0.9 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.2, 23.1, 22.4, 22.3 (2C, CHCH2CH(CH3)2), 24.9 (CHCH2CH(CH3)2), 43.5 (CHCH2CH(CH3)2), 53.8, 53.3 (CHCH2CH(CH3)2), 67.8, 67.7 (CH2Ph), 120.7 (‘o’ OPh), 126.4 (‘p’, OPh), 130.2, 129,1, 128.8, 128.7 (‘m’OPh, CH2 Ph), 135.8 (‘ipso’, CH2Ph), 150.2 (‘ipso’, OPh), 174.1 (COOCH2Ph).
Synthesis of p-nitrophenyl-(benzoxy-L-leucinyl)-phosphorochloridate. C19H22ClN2O6P, MW=440.81
Figure USRE047589-20190903-C00112
This is synthesised according to Standard procedure 4, using L-leucine benzyl ester hydrochloride (1.08 g, 5.01 mmol), para-nitrophenyl-dichloro phosphate (1.362 g, 5.01 mmol), and TEA (1.4 mL, 1.4 mmol) in DCM (40 mL), to yield 2.08g (95%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz); δ 9.87, 9.38.
1H-NMR (CDCl3; 300 MHz): δ 8.25-8.10 (2H, m, OPh), 7.35-7.25 (7H, m, OPh+CH2 Ph), 5.15 (2H, 2s, CH 2Ph), 4.95 (1 H, bs, NH), 4.15 (1H, m, CHCH2CH(CH3)2), 1.95 (1H, m, CHCH2CH(CH3)2), 1.7 (2H, m, CHCH2CH(CH3)2), 1.0-0.9 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.2, 23.1, 22.1, 22.0 (2C, CHCH2CH(CH3)2), 24.8 (CHCH2CH(CH3)2), 43.4, 43.3 (CHCH2CH(CH3)2), 54.2, 53.9 (CHCH2CH(CH3)2), 68.0 67.9 (CH2Ph), 121.6 (‘o’ OPh), 126.2, 126.1 (‘m’OPh), 129.2, 129.0 (CH2 Ph), 135.4, 135.3 (‘ipso’, CH2Ph), 145.8, 145.7 (‘ipso’, OPh), 154.7, 154.5 (‘p’, OPh), 173.0, 172.8 (COOCH2Ph).
Synthesis of pchlorophenyl-(benzoxy-L-leucinyl)-phosphorochloridate. C19H22Cl2NO4P, MW=430.26
Figure USRE047589-20190903-C00113
This is synthesised according to Standard procedure 4, using L-leucine benzyl ester hydrochloride (0.644 g, 2.5 mmol), para-chlorophenyl-dichlorophosphate (0.613 g, 2.5 mmol), and TEA (0.7 mL, 5 mmol) in DCM (20 mL), to yield 0.968 g (90%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 9.71, 9.55.
1H-NMR (CDCl3; 300 MHz): δ 7.4-7.0 (9H, m, OPh+CH2 Ph), 5.15 (2H, s, CH 2Ph), 4.5 (1H, d, 3J=7 Hz, NH), 4.0 (1H, m, CHCH2CH(CH3)2), 1.9-1.8 (1H, m, CHCH2CH(CH3)2), 1.7 (2H, m, CHCH2CH(CH3)2), 0.85 (6H, m, CHCH2CH(CH3)2).
13C-NMR (CDCl3; 75 MHz): δ 23.4, 23.3, 22.5, 22.4 (2C, CHCH2CH(CH3)2), 25.0 (CHCH2CH(CH3)2), 43.8, 43.7 (CHCH2CH(CH3)2), 54.0, 53.8 (CHCH2CH(CH3)2), 68.2 (CH2Ph), 122.5 (‘o’ OPh), 130.5, 130.4, 129.3, 129.2 (‘m’OPh, CH2 Ph), 133.2 (‘p’, OPh), 135.7 (‘ipso’, CH2Ph), 149.9, 149.8 (‘ipso’, OPh), 173.4, 173.2 (COOCH2Ph).
Synthesis of 4-chlorophenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate. C11H14Cl2NO4P, MW=326.11
Figure USRE047589-20190903-C00114
This is synthesised according to Standard procedure 4, using 2-aminoisobutyrate methyl ester hydrochloride (280.0 mg, 1.82 mmol), 4-chlorophenylphosphodichloride (447.4 mg, 1.82 mmol), and TEA (368.3 mg, 3.64 mmol, 507.3 μL) in DCM (20 mL), to yield 554 mg (yield 91.1%) of crude product used without further purification.
31P-NMR (CDCl3, 121 MHz): δ 7.05 (s)
1H-NMR (CDCl3; 300 MHz): δ 7.38 (2H, d, 3J=9.0 Hz, OPh), 7.29-7.24 (2H, 2d, 3J=9.0 Hz, OPh), 4.87-4.83 (1H, 2bs, NH) 3.84 (3H, s, OCH 3), 1.73-1.71 (6H, 2s, [CH 3]2C)
13C-NMR (CDCl3; 75 MHz): δ 27.0, 27.3, ([CH3]2C), 53.7 (OCH3), 58.9 (C[CH3]2), 122.5 (‘o’, OPh), 129.7 (‘m’, OPh), 131.8 (‘p’, OPh) 148.7, 148.9 (‘ipso’, OPh), 175.5, 175.7 (COOCH3).
Synthesis of 4-chlorophenyl-phosphodichloridate. C6H4Cl3O2P, MWW=245.43
Figure USRE047589-20190903-C00115
This was synthesised according to Standard procedure 3, using phosphorus-oxychloride 1533 mg, 10.00mmol, 932 μL), 4-chlorophenol (1.285 g, 10.00 mmol) and TEA (1.011 g, 0.00 mmol, 1394 μL) in ethylether (100 mL) to give an oil (1.897 g, 77.3% yield).
31P-NMR (CDCl3, 121 MHz): δ 5.18.
1H-NMR (CDCl3; 300 MHz): δ 7.45 (2H, d, 3J=9.0 Hz, OPh), 7.30 (2H, d, 3J=9.0 Hz, OPh).
13C-NMR (CDCl3; 75 MHz): δ 122.5 (‘o’, OPh), 130.6 (‘m’, OPh), 133.2 (‘p’, OPh), 148.5 (‘ipso’, OPh).
Synthesis of 4-(trifluoromethyl)-phenyl-phosphodichloridate. C7H4ClF3O3P, MW=278.98
Figure USRE047589-20190903-C00116
This was synthesised according to Standard procedure 3, using phosphorus-oxychloride (1.570 mg, 10.24 mmol, 954.5 μL), 4-trifluoromethylphenol (1660 g, 10.24 mmol) and TEA (1.036 g, 10.24 mmol, 1427 μL) in ethylether (100 mL) to give an oil (2.521 g, 88.2% yield).
31P-NMR (CDCl3, 121 MHz): δ 4.75.
1H-NMR (CDCl3; 300 MHz): δ 7.77 (2H, d, 3J8.4 Hz, OPh), 7.49 (2H, d, 3J=8.4 Hz,
13C-NMR (CDCl3; 75 MHz): δ 121.6 (‘o’, OPh), 123.6 (CF3, J=271 Hz, OPh), 128.2 (‘m’, OPh), 129.7 (‘p’, J=33 Hz), 152.7 (‘ipso’, OPh).
Synthesis of 4-fluorophenyl-phosphodichloridate. C6H4Cl2FO2P, MW=228.97
Figure USRE047589-20190903-C00117
This was synthesised according to Standard procedure 3, using phosphorus-oxychloride (1.395 mL, 15.00 mmol), 4-chlorophenol (1.68 g, 15.00 mmol) and TEA (2.1 mL, 15.00 mmol) in ethylether (140 mL) to give an oil (3.96 g, 96% yield).
31P-NMR (CDCl3, 121 MHz): δ 5.52.
1H-NMR (CDCl3; 300 MHz): δ 7.15 (2H, d, 3J=8.0 Hz, OPh), 7.05 (2H, d, 3J=8.0 Hz, OPh).
13C-NMR (CDCl3; 75 MHz): δ 116.8 (‘o’, OPh), 122.1 (‘m’, OPh), 146.7 (‘p’, OPh), 158.7 (‘ipso’, OPh).
Experimental data are given in Table I illustrating the activity of compounds embodying the present invention, and of some comparative compounds, with respect to human breast cancer cell line NDA MB231, human colon cancer cell line HT115 and human prostrate cancer cell line PC-3. The compounds include those whose preparations are described above and compounds made by preparative methods corresponding to the methods described above.
The experimental procedures used human colon cancer cell line (HT115), human prostate cancer cell line (PC-3), human breast cancer cell line (MDA MB 231) and normal human umbilical vein endothelial cell (HUVEC). Compounds were diluted over a range of concentrations and added to cells over 1 to 3 days. The cytotoxity was determined using a MTT assay at the end of each experiment.
In the Table:
ArO refers to Ar as defined above with respect to formula I;
J refers to the moiety of the present compounds represented by, respectively, ROCOCR′R″NH—, as defined above with respect to formula I, or, with respect to Examples 51, 52 and 53, HOCOCR′R″NH—, as defined above with respect to formula II; and
B refers to the base moiety of the present compounds as defined above with respect to formula I or formula II.
BVU stands for 2-bromovinyl uridine.
5-(C═CC[O]O)MeU stands for methyl propenoate-2′-deoxyuridine.
GemCyt stands for Gemcitabine.
Examples A, 1, 67 and G are comparative Examples.
Example A is 5-(2-Bromovinyl)-2′-deoxyuridine.
Example 1 is Example 1 above corresponding to compound (7) above.
Example 67 is propenate-2′-deoxyuridine.
Example G is gemcitabine.
Examples 51, 52 and 53 are compounds embodying formula II above.
TABLE
EC50/μM
Breast EC50/μM EC50/μM
MDA Colon Prostate
Ex ArO J B MB231 HT115 PC-3
A — — BVU 125 78.7 120
1 PhO MeAlaNH BVU 79 244.5 155
2 PhO BnAlaNH BVU 34 1.4 19
3 PhO EtAlaNH BVU 56 52 36
4 p-CF3PhO BnAlaNH BVU 31 7.4 9.3
5 p-FPhO MeAlaNH BVU 159 17 58
6 p-FPhO EtAlaNH BVU 46 11 42
7 p-FPhO BnAlaNH BVU 17 3.5 16
8 p-NO2PhO BnAlaNH BVU 28 9
9 p-NO2PhO EtAlaNH BVU 177 118.7 365
10 p-NO2PhO MeAlaNH BVU 105 96.7 10.4
11 p-CIPhO EtAlaNH BVU 28.7 14.9 3.4
12 p-CIPhO BnAlaNH BVU 6.2 3.4 2.4
13 p-CIPhO MeAlaNH BVU 61 70.2 13
14 PhO Bn(Me2Gly)NH BVU 19 14.5 5.1
15 p-CF3PhO MeAlaNH BVU 47 79.2 15
16 PhO Me(cPntGly)NH BVU 79 77 16
17 PhO Et(cPntGly)NH BVU 44 81.3 41
18 PhO Bn(cPntGly)NH BVU 78 9.7 33
19 p-NO2PhO Me[cPntGly]NH BVU 56 38.2 88
20 p-NO2PhO Et[cPntGly)NH BVU 13 57.3 15
21 p-NO2PhO Bn[cPntGly]NH BVU 8.4 17.2 2.2
22 PFPhO Me[cPntGly]NH BVU 57 59.7 51
23 PFPhO Et[cPntGly]NH BVU 9.9 18.1 2.7
24 PFPhO Bn[cPntGly]NH BVU 9.4 17 3.7
25 p-CF3PhO EtAlaNH BVU 33.8 4.6
26 PhO Me(Me2Gly)NH BVU 41.1 77.9 1.5
27 PhO Et(Me2Gly)NH BVU 217.9 39.7 76.1
28 p-CF3PhO Me(cPntGly)NH BVU 28.8 21.2
29 p-CF3PhO Et(cPntGly)NH BVU 45.6 15.1 4.3
30 p-CF3PhO Bn(cPntGly)NH BVU 6.9 6.4
32 p-CIPhO Me[cPntGly]NH BVU 2.6 99.3 52.2
33 p-CIPhO Et[cPntGly]NH BVU 12 97.9 83.2
34 p-CIPhO Bn[cPntGly]NH BVU 3.9 8.9 6.3
35 PhO MeLeuNH BVU 18.5 7.7 75.7
36 PhO Me[Phe]NH BVU 19.8 32.1 86.9
37 PhO BnLeuNH BVU 2.8 7 7.16
38 p-NO2PhO BnLeuNH BVU 6.3 10.7 7.2
39 p-CIPhO BnLeuNH BVU 4.3 288.5 193.1
42 p-CIPhO Me(Me2Gly)NH BVU 8.7 183.4 441.6
43 p-CIPhO Et(Me2Gly)NH BVU 5.9 174.3 1.15
44 p-CIPhO Bn(Me2Gly)NH BVU 2.3 4.5 9.12
45 p-NO2PhO Me(Me2Gly)NH BVU 9.4 24.7 222.8
46 p-NO2PhO Et(Me2Gly)NH BVU 2 224 82.4
47 p-NO2PhO Bn(Me2Gly)NH BVU 4.5 16.7 27.2
48 p-CF3PhO Bn(Me2Gly)NH BVU 1.3 7 0.61
49 o-CIPhO BnAlaNH BVU 5.4 16.2 5.4
50 o-CIPhO Bn(Me2Gly)NH BVU 5.7 3.9 6.59
51 - L-AlaNH BVU 295.4
52 - LeuNH BVU 438.1
53 - PhAlaNH BVU 66
54 PhO Bn[PhAla]NH BVU 5.1
55 PhO Me[D-Ala]NH BVU 392.7
56 PhO Bn[D-Ala]NH BVU 20.8
57 p-NO2PhO Bn[D-Ala]NH BVU 20.2
58 p-CF3 Me[Me2Gly]NH BVU 83.6
59 p-CF3 Et[Me2Gly]NH BVU 24.7
60 p-FPhO Et[Me2Gly]NH BVU 86.8
61 p-CF3PhO Bn[L-PhAla]NH BVU 6.3
62 p-CF3PhO Bn[L-Leu]NH BVU 1.9
63 PhO tBu[L-Ala]NH BVU 31.5
64 p-NO2PhO Bn[L-PhAla]NH BVU 16.6
65 p-FPhO Me{Me2Gly)NH BVU
66 p-NO2PhO Me(Me2Gly)NH 5-(C═ 20.7
CC[O]O
Me)U
67 — — 5-(C═ 93.7
CC[O]O
Me)U
69 PhO MeMetNH BVU — — 6.3
70 PhO MeTrpNH BVU — — 16
71 PhO BnMetNH BVU — — 6.3
72 PhO BnIleNH BVU — — 1.6
73 PhO EtIleNH BVU — — 30.6
74 PhO MeGlyNH BVU — — 31
75 PhO BnGlyNH BVU — — 29
77 p-Cl PhO BnGlyNH BVU — — 150
78 p-CF, PhO BnValNH BVU — — 1.6
80 PhO Me2AspNH BVU — — 158
81 PhO Et2GluNH BVU — — 31
82 m-CIPhO BnAlaNH BVU — — 21
83 m-CIPhO BnMe2GlyNH BVU — — 6.3
84 p-Fph0 BnMe2GlyNH BVU — — 4.5
85 PhO BnVaINH BVU — — 31.2
86 p-CIPho BnVaINH BVU — — 0.9
87 p-Fph0 BnVaINH BVU — — 1.6
88 PhO BnPhGlyNH BVU — — 0.75
89 p-CIPhO BnPhGlyNH BVU — — 6.5
91 p-CF3PhO BnPhGlyNH BVU — — 0.7
94 PhO i-BuAlaNH BVU — — 51
95 PhO 2-BuAlaNH BVU — — 6.8
G — — GemCyt 2.8 606.1 3.12
31 PhO BnAlaNH GemCyt 42.6 5.7 0.22
40 p-ClPhO BuAlaNH GemCyt 9.2 16.1 15.4
41 p-ClPhO Bn[Me2Gly]NH GemCyt 3.1 317.1 68.8
Gemcitabine (Example G in the Table) and compound CPF31 (Example 31 in the Table: gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate) were compared in a mouse model with xenografts of human cancer (colon HT115 and prostrate PC3).
Mice were dosed daily at a range of concentrations (0.01-10 μM) and tumour volume assessed versus control.
Kaplan-Meier statistics were computed regarding incident-free survival.
In the attached drawings:
FIG. 1 shows for the mouse xenograft the tumour volume for prostate data at day 13 using Gemzar™ (gemcitabine available ex. Lilly);
FIG. 2 shows for the mouse xenograft the tumour volume for prostate data at day 13 using CPF31;
FIG. 3 shows the incident free survival functions v. day for each of CPF31 and gemcitabine; and
FIG. 4 shows for the mouse xenograft the tumour volume for colon data at day 24 using, respectively, Gemzar and compound CPF31.
Referring to the drawings, CPF31 can be seen to be significantly less toxic than gemcitabine.
CPF31 was significantly effective at reducing prostate and colon tumour volume relative to control at daily dosing of 5 and 10 μM (3 and 6 μg/ml). Gemcitabine was not effective at the highest non-toxic concentration.
Gemzar is seen from FIG. 1 to be toxic above 1 μM. In contrast, CPF31 is seen from FIG. 2 to have substantially lower toxicity.
FIG. 3 shows that CPF31 has significantly lower side effects on a comparable basis: 3 animals show serious toxicity (10% body mass loss) in GMZ and in CPF31 on day 10, collectively 4 in GMZ and 1 in CPF31 on day 11 and 5 in GMZ and 1 in CPF on day 13. Using Chi square analysis by combining 5 and 10 μM groups, the significance is p=0.193, 0,078 and 0.0289 on day 10, 11 and 13. It is clear that by day 13, CPF31 displayed signficantly less side effects, and the anti-cancer effects continue to exceed that of Gemzar.
FIG. 3 shows the Kaplan-Meier survival curve, incidence free survival: based on the loss according to weight loss. A Cox proportion analysis shows that CPF31 is far less toxic than GMZ based on the weight-loss calculated loss (p=0.043).
CPF31 was found to be active at 5 μM in vitro, whereas Gemzar was found to be active at 600 μM, with respect to the same colon cell line. FIG. 4 shows the results of testing both in vivo at 5 μM. The greater activity of CPF31 in reducing tumour volume is shown in FIG. 4.

Claims (25)

The invention claimed is:
1. A chemical compound having formula I:
Figure USRE047589-20190903-C00118
wherein:
R is selected from the group comprising alkyl, aryl and alkylaryl;
R′ and R″ are independently selected from the group comprising H, alkyl and alkylaryl, or
R′ and R″ together form an alkylene chain so as to provide, together with the C atom to which they are attached, a cyclic system;
Q is selected from the group comprising —O— and —CH2—;
X and Y are independently selected from the group comprising H, halogen, OH and —CH3;
Ar is a monocyclic aromatic ring moiety or a fused bicyclic aromatic ring moiety, either of which said ring moieties is carbocyclic or heterocyclic and is optionally substituted, any such substituent being selected from the group comprising halogen, halomethyl, oxo, hyroxy, carboxy, carboxyC1-16 alkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl, aryloyloxy, amino, C1-6alkylamino, diC1-6alkylamino, cyano, azide, nitro, thiol, C1-6 alkylthiol, sulphony, sulphoxide, heteocyclic groups, alkyl groups and aryl groups;
Z is H,
n is 0,
Z′ is —NH2 and a double bond exists between position 3 and position 4,
or a pharmaceutically acceptable derivative of a compound of formula I the derivative which upon administration to a recipient is capable of providing directly or indirectly a compound of formula I.
2. A compound according to claim 1 wherein R is selected from the group comprising a C1-16 primary or secondary alkyl group, a C5-7 carbocyclic aryl group or a C1-6alkylC5-11 aryl group.
3. A compound according to claim 2 wherein R is selected from the group CH3, —C2H5 and —CH2C6H5.
4. A compound according to claim 3 wherein R is —CH2C6H5.
5. A compound according to claim 1 wherein Ar is an optionally substituted C6 monocyclic aromatic ring moiety.
6. A compound according to claim 5 wherein Ar is selected from the group comprising —C6H5, pCF3C6H4—, pFC6H4—, pNO2C6H4—, pClC6H4— and oClC6H4—.
7. A compound according to claim 1 wherein R′ and R″ are, independently, selected from the group comprising H, C1-6 primary, secondary and tertiary alkyl, C1-3alkylC5-7 aryl, or, when together they form an alkylene chain, they provide, together with the C atom to which they are attached, a C3-8 carbocyclic aliphatic ring.
8. A compound according to claim 7 wherein R′ and R″ are, independently, selected from the group comprising H, methyl, benzyl and CH2CH(CH3)2, or, R′ and R″ together with the C atom to which they are attached, provide a C5-6 ring.
9. A compound according to claim 8 wherein R′ and R″ are each methyl.
10. A compound according to claim 8 wherein one of R′ and R″ is H and one of R′ and R″ is methyl.
11. A compound according to claim 8 wherein R′ and R″, together with the C atom to which they are attached, provide a pentyl ring.
12. A compound according to claim 1 wherein R′ and R″ correspond to the side chains of a naturally occurring amino acid.
13. A compound according to claim 1 wherein Q is O.
14. A compound according to claim 1 wherein, each of X and Y is F.
15. A compound according to claim 1 wherein, X is OH and Y is H.
16. A compound according to claim 1 wherein, X is H and Y is OH.
17. A compound selected from the group comprising:
Gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate;
Gemcitabine-[para-chlorophenyl-(benzoxy-L-alaninyl)]-phosphate and
Gemcitabine-[para-chlorophenyl-(benzoxy-α,α-dimethylglycinyl)]-phosphate.
18. A compound according to claim 1 for use in the treatment of cancer.
19. A method for the treatment of cancer comprising administration to a patient in need of such treatment an effective dose of a compound according to claim 1.
20. A pharmaceutical composition comprising a compound according to claim 1 with a pharmaceutically acceptable carrier, diluent or excipient.
21. A method of preparing a pharmaceutical composition comprising the step of combining a compound according to claim 1 with a pharmaceutically acceptable excipient, carrier or diluent.
22. A process for the preparation of a compound of formula I according to claim 1, the process comprising reacting of a compound of formula (III):
Figure USRE047589-20190903-C00119
with a compound of formula (IV)
Figure USRE047589-20190903-C00120
wherein Ar, n, Q, R, R′, R″, X, Y, Z and Z′ ″ have the meanings described in claim 1 and a double bond exists between position 3 and position 4.
23. A compound of formula:
Figure USRE047589-20190903-C00121
wherein Bn is benzyl.
24. A pharmaceutical composition comprising an effective amount of the compound of claim 23 and a pharmaceutically acceptable excipient, carrier, or diluent.
25. A method for the treatment of cancer comprising administering to a patient in need thereof an effective amount of the compound of claim 23.
US15/279,611 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use Active 2026-07-25 USRE47589E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/279,611 USRE47589E1 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0317009.9 2003-07-21
GBGB0317009.9A GB0317009D0 (en) 2003-07-21 2003-07-21 Chemical compounds
US15/279,611 USRE47589E1 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use
US10/560,887 US7951787B2 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use
PCT/GB2004/003148 WO2005012327A2 (en) 2003-07-21 2004-07-20 Nucleotide phosphoramidates as anticancer agents

Publications (1)

Publication Number Publication Date
USRE47589E1 true USRE47589E1 (en) 2019-09-03

Family

ID=27772362

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/560,887 Ceased US7951787B2 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use
US15/279,611 Active 2026-07-25 USRE47589E1 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/560,887 Ceased US7951787B2 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use

Country Status (20)

Country Link
US (2) US7951787B2 (en)
EP (5) EP3904365B1 (en)
JP (1) JP4923216B2 (en)
AU (1) AU2004261455B2 (en)
CA (1) CA2518115C (en)
CY (5) CY1117960T1 (en)
DK (4) DK1646639T3 (en)
ES (4) ES2928202T3 (en)
FI (1) FIC20230013I1 (en)
FR (1) FR23C1014I2 (en)
GB (1) GB0317009D0 (en)
HU (4) HUE042282T2 (en)
MX (1) MXPA05012606A (en)
NO (1) NO333603B1 (en)
NZ (1) NZ541974A (en)
PL (4) PL1646639T3 (en)
PT (4) PT3904365T (en)
SI (2) SI2955190T1 (en)
TR (1) TR201901246T4 (en)
WO (1) WO2005012327A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180346504A1 (en) * 2017-05-01 2018-12-06 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11266666B2 (en) 2014-10-29 2022-03-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US11377467B2 (en) 2015-12-23 2022-07-05 NuCana plc Crystalline form of gemcitabine
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
US11560400B2 (en) 2017-12-05 2023-01-24 NuCana plc Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
ES2624353T3 (en) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Methyl nucleosides in combination with interferon and Flaviviridae mutation
EP1633766B1 (en) * 2003-05-30 2019-03-06 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
ES2769377T3 (en) * 2004-09-14 2020-06-25 Gilead Pharmasset Llc D-ribonolactone intermediates with 2-fluoro-2-alkyl substitution
JP2008523082A (en) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Nucleotides having antibacterial and anticancer activities
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
DE102006037786A1 (en) 2006-08-11 2008-03-20 Resprotect Gmbh Nucleosides, pharmaceuticals containing them and their use
DK2099461T3 (en) * 2006-11-13 2012-07-02 Santaris Pharma As LNA Nucleoside Phosphoramidates
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2014233579B2 (en) * 2007-03-30 2016-06-23 Gilead Sciences, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
FR2922551B1 (en) * 2007-10-17 2009-12-25 Univ Claude Bernard Lyon PRODRUGS PHOSPHOESTERS OF GEMCITABINE AS ANTICANCER AGENTS
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
CN102325783A (en) * 2008-12-23 2012-01-18 法莫赛特股份有限公司 Synthesis of purine nucleosides
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
MX2012011171A (en) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Nucleoside phosphoramidates.
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
PE20171640A1 (en) 2010-09-22 2017-11-09 Alios Biopharma Inc REPLACED NUCLEOTIDE ANALOGS
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
WO2012094248A1 (en) 2011-01-03 2012-07-12 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9156874B2 (en) 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
RS62721B1 (en) 2011-03-01 2022-01-31 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
ES2659216T5 (en) 2011-09-16 2021-06-09 Gilead Pharmasset Llc Methods for treating HCV
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
PT107925A (en) 2011-10-21 2014-12-03 Abbvie Inc TREATMENT OF AAD COMBINATION (EG WITH ABT-072 OR ABT-333) FOR USE IN HCV TREATMENT
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104011061B (en) 2011-12-20 2017-06-13 里博科学有限责任公司 As HCV rna replicon inhibitor 2 ', ' the methyl substituted nucleoside derivates of 4 ' difluoro 2
IN2014CN04530A (en) 2011-12-20 2015-09-11 Hoffmann La Roche
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN104203969B (en) 2012-03-28 2016-08-31 富士胶片株式会社 The salt of 1-(2-deoxidation-2-fluoro-4-sulfur generation-β-D-arabinofuranosidase glycosyl) cytosine
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
UY34824A (en) 2012-05-25 2013-11-29 Janssen R & D Ireland NUCLEOSIDES OF URACILO SPYROOXETHANE
CN104640444B (en) * 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 Double liver target phosphoramidates and aminophosphonic acid ester prodrugs
PL2883866T3 (en) 2012-08-13 2019-07-31 Fujifilm Corporation INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-beta-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
MD20150036A2 (en) 2012-10-08 2015-08-31 Idenix Pharmaceuticals, Inc. 2'-Chloro nucleoside analogs for HCV infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EA028871B1 (en) 2012-11-16 2018-01-31 Юниверсити Колледж Кардифф Консалтантс Лимитед Process for preparing chemical compounds
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CN105748499B (en) 2013-01-31 2018-12-28 吉利德制药有限责任公司 The combination preparation of two antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP2984098A2 (en) 2013-04-12 2016-02-17 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
KR20160039154A (en) 2013-05-16 2016-04-08 리보사이언스 엘엘씨 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
CA2912682C (en) 2013-05-16 2021-07-06 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
KR102239196B1 (en) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 Combination formulation of two antiviral compounds
US20160271160A1 (en) * 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
MX2016006919A (en) * 2013-11-27 2016-08-17 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer.
WO2015125781A1 (en) 2014-02-18 2015-08-27 富士フイルム株式会社 Method for producting thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
JP6204223B2 (en) 2014-02-19 2017-09-27 富士フイルム株式会社 Method for producing thiopyranose compound, etc.
CN103804446A (en) * 2014-02-27 2014-05-21 苏州东南药业股份有限公司 Preparation method of 3,5-dibenzoyl-2-deoxy-2-fluoro-2-methyl-D-ribo-gamma-lactone
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CA2944966C (en) * 2014-06-25 2022-10-25 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
SI3160978T1 (en) 2014-06-25 2020-11-30 NuCana plc Gemcitabine prodrugs
JP6646663B2 (en) * 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ Method for producing gemcitabine- [phenyl (benzoxy-L-alaninyl)] phosphate Method for producing phosphoric acid derivative
CN107074826B (en) 2014-08-25 2020-05-22 美迪维尔公司 Dioxolane analogues of uridine for the treatment of cancer
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3212658A4 (en) * 2014-10-31 2018-07-25 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
TWI678373B (en) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 Thionucleoside derivative or its salt and pharmaceutical composition
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
CN107207554B (en) 2014-11-28 2020-09-11 努卡那有限公司 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US10683319B2 (en) 2014-12-15 2020-06-16 Emory University Phosphoramidates for the treatment of hepatitis B virus
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
KR102363946B1 (en) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for the treatment of HCV
US10662214B2 (en) 2015-04-03 2020-05-26 Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
PT3197456T (en) 2015-05-14 2018-05-22 NuCana plc Cancer treatments
TWI695841B (en) * 2015-06-22 2020-06-11 瑞典商米迪維艾克提伯拉公司 Prodrugs for the treatment of cancer
CN106543252A (en) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 The Preparation Method And Their Intermediate of nucleoside phosphoramidate class prodrug
CN106543220A (en) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 Phosphoramidate compounds and preparation method thereof and crystal
CN106478753A (en) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 A kind of preparation method of NUC 1031 individual isomer and purposes
KR20180063075A (en) * 2015-10-05 2018-06-11 뉴카나 피엘씨 Combination therapy
MX2018005872A (en) * 2015-11-16 2019-05-16 Ichorion Therapeutics Inc Nucleic acid prodrugs.
AU2016367237B2 (en) 2015-12-11 2020-12-24 Laurus Labs Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
KR102566461B1 (en) 2015-12-23 2023-08-14 뉴카나 피엘씨 combination therapy
MA51576A (en) * 2015-12-23 2020-11-18 NuCana plc POLYTHERAPY
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
EA201990059A1 (en) 2016-06-24 2019-07-31 Эмори Юниверсити PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
TWI787201B (en) 2016-08-31 2022-12-21 日商富士軟片股份有限公司 Antitumor agent, antitumor effect enhancer, and antitumor kit
CA3187650A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN109134568B (en) * 2017-06-15 2022-11-22 北京美倍他药物研究有限公司 Nucleoside phosphate/amide derivatives and medicinal use thereof
EP3677267A4 (en) * 2017-09-01 2021-06-02 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
EP3684374A4 (en) 2017-09-21 2021-06-16 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
TW201932119A (en) 2018-01-29 2019-08-16 日商富士軟片股份有限公司 Antitumor agent for biliary cancer and treatment method of biliary cancer
SG11202007381YA (en) * 2018-02-02 2020-08-28 Maverix Oncology Inc Novel small molecule drug conjugates of gemcitabine derivatives
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
JP6810763B2 (en) * 2019-03-06 2021-01-06 ニューカナ パブリック リミテッド カンパニー Cancer treatment
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
WO2022031150A1 (en) * 2020-08-07 2022-02-10 주식회사 피노바이오 Conjugate including deoxycytidine-based anticancer agent and silyl ether-containing linker

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5814639A (en) 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO1999049873A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6180639B1 (en) 1990-05-02 2001-01-30 Biochem Pharma Inc. 1,3-oxathiolane nucleoside analogues
WO2001007454A1 (en) 1999-07-22 2001-02-01 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
US20030109697A1 (en) * 1998-01-23 2003-06-12 Shepard H. Michael Novel phosphoramidate compounds and methods of use
WO2003053989A1 (en) * 2001-12-13 2003-07-03 Mrc Technology Limited Masked phosphate containing nucleoside derivatives and their use as antivirals
WO2003068164A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Dosing regimen for gemcitabine hcv therapy
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20040167096A1 (en) * 2003-02-19 2004-08-26 Yung-Chi Cheng Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
US20170226147A1 (en) * 2014-10-06 2017-08-10 Nucana Biomed Limited Methods of separating gemcitabine-phosphate diastereoisomers
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
US10005810B2 (en) 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
US20180271889A1 (en) 2015-10-05 2018-09-27 NuCana plc Combination therapy for cancer
US20180289733A1 (en) 2015-05-14 2018-10-11 NuCana plc Cancer treatments based on gemcitabine prodrugs
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
US20180362571A1 (en) 2015-12-11 2018-12-20 NuCana plc Diastereoselective synthesis of phosphate derivatives
US20180369266A1 (en) 2015-12-23 2018-12-27 NuCana plc Formulations of phosphoramidate derivatives of nucleoside drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538397A1 (en) 1982-12-24 1984-06-29 Charbonnages Ste Chimique CONTINUOUS PROCESS FOR THE PRODUCTION OF HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP1251836A2 (en) 1999-12-23 2002-10-30 NewBiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
US20020147175A1 (en) 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
CN100348607C (en) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 For the treatment of Flaviviridae viral infection in 2 'and 3'-nucleoside prodrugs
EP1633766B1 (en) 2003-05-30 2019-03-06 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5814639A (en) 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6180639B1 (en) 1990-05-02 2001-01-30 Biochem Pharma Inc. 1,3-oxathiolane nucleoside analogues
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
JP2001220397A (en) 1998-01-23 2001-08-14 Newbiotics Inc Therapeutic agent catalyzed by enzyme
US6339151B1 (en) * 1998-01-23 2002-01-15 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
JP2002500880A (en) 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド Therapeutic agents catalyzed by enzymes
US20030109697A1 (en) * 1998-01-23 2003-06-12 Shepard H. Michael Novel phosphoramidate compounds and methods of use
WO1999049873A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
WO2001007454A1 (en) 1999-07-22 2001-02-01 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
WO2003053989A1 (en) * 2001-12-13 2003-07-03 Mrc Technology Limited Masked phosphate containing nucleoside derivatives and their use as antivirals
WO2003068164A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Dosing regimen for gemcitabine hcv therapy
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20040167096A1 (en) * 2003-02-19 2004-08-26 Yung-Chi Cheng Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
US10005810B2 (en) 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
US20180273575A1 (en) 2012-11-16 2018-09-27 NuCana plc Process for preparing nucleoside prodrugs
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
US20190022118A1 (en) 2014-06-25 2019-01-24 NuCana plc Formulation comprising a gemcitabine-prodrug
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
US20170226147A1 (en) * 2014-10-06 2017-08-10 Nucana Biomed Limited Methods of separating gemcitabine-phosphate diastereoisomers
US20180289733A1 (en) 2015-05-14 2018-10-11 NuCana plc Cancer treatments based on gemcitabine prodrugs
US20180271889A1 (en) 2015-10-05 2018-09-27 NuCana plc Combination therapy for cancer
US20180362571A1 (en) 2015-12-11 2018-12-20 NuCana plc Diastereoselective synthesis of phosphate derivatives
US20180369266A1 (en) 2015-12-23 2018-12-27 NuCana plc Formulations of phosphoramidate derivatives of nucleoside drugs

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
Abraham et al., "Synthesis and Biological Activity of Aromatic Amino Acid Phosphoramidates of 5-Fluoro-2'-deoxyuridine and 1-beta-Arabinofuranosylcytosine: Evidence of Phosphoramidate Activity", J. Med. Chem. 39:4569-4575 (1996).
Bundgard, H. in "Design of Prodrugs" (Bungaard, H., ed.) (1985) (Elsevier Science Publishers, Biomedical Division: Amsterdam) pp. 1-92. *
David B. Lackey et al., "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase", Biochemical Pharmacology, 61 (2001), pp. 179-189.
Edward J. McIntee, et al., "Amino Acid Phosphoramidate Nucleosides: Potential ADEPT/GDEPT Substrates", Bioorganic & Medicinal Chemistry Letters, 11 (2001), pp. 2803-2805.
Galmarini, C. M., et al. Leukemia (2001). 15; pp. 875-890. *
Gromova et al., "Optical Rotary Dispersion and Circular Dichroism of Mono- and Oligonucleotide-Amino Acids (Amidates)", Biochim Biophys Acta 240:1-11 (1971).
Harris et al., "Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromoviny1)-2'-deoxyuridine", Antiviral Chemistry and Chemotherapy, vol. 12 (2001), pp. 293-300.
Juodka et al., "Oligonucleotides and nucleotide-peptide. XXXIV. Synthesis and some properties of complex nucleotidyl (oligonucleotidyl)-(P-N)-aminoacids (peptides) and their ethyl esters"; J Carbohydrates Nucleosides Nucleotides 6(4):333-357 (1979).
Juodka et al., "Oligonucleotides and Nucleotide-Peptides. XXXV. Some Properties of Nucleotidyl-(5'→N)-Amino Acid Esters Differing in Amino Acid and Nucleotide Components)", J Carbohydrates Nucleosides Nucleotides 8 (1): 19-39 (1981).
Juodka et al., "Oligonucleotides and nucleotide-peptides. XXXVII. On the Mechanism of Hydrolysis of Uridyly1-(5'→N)-amino acids. Intramolecular catalysis by the alpha-carboxyl group of amino acids"; J Carbohydrates Nucleosides Nucleotides 8(6):519-535 (1981).
Juodka et al., "Oligonucleotides and Nucleotide-Peptides. XXXV. Some Properties of Nucleotidyl—(5'→N)-Amino Acid Esters Differing in Amino Acid and Nucleotide Components)", J Carbohydrates Nucleosides Nucleotides 8 (1): 19-39 (1981).
Lehsten et al., "An improved procedure for the synthesis of nucleoside amidates"; Organic Process Research & Development 6:819-822 (2002).
Liorancaite et al., "Synthesis and Some Properties of Oligonucleotidyl-(Pm->N)-Serines", Nucleic Acids Symposium Series 9:215-18 (1981).
Lisa J. Whalen, et al., "Synthesis and Evaluation of Phosphoramidate Amino Acid-Based Inhibitors of Sialyltransferases", Bioorganic & Medicinal Chemistry Letters, 13 (2003), pp. 301-304.
McGuigan et al. Antiviral Chem. Chemotherapy (2000) 11: 111-116. *
McGuigan et al. Antiviral Chemistry & Chemotherapy 1993; 4:97-101.
McGuigan et al. Antiviral Research 1991; 15:255-263.
McGuigan et al., "Synthesis and Evaluation of some masked phosphate esters of the anti-herpesvirus drug 882C (Netivudine) as potential antiviral agents", Antiviral Chemistry & Chemotherapy 9:233-243 (1998).
Negishi et al., "N4-Aminocytidine, a Nucleoside Analog that has an Exceptionally High Mutagenic Activity", Nucleic Acids Research 11(15):5223-5233 (1993).
Parker et al. Mol. Pharmacol. 1999; 55:515-520.
Patani et al. Chem. Rev. (1996) 96: 3147-3176. *
Ramirez, M et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 1991; 43: 49-54.
Remy et al., "Studies on fluorinated pyrimidines. XIV. The synthesis of derivatives of 5-fluoro-2'-deoxyuridine-5'-phosphate and related compounds"; J Org Chem 27:2491-2500 (1962).
Sa Harris, et al., "Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2′-deoxyuridine", Antiviral Chemistry and Chemotherapy, vol. 12 (2001), pp. 293-300.
Search Report issued by the European Patent Office in corresponding Application No. EP 15154759.3, dated Jun. 20, 2017.
Siddiqui et al., "Design and Synthesis of Liphophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structure Determinants for in Vitro Activity and QSAR", J Med Chem 42 (1999), pp. 4122-4128.
Slusarczyk, "Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development," J Med Chem, 57:1531-1542 (2014).
Stryer, L., "DNA and RNA: Molecules of Heredity", Biochemistry, Fourth Ed., Ch. 4. pp. 75, 76, 80-83 (1995).
Stryer, L., "Flow of Genetic Information". Biochemistry, Fourth Ed., Ch. 5, pp. 95-97 (1995).
Torres-Lopez, MI. Et al. Gut 1996; 38: 260-264.
Wagner, et al. Bioorganic & Medicinal Chemistry Letters 1995; 5 (16):1819-1824.
Wattig, B. et al. Acta Histochem Suppl. 1992; 42:333-339 (Abstract only).
Zhou et al., "Simultaneous Formation of Peptides and Nucleotides from N-Phosphothreonine", Origins of Life and Evolution of the Biosphere 26:547-560 (1996).

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US11344565B2 (en) 2014-10-29 2022-05-31 Gilead Sciences, Inc. Methods for the preparation of ribosides
US11266666B2 (en) 2014-10-29 2022-03-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11382926B2 (en) 2015-09-16 2022-07-12 Gilead Sciences, Inc. Methods for treating Arenaviridae and Coronaviridae virus infections
US11377467B2 (en) 2015-12-23 2022-07-05 NuCana plc Crystalline form of gemcitabine
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10836787B2 (en) * 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US12030906B2 (en) 2017-05-01 2024-07-09 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US11597742B2 (en) 2017-05-01 2023-03-07 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US20180346504A1 (en) * 2017-05-01 2018-12-06 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11975017B2 (en) 2017-07-11 2024-05-07 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11560400B2 (en) 2017-12-05 2023-01-24 NuCana plc Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US12012431B2 (en) 2020-03-12 2024-06-18 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
US11903953B2 (en) 2020-05-29 2024-02-20 Gilead Sciences, Inc. Remdesivir treatment methods
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11851438B2 (en) 2022-03-02 2023-12-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and methods for treatment of viral infections

Also Published As

Publication number Publication date
ES2667698T3 (en) 2018-05-14
EP3486251A1 (en) 2019-05-22
WO2005012327A3 (en) 2005-04-21
GB0317009D0 (en) 2003-08-27
ES2589738T3 (en) 2016-11-16
HUS2300012I1 (en) 2023-03-28
EP3040340B1 (en) 2018-11-14
PT2955190T (en) 2018-05-07
EP1646639B8 (en) 2016-12-21
DK2955190T3 (en) 2018-05-22
PL2955190T3 (en) 2018-09-28
PL3040340T3 (en) 2019-05-31
CY1117960T1 (en) 2017-05-17
AU2004261455A1 (en) 2005-02-10
NO20053993D0 (en) 2005-08-26
EP1646639B1 (en) 2016-08-17
PT3040340T (en) 2019-02-06
EP1646639A2 (en) 2006-04-19
FR23C1014I2 (en) 2024-02-09
CY1120202T1 (en) 2018-12-12
FIC20230013I1 (en) 2023-03-01
JP2006528162A (en) 2006-12-14
NO20053993L (en) 2005-11-02
NZ541974A (en) 2009-03-31
CY1125603T1 (en) 2023-06-09
EP3040340A1 (en) 2016-07-06
WO2005012327A2 (en) 2005-02-10
SI2955190T1 (en) 2018-08-31
DK1646639T3 (en) 2016-09-12
US7951787B2 (en) 2011-05-31
DK3040340T3 (en) 2019-02-25
CA2518115A1 (en) 2005-02-10
EP3904365B1 (en) 2022-09-07
MXPA05012606A (en) 2006-02-08
US20060142238A1 (en) 2006-06-29
DK3904365T3 (en) 2022-10-17
EP2955190B1 (en) 2018-03-28
AU2004261455B2 (en) 2010-12-23
CY2023008I2 (en) 2024-02-16
FR23C1014I1 (en) 2023-05-05
CY1121218T1 (en) 2020-05-29
CA2518115C (en) 2012-03-20
PL1646639T3 (en) 2016-12-30
EP3904365A1 (en) 2021-11-03
SI3040340T1 (en) 2019-03-29
EP2955190A2 (en) 2015-12-16
HUE030374T2 (en) 2017-05-29
PT3904365T (en) 2022-10-13
ES2928202T3 (en) 2022-11-16
ES2708570T3 (en) 2019-04-10
TR201901246T4 (en) 2019-02-21
NO333603B1 (en) 2013-07-22
HUE042282T2 (en) 2019-06-28
PT1646639T (en) 2016-09-05
JP4923216B2 (en) 2012-04-25
PL3904365T3 (en) 2022-11-07
EP2955190A3 (en) 2016-03-16
CY2023008I1 (en) 2024-02-16
HUE059970T2 (en) 2023-01-28

Similar Documents

Publication Publication Date Title
USRE47589E1 (en) Phosphoramidate compounds and methods of use
AU2012223012C1 (en) Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
US9321798B2 (en) Phosphoramidite derivatives of gemcitabine for use in the treatment of cancer
AU610344B2 (en) 2'-deoxy-5-fluorouridine derivatives
PT707591E (en) METHYLPHOSPHONIC ACID ESTERS, PROCESS FOR PREPARING AND USING THEM
WO2007112348A2 (en) Prodrug composition
US11414451B2 (en) Floxuridine synthesis
KR20070103012A (en) Novel pyrimidine nucleoside compound or its salt
CZ295706B6 (en) 5 -Deoxycytidine derivative, process for its preparation and pharmaceutical composition and kit containing thereof
JPWO2008010571A1 (en) 2'-cyanopyrimidine nucleoside compounds
GB2104060A (en) Fluorinated hexene diamine derivatives
JPH08134093A (en) Carcinostatic agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: NUCANA PLC, UNITED KINGDOM

Free format text: CHANGE OF NAME;ASSIGNOR:NUCANA BIOMED LIMITED;REEL/FRAME:048621/0306

Effective date: 20170829

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12